


PATENT COOPERATION TREATY



PCT

From the INTERNATIONAL BUREAU

**NOTICE INFORMING THE APPLICANT OF THE
COMMUNICATION OF THE INTERNATIONAL
APPLICATION TO THE DESIGNATED OFFICES**

(PCT Rule 47.1(c), first sentence)

To:

NEWELL, William, Joseph
Wynne-Jones Laine and James
Morgan Arcade Chambers
33 St. Mary Street
Cardiff CF10 1AF
ROYAUME-UNI

Date of mailing (day/month/year)

18 May 2000 (18.05.00)

Applicant's or agent's file reference

WN/NV/WCM.69

IMPORTANT NOTICE

International application No.

PCT/GB99/03654

International filing date (day/month/year)

05 November 1999 (05.11.99)

Priority date (day/month/year)

07 November 1998 (07.11.98)

Applicant

UNIVERSITY OF WALES COLLEGE OF MEDICINE et al

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:

AU,JP,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:

CA,EP

The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).

3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on 18 May 2000 (18.05.00) under No. WO 00/28025

REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. (41-22) 740.14.35

Authorized officer

J. Zahra

Telephone No. (41-22) 338.83.38

**NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF
THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES**

Date of mailing (day/month/year) 18 May 2000 (18.05.00)	IMPORTANT NOTICE
Applicant's or agent's file reference WN/NV/WCM.69	International application No. PCT/GB99/03654
<p>The applicant is hereby notified that, at the time of establishment of this Notice, the time limit under Rule 46.1 for making amendments under Article 19 has not yet expired and the International Bureau had received neither such amendments nor a declaration that the applicant does not wish to make amendments.</p>	

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : C12N 15/12, 15/62, C07K 14/435, G01N 33/542, 33/533, 33/84		A1	(11) International Publication Number: WO 00/28025
			(43) International Publication Date: 18 May 2000 (18.05.00)
(21) International Application Number: PCT/GB99/03654 (22) International Filing Date: 5 November 1999 (05.11.99) (30) Priority Data: 9824357.9 7 November 1998 (07.11.98) GB (71) Applicant (for all designated States except US): UNIVERSITY OF WALES COLLEGE OF MEDICINE [GB/GB]; Heath Park, Cardiff CF4 4XW (GB). (72) Inventor; and (75) Inventor/Applicant (for US only): CAMPBELL, Anthony, Keith [GB/GB]; 14 Maillard's Haven, Penarth, Vale of Glamorgan CF65 5RF (GB). (74) Agents: NEWELL, William, Joseph et al.; Wynne-Jones Laine and James, Morgan Arcade Chambers, 33 St. Mary Street, Cardiff CF10 1AF (GB).			(81) Designated States: AU, CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: PHOLASIN			
(57) Abstract A bioluminescent oxidative indicator responds to oxygen or one of its metabolites producing light or radiation of altered characteristics when there is a change in the amount of oxygen or its metabolites present. The indicator may also be modified so that its light emission or radiation characteristics change when it is modified covalently, is linked to another protein, interacts with or binds a substance, or when coupled to a specific promoter or enhancer gene thereby acting as a reporter gene.			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PHOLASIN

The present invention relates to a protein, capable of bioluminescence, cDNA coding therefor and their uses, *inter alia*, in diagnostics and therapy. In particular, this invention
5 relates to the cloning and sequencing of cDNA coding for pholasin from the bivalve mollusc *Pholas dactylus*.

The term 'bioluminescence' refers to the emission of light resulting from a chemical reaction within, or produced by, a living organism. The essential components to the
10 chemical reaction are: an organic molecule, usually comprising a luciferin; oxygen or one of its metabolites; and an enzyme or luciferase that catalyses the oxidation of the luciferin. The chemiluminescent reaction responsible for bioluminescence may be represented as follows:

15 Luciferin + O₂, or O₂⁻, or H₂O₂, or ·OH or OC1⁻ or OX⁻ or ¹O₂ (+ luciferase) ———→
oxyluciferin + light.

Up to three other substances may also be required to generate light or to generate light of the required colour and intensity. These are as follows:

20

- (a) A cation, such as H⁺, Ca²⁺, Mg²⁺ or a transition metal cation (eg Cu⁺/Cu²⁺, Fe²⁺/Fe³⁺, La³⁺ and V³⁺);
- (b) A co-factor such as NAD(P)H, FMN or ATP; and/or
- (c) A fluor as an energy transfer acceptor.

25

Five chemical families of luciferin are known:

- (a) Aldehydes (found in the freshwater limpet *Latia*, earthworms, and with FMN in bacteria);
- 30 (b) Imidazolopyrazines, which are the compounds most commonly responsible for bioluminescence in the sea (found in Sarcomastigophora, Cnidaria, Ctenophora, Annelida, Chaetognatha, some Arthropoda, some Mollusca and some Chordata);
- (c) Benzothiazoles (found in beetles such as fireflies and glow-worms);

- (d) Linear tetrapyrroles (found in dinoflagellates, euphausiid shrimp and some fish);
and
- (e) Flavins (found in bacteria, fungi, polychaete worms and some molluscs).

5 Chemiluminescent reactions involving these luciferins may produce a glow or a flash with an emission of violet, blue, blue-green, green, yellow, orange or red light, or occasionally UV or IR light. The light emission may be linearly or circularly polarised. The luciferin or its product may also be detected and quantified by fluorescence or phosphorescence. As a chemical reaction is directly responsible for the light emission, it does not require
10 exposure to UV, visible or IR light. However, some bioluminescent systems, such as that in the red organ of the deep sea fish *Malacosteus*, exhibit a photo-chemiluminescence, where light can trigger or enhance the chemiluminescent reaction. [Reference is directed to Chemiluminescence: Principles and Applications in Biology and Medicine, A K Campbell (1988), Horwood/VCH Chichester, Weinheim.]

15

In the case of some bioluminescent proteins, the luciferin is so tightly or covalently bound to the protein molecule that it does not diffuse away into the surrounding fluid as a result of the chemiluminescent reaction. In this case, the protein-luciferin complex is known as a photoprotein; and the protein itself is referred to as an apophotoprotein. Some
20 bioluminescent proteins are proteins whose light emission or radiation depends on or may be altered by oxygen or one of its metabolites; these bioluminescent proteins are hereinafter referred to as 'bioluminescent oxidative indicator proteins' (BOIPs). BOIPS may thus be photoproteins or luciferin-luciferase systems.

25 BOIPs, therefore, may be used to detect and quantify oxygen or one of its metabolites in individual cells, defined compartments of living cells such as the nucleus, whole organs and organisms - both animals and plants, including microbes such as viruses and bacteria and protozoa - as well as substances of biological interest such as substrates, metabolites, vitamins, drugs, intra- and extra-cellular signals, enzymes, antigens, antibodies and
30 nucleic acids. Heretofore, it has only been known to employ native BOIPs extracellularly.

The present invention therefore relates to a method for the detection and/or measurement

of oxygen or one of its metabolites in live cells (intracellular), which method comprises providing a BOIP, such as native or chemically- (or genetically-) modified BOIP or a 'rainbow protein' based on such a BOIP, intracellularly and thereafter detecting and/or quantifying light emission therefrom and/or changes in colour, intensity and/or polarisation of emission(s) therefrom.

Furthermore, it has now been found that, by sequencing the BOIP and identifying the cDNA encoding therefor, the recombinant BOIP can also be used in such a method, or chemically- or genetically-modified recombinant BOIP, or a 'rainbow protein' based on such a BOIP. For example, the bivalve mollusc *Pholas dactylus* has been shown to comprise a native photoprotein, which interacts with a luciferase, when they are secreted together by the mollusc to produce light when O_2 or one of its metabolites is present. References to the Purification and Properties of *Pholas Dactylus* Luciferin and Luciferase can be found by Michelson in Methods in Enzymology LVII 385-406 (1978). References to detection of activation of neutrophils by detection of superoxide anion can be found by Roberts in Anal Biochem 160 139-148 (1987) and by Müller *et al* in J Biolum Chemilum 3 105-113 (1989). The native photoprotein (known as pholasin) is made up of a glycosylated apoprotein (34kDa) with a small organic molecule, the luciferin, tightly bound to it. This luciferin (whose structure is unknown - Müller and Campbell in J Biolum Chemilum 5 25-30 (1990)) can be extracted from the protein moiety - the apopholasin - or from the organism by a standard treatment, such as mild acid. The pholasin may be collected from live molluscs found in sedimentary rocks at low water along the south coast of England from Plymouth to Folkestone and also along the French channel coast and in the Mediterranean. Further details may be obtained from marine fauna and the references cited herein.

We have surprisingly found that pholasin can generate light even without the presence of the corresponding luciferase by addition of oxygen metabolites such as O_2^- , H_2O_2 , OCl^- or other oxyhalide anions, or organic peroxides, and certain organic solvents such as dimethyl sulphide (DMSO) or dimethyl formamide (DMF).

We have now identified the cDNA encoding for the (non-glycosylated) apoprotein of pholasin, which may also be called 'apopholasin'. Accordingly, the present invention

therefore further provides an isolated, purified or recombinant nucleic acid sequence comprising:

- (a) The apophotoprotein of pholasin (alternatively, 'apopholasin');
- 5 (b) A sequence substantially homologous to or that hybridises to sequence (a) under stringent conditions; or
- (c) A sequence substantially homologous to or that hybridises under stringent conditions to the sequence (a) or (b) but for the degeneracy of the genetic code; or
- (d) An oligonucleotide specific for any of the sequences (a), (b) or (c).

10

The present invention will now be further described with reference to the accompanying Figures, in which:

Figure 1 shows three different cDNAs encoding apopholasin, referred to as clones 40, 3
15 and 5. Nucleotides in bold type show codons used for initiation and termination of translation;

Figure 2 shows the three sequences of Figure 1 aligned to demonstrate the sequence
similarity. This figure was generated by Clustal. Positions which are indicated with a
20 star are identical in all three clones. The codons for the initiation and termination of translation are highlighted in bold;

Figure 3 shows the oligonucleotides used for the complete sequencing of the positive
clones. These were identified from the cDNA library; their positions in clone 40 are
25 shown. Oligonucleotides are shown in bold type, portions of the flanking sequence of the Bluescript plasmid are shown in italic type;

Figure 4 describes the protein sequence described by the DNA sequence coding for
apopholasin and shows, in Figure 4A, the complete sequence of the positive clone 40
30 identified from the *Pholas dactylus* light organ library. The first 20 amino acids at the N-terminus are a signal peptide, and this can either be retained or removed when generating the BIOP as described in this invention and, in Figure 4B, the cDNA coding for apopholasin with untranslated 5' and 3' ends. The untranslated regions are also shown;

Figure 5 describes the protein sequence for pholasin with (5B) and without (5A) the signal peptide;

- 5 Figure 6 shows the sequence for apopholasin genomic DNA. Two gDNA clones were indentified but no introns were found; the Figure shows an alignment of the cDNA from cDNA clone 40 and the gDNA amplified by both *rTth* DNA polymerase XL and BioXAct polymerase. The sequences of the PCR product and the inserts in pGEM T were aligned with the sequence of the cDNA of clone 40 and were identical to this cDNA;
- 10 Figure 7 describes the oligonucleotides used for screening and expression. Degenerate oligonucleotides for library screening are shown in Figure 7A; non-degenerate ones in Figure 7B; and oligonucleotides used for protein expression are shown in figure 7C;
- Figure 8 lists the main restriction sites in the DNA for engineering pholasin;
- Figure 9 is a schematic representation of Figure 8 mapped to the sequence of Figure 4A
- 15 (translated region), and
- Figure 10 is a time course of hypo-chlorite triggered chemiluminescence.

Accordingly, the present invention provides recombinant DNA encoding the apophotoprotein apopholasin and comprising the nucleotide sequence of the sequence

20 disclosed in Figure 4B. Three different cDNAs coding for apopholasin have been isolated, having differing non-coding regions, respectively disclosed in Figure 1. The genomic DNA (gDNA), which contains no introns, has been shown (Figure 6) to comprise the same basic sequence as the cDNA.

Pholasin is a glycoprotein having 11.1 glusamine, 9.8 fructose, 7.1 mannose and 5.2

25 galactose residues. The cDNA for apopholasin has a molecular weight of 23,456 compared to 34,600 of the pholasin extracted from *Pholas*. The difference in the molecular weights of native versus recombinant apopholasin is due to the glycosylation of the native protein and luciferin. The isoelectric point of the translated protein calculated by the ISOELECTRIC command of the GCG programme is at 3.84. The native protein

30 has a lower isoelectric point (<3.5), probably due to the presence of bound sulphate.

The three clones (Figure 2) isolated from the library encode a unique protein (Figures 4 and 5), which does not have the same amino acid sequence as any known protein in the SwissProt database. The present invention therefore not only provides cDNA and RNA

coding for the protein, but also the recombinant protein *per se*, with or without glycosylation units. A comparison of segments of the pholasin protein sequence with the proteins in the SwissProt database identified several proteins with regions having a high sequence similarity to regions of the cloned protein. These included several proteins which interact with nucleotides (Table 1).

Table 1 *A comparison of sections of the sequence of the cloned protein with sections of proteins which interact with nucleotides.*

Protein	Homologous region cloned protein homology (+ denotes a conserved amino acid) selected protein
tRNA-splicing endonuclease β subunit <i>Saccharomyces cerevisiae</i> EC 3.1.27.9	SLYDEDNNGVMDEGKVIPSETIE +L DEDNN + + G ++P E++E NLRDEDNNLLDENGDLLPLESLE LDQDVELDYTEW LD DV DYTEW LDHDSKDYTW
ATP-AMP transphosphorylase <i>Cyprinus carpio</i> EC 2.7.4.3	VMDEGKVIPSETIEDDIKDCGLLDQDVELDY +M +G+++P +T+ D IKD + DV Y IMQKGELVPLDTVLDMIKDAMIADVSKGY
DNA primase <i>Synechocystis sp.</i> EC 2.7.7. -	EEVQCAMNWTQANEYVFENV ++VQ M ++Q+ + +FN D DQVQSLMRFSQSKQIIFNFD
purine permease <i>Emericella nidulans</i>	VQCAMNWTQANEYV + C+++WT+ N ++ IMCSVDWTRRNRFI
DNA repair protein complementing XP-A cells homologue <i>Drosophila melanogaster</i>	PDTVDEAEDTPSET PDT DE EDT + T PDTYDEEEDTYTHT
ATP synthase β chain <i>Peptococcus niger</i> EC 3.6.1.34	DTVDEAEDTPSET D +DEA + PSET DPIDEAGEVPSET
DNA polymerase α <i>Homo sapiens</i> EC 2.7.7.7	DEDNNGVMDEGKVIPSETIEDDIKD D+D G +++G+ I + +EDD D DDDGIGYVEDGREIFDDLEDDALD

Similarity was found between the *Vargula* luciferase and *Renilla* LBP, but no other bioluminescent protein.

Sequence homology between the cloned protein and (a) *Vargula* luciferase (b) *Renilla* LBP. An area of high homology in all three proteins is in bold print.

5
 (a) 148 206
 GTIVVTV**VRVSLY**DEDNNGVMDEGKVIPSETIEDDIKDCGLLD-QDVELDYTWQNECDL
 V+VSL D + + + T+ D I D + V++ + +
 YWNTWDV**KVSLRD**VESYTEVEKVTIRKQSTVVDLIVDGKQVKVGGVDVSI PYSSSENTSI
 10 353 412
 (b)
 105 166
 STMPGTYYMLMDVCATRDADDKCI EGTIVVTV**VRVSLY**DEDNNGVMDEGKVIPSETIEDDIKDC
 + TR + **VR+S+** + N+ K I
 15 AIKIAKLSAEKAEETRGLRVADQLGLAPGV**RI**SVEEAAVNATDSLKKMAEEKAMAVIQSL
 41 104

Three potential glycosylation sites on the protein have the consensus triplet sequence Asn-Xaa-Ser/Thr (where Xaa can be any residue except proline). Thr 216 was identified as a potential site of O-linked glycosylation by a neural network which has been trained to identify this type of glycosylation. The amino acid sequence was also entered into a neural network which had been trained to identify eukaryotic signal peptides. This confirmed that the most likely cleavage site is between positions 20 and 21 (GSG-EE).

25 Many families of proteins contain a "signature" sequence of amino acids. The sequence of the clones did not contain any of these signatures present in the PROSITE database. The amino acids from 170 to 185 correspond to the calcium binding consensus sequence [DENQST]X[DENQST]X[DENQST]X[DENQST]X[DENQST]XX[DENQST]. Thirteen potential phosphorylation sites were discovered that matched the consensus sequences for either the kinase phosphorylation site [RK](2)-x-[ST], the protein kinase C phosphorylation site [ST]-x[RK] or the casein kinase II phosphorylation site [ST]-x(2)-[DE].
 30

Three N-linked glycosylation sites were identified in the translated sequence of the clones A neural network has been trained to identify this type of glycosylation which identified Thr

216 as a potential site of O-linked glycosylation. At least one of these sites must be glycosylated in the native protein in order to account for the presence of the sugar residues. A putative signal peptide region preceded the N terminus of the secreted protein (determined by amino acid sequencing and was identified as a signal peptide by a neural network). To confirm this result the protein sequence was searched with PSORT for motifs which would locate the cloned protein in a cellular compartment. The protein sequence did not contain any transmembrane regions or N-myristoylation patterns which would indicate the presence of a lipid anchor. No targeting or retention sequences were found for the nucleus, mitochondria, endoplasmic reticulum or peroxisome.

10

The fact that the clones had some sequence similarity with proteins that interact with nucleotides may suggest that pholasin binds a co-factor as part of the chemiluminescent reaction. Beetle luciferases require ATP binding for chemiluminescent activity. There is no P-loop binding motif ((A,G)x4GK(S,T) or (A)x{4}GK(T)) in the amino acid sequence of these clones. However, not all ATP binding proteins contain this motif. Neither does the cloned protein contain the GXGXXG phosphate binding consensus sequence necessary for the binding of other co-factors such as nicotinamide adenine dinucleotide.

15

The amino acid and sugar components of pholasin are not able to emit light at the wavelength of the native protein (490nm). This indicates that there must be a chromophore bound to the protein. There are, however, proteins in which the chromophore is composed of modified amino acid residues within the polypeptide. The best characterised of these is the green fluorescent protein (GFP). This has a chromophore which is a ring formed by the autocatalytic cyclisation of the residues Ser-dehydroTyr-Gly. The serine may be mutated to a threonine, which increases the amplitude of the emission at 488nm. Pholasin had no similar amino acid sequence. Putative luciferin binding regions have been identified for two bioluminescent chemistries. Aequorin has a putative coelenterazine binding region, which is also present in two sections of the *Vargula hilgendorfii* luciferase. The sequence of the cloned protein has no homology to the putative luciferin binding site of aequorin, but the region of the *Vargula* luciferase from residue 353 to 411 has some similarity, as does the LBP of *Renilla reniformis*, which also binds an imidazolopyrazine. This may indicate that the chemistry of pholasin bioluminescence involves an imidazolopyrazine luciferin. However, the region of homology is very small. The beetle luciferases contain an area of

20

25

30

low sequence homology which may bind the benzothiazole luciferin. This low homology may account for the different colours of beetle bioluminescence. used a luciferin analogue (2-(4-benzoylphenyl) thiazole-4-carboxylic acid which photoinactivated the luciferase active site of the firefly *Photinus pyralis*. This photoinactivation was directly linked to the degradation of a small peptide sequence HHGF (residues 244-257). This is therefore postulated as a luciferin-binding site. The cloned protein does not have any sequence homology with these putative binding regions. Two strongly conserved regions of amino acids have also been found in both the luciferase and the luciferin binding protein of the dinoflagellate *Gonyaulax polyedra*. These regions were compared to the cloned protein, but no sequence similarity was found. No sequence identity could be established between the bacterial luciferases and the cloned protein.

Therefore, the present invention provides cloned apophotoprotein apopholasin (and the cDNA coding therefor), which has identical properties to native (but non-glycosylated) apopholasin with respect to molecular weight, amino acid composition, potential for glycosylation, its highly acidic pI and its cellular location. Hence, the present invention can further provide the corresponding BOIP or modified BOIP, according to standard methods.

The corresponding BOIP is preparable by bringing the apophotoprotein pholasin into association with the luciferin, also using standard methods. Although the luciferin is tightly bound in the native pholasin BOIP, it has been found that it may not be the case in the recombinant pholasin BOIP; indeed the luciferin may be weakly bound or merely present with the apoprotein. For example, a methanol, aqueous, acidic or other extract of *Pholas dactylus* (whole organism or light organ dissected from the animal) containing the 'luciferin', or the pure luciferin, may be added to the solution, cell or organism (Figure 10 shows the time course of hypo-chlorite triggered luminescence in these circumstances). A time course of apopholasin reactivation was performed by incubating partially purified recombinant pholasin secreted by insect cells with acid:menthanol extract of *Pholas dactylus* (●) for 0 (solid line), 1 (---), 2 (-- —), 6(- —) or 24 hours (— —), or incubated without extract (o). Controls of buffers only with no protein or acid:menthanol extract () and extract alone (■) were treated in identical conditions. Chemiluminescence was

triggered by the addition of 2% sodium hypochlorite at 10 seconds (arrow) and is shown as chemiluminescent counts minus background light. A typical curve obtained by hypochlorite triggering of native pholasin is also shown (X). A representative experiment carried out in duplicate is shown.

5

The luciferin associates with the apo-BOIP forming the photoprotein or remains loosely bound so that it turns over like a luciferase.. The luciferin on the photoprotein then reacts with oxygen or one of its metabolites to produce light, in the presence or absence of the luciferase. The light emission may be detected, quantified, or imaged using a
10 luminometer, photographic film or imaging camera, or by the naked eye. Alternatively, light emission may be generated spontaneously by intra- or extra-cellular metabolites reacting with the apo-BOIP.

Although illustrated with respect to pholasin, the following may apply to any BOIP: the
15 BOIP can be produced directly from native DNA, or from DNA engineered or amplified by the polymerase chain reaction. By this means, sites can be inserted within the protein by splitting the DNA into two or more pieces, or by adding DNA sequences to the 5' or 3' ends. For example, the DNA may be expressed in bacteria, yeast, an insect or human cell, or other suitable organism to produce protein which can be extracted and used.

20

In this instance, the protein produced from the cloned DNA reacts with oxygen or a metabolite of oxygen, such as the superoxide anion (O_2^-), hydrogen peroxide (H_2O_2), hydroxy radical (OH^\cdot), an oxyhalide anion (OCI^- , OBr^- , OI^- , $OSCN^-$), nitric oxide (NO), an organic hydroperoxide or a radical ROO^\cdot . The change in light emission enables the
25 oxygen or metabolite(s) to be detected and quantified in live cells, organelles, or on the outer or inner surface of the plasma membrane, or within an organ of a live organism without the need to break them open or the need to separate bound and free fractions. This also enables an enzyme producing oxygen or one of its metabolites, such as chlorophyll, or enzymes such as oxidases and oxygenases which react directly with
30 oxygen or one of its metabolites to attach oxygen to the substrate to be detected and quantified in live cells, organs and whole organisms, or extracts from any one of these.

Also the BOIP can be made *in vitro* by transcription/translation in a cell lysate such as

rabbit reticulocyte lysate or wheat germ extract containing RNA polymerase. The DNA for the BOIP is first engineered to contain an RNA polymerase promoter, such as T7, SP6; bacterial promoter(s), such as lac, ara or trp; or mammalian promoter(s), such as actin, myosin, myelin proteins, TK, MRT-V, SV40, CMV, RSV, metallothionine, antibody, G6P dehydrogenase, and can be amplified *in vitro* using the polymerase chain reaction. A poly-A tail may be added at the 3' end and a tissue specific promoter or enhancer sequence added to the 5' or 3' end of the DNA coding for the BOIP or modified BOIP, enabling it to be expressed specifically in a target cell, such as a myocardial cell or a cancer cell. The expression of the BOIP in the target cell is detected and quantified by light intensity, colour or polarisation, as previously mentioned.

The BOIP, or its DNA or RNA, may be incorporated into a live bacteria or eukaryotic cell using phage, virus, plasmid, calcium phosphate transfection, electroporation, liposome fusion, membrane pore forming proteins, micro-injection or DNA gun. Once inside cells or an appropriate extracellular environment, cell activation or injury will initiate or change the light emission from the BOIP. For example, expression in live organisms by micro-injection of protein, RNA or DNA, or by transgenic manipulation to produce a cell, such as a bacterial, microbial, animal or plant cell, *eg* a white blood cell, a heart cell, or a yeast, protozoan, fruit fly (*Drosophila*), nematode worm, polychaete worm, fish, human, mouse, rat, sheep, pig, horse or plant, which can generate its own light.

The BOIP can also be incorporated into a defined part of a live cell by chemical means or by genetically engineering the BOIP to contain a signal peptide, which locates the BOIP to the inner or outer surface of the plasma membrane or within a particular organelle, such as peroxisome, mitochondrion, chloroplast, tonoplast, endoplasmic, reticulum, Golgi apparatus, endosome, lysosome, secretory vesicle, nucleus, nucleolus, nuclear membrane, plasma membrane, proteosome, or gap junction, or structure such as membrane receptor ion channel microtubule, cytoskeleton, nuclear skeleton, nuclear receptor, mitotic spindle or microfilaments. The signal peptide, added either chemically or genetically, will normally target the normal or modified BOIP to a particular intra- or extra-cellular site. For example, the sequence MLSRLSLRLLSRYLL or part of cytochrome oxidase on the N-terminus will target the BOIP to the mitochondrion; KKSALLALMYVCPGKADKE

or MLLPVPLLGLLGLAA at the N-terminus will target the BOIP to the endoplasmic reticulum, a KDEL or HDEL or KEEL sequence at the C-terminus retaining it there. SKL at C-terminus targets BOIP to the peroxisome; PKKKRKV or an extension of this SV40 large T-antigen signal will target it to the nucleus; and a palmitoylation and/or a myristoylation signal will target it to the plasma membrane. By coupling the BOIP to another protein that targets itself to a particular site, the BOIP can also be targeted there. For example, coupling the nuclear proteins nucleoplasmin or lamin B receptor to BOIP targets it to the nucleus; cytochrome oxidase at the N-terminus targets BOIP to the mitochondria; chlorophyll at the N-terminus targets BOIP to the chloroplast; a connexin at the N-terminus targets BOIP to the gap junction or plasma membrane; and SNAP 25 to the plasma membrane.

Other modifications to the apoprotein, BOIP, or nucleotides coding therefor include, but are not limited to:

15

The apoprotein, such as apopholasin, may also be glycosylated, and used to detect and quantify secretion or movement of proteins through the secretory pathway.

Nucleic acid coding for the BOIP when expressed inside a live cell may not only be modified but also regulated in this cell by gene expression, such as by promoters, enhancers or oncogenes. For example, the apoprotein, such as apopholasin, may be coupled to a gene regulator protein, such as a transcription factor, by genetic or chemical manipulation, such that the movement through a cell or of the regulator protein or its activity, can be detected or quantified.

25

The BOIP or apoprotein, or its DNA may be linked to another protein or DNA used in therapy, such that the other protein or DNA can be detected in live cells or in a whole organism, *eg* a human.

30 The apoprotein, such as apopholasin, can also engineered genetically or chemically to contain a site or sites which can be covalently modified by enzymes such as phosphorylation (including ser/thr, his and tyr kinases and phosphatases), transglutamination, proteolysis, ADP ribosylation, gly- or glu-cosylation, halogenation,

oxidation, methylation, palmitoylation, myristylation and farnesylation.

The apoprotein, such as apopholasin, can be engineered genetically or chemically to contain an antigen or intracellular signal binding site, such as Ca^{2+} , cyclic AMP, cyclic
5 GMP, cyclic CMP, IP_3 , IP_4 , diacyl glycerol, ATP, ADP, AMP, GTP, or any oxy- or deoxy-ribose nucleoside or nucleotide, a substrate, a drug, a nucleic acid and/or a gene regulator protein.

The BOIP may also be converted to a rainbow protein by engineering a particular site
10 such as described hereinabove into the BOIP, at the N- or C-terminus, or between a chimera of the BOIP and an energy transfer acceptor, such as GFP (wild type or any of the mutant GFPs). This is known as chemiluminescence, bioluminescence or fluorescence resonance transfer (CRET, BRET or FRET, respectively). Conversion of the BOIP to a 'rainbow protein' may be effected by reaction with a cellular substance,
15 modification genetically or chemically, or by linking the BOIP to a fluor, such as the green fluorescent protein or the red fluorescent protein in the deep sea fish *Malacosteus*. The result is a BOIP which changes its colour and/or intensity and/or polarisation of emission. The change in colour occurs by energy transfer, *eg* resonance transfer (CRET or FRET) or electron transfer.

20

The initial (unmodified) BOIP may be the apophotoprotein, its DNA or RNA, from the bivalve mollusc *Pholas dactylus*, or it may be another BOIP, such as one from the mollusc *Rocellaria grandis* or the squid *Ommastraphes*, or earthworm luciferase, which produce light with oxygen metabolites in a way very similar to *Pholas dactylus*.

25

The BOIP, apo-BOIP, or nucleic acid coding for it, whether modified or not, may therefore be used in a range of biology and investigations such as:

- (a) Detection, location and measurement of signals in substrates, such as live cells,
30 organs or organisms, or in extracellular fluids;
- (b) Detection, location and measurement of oxygen and its metabolites in substrates, such as live cells, organs or organisms, or in extracellular fluids, water (sea and fresh), soil or the atmosphere;

- (c) Detection and location of normal cells such as microbes (protozoa, yeast, fungi, moulds, bacteria, viruses);
 - (d) Detection and location of abnormal cells, such as cancer cells, hyperactive cells in rheumatoid arthritis and other inflammatory diseases, cells infected with a pathogen, such as a virus or other infectious agents, cells damaged by physical, chemical or biological attack, cells damaged by perfusion or reperfusion injury or cells damaged by oxygen or one of its metabolites;
 - (e) Measurement and location of enzymes, particularly those producing oxygen or its metabolites, and other tumour reactions in cells or biological fluids;
 - (f) DNA and RNA binding assays;
 - (g) Immunoassay and other protein binding assays;
 - (h) In genetic engineering, in the development of transgenic animals and plants, and microbes; in horticulture; agriculture; medicine and veterinary medicine; and/or
 - (i) in genetic entertainment by incorporation into light sticks, greeting cards or toys to produce light of various colour, intensities, oscillations, flashes and glows; or in comestibles, such as food, drinks, including beers, wines, spirits, colas and other soft drinks.
- Accordingly, the present invention further provides an apoprotein, such as pholasin apoprotein (or apopholasin) in both unglycosylated and glycosylated forms, and a BOIP thereof, such as pholasin, either alone (but excluding native proteins *per se* that have already been isolated, such as native pholasin *per se*) or in association with one or more of: a targeting or signal peptide; a glycosylate; a site capable of modification by an enzyme; an antigen or intracellular signal binding site; a promoter, an enhancer or an oncogene or a pharmacologically active substance; or the like. The present invention further provides a recombinant construct comprising a nucleic acid sequence encoding for any of these proteins; a vector containing a nucleic acid sequence encoding for any of these proteins; a host transformed by such vector; a live cell, such as bacterial, insect, eukaryotic, prokaryotic, archae or plant cells containing or expressing any of these proteins; and a rainbow protein, as described herein, together with a nucleic acid sequence encoding therefor.

The present invention will now be illustrated with reference to the following non-limiting examples, in which the methodology referred to is known to those skilled in the art and/or may be carried out by analogy with reference to the protocols disclosed in the following references, the contents of which are herein incorporated by reference in their entirety:

5 **BOOKS**

1. Campbell,AK. (1988). Chemiluminescence: principles and applications in biology and medicine, pp608. Horwood/VCH, Chichester and Weinheim.
2. Campbell,AK. (1994). Rubicon: the fifth dimension of biology. pp 304. Duckworth, London.

10 **PAPERS**

1. Campbell,AK Patel,A. (1983) Biochem J. 216:185-194. A homogeneous immunoassay for cyclic nucleotides based on chemiluminescence energy transfer.
2. Roberts,PA Knight,J Campbell,AK. (1987) Anal. Biochem. 160:139-148. Pholasin - a bioluminescent indicator for detecting activation of single neutrophils.
- 15 3. Mueller,T Davies,EV Campbell,AK. (1989) J. Biolum. Chemilum. 3:105-113. Pholasin Chemiluminescence Detects Mostly Superoxide Anion Released from Activated Human Neutrophils.
4. Mueller,T Campbell,AK. (1989) J. Biolum. Chemilum. 5:25-30. The Chromophore of Pholasin: A Highly Luinescent Protein.
- 20 5. Sala-Newby,G and Campbell,AK (1991) Biochem.J. 279:727-732. Engineering a bioluminescent indicator for cyclic AMP dependent protein kinase .
6. Campbell, AK, Trewavas, AJ and Knight, MR (1996). Calcium imaging shows differential sensitivity to cooling and communication in luminous transgenic plants. Cell Calcium 19: 211-218.
- 25 7. Kendall, JM, Sala-Newby, G Badminton, M, Campbell AK and Rembold, CR (1996). Free Ca^{2+} in the endoplasmic reticulum of living cells measured using aequorin as a pseudo luciferase. Biochem.J 318:383-387
8. Badminton, MN, Campbell, AK and Rembold, CR (1996). J.Biol. Chem. 271:31210-31214. Differential regulation of nuclear and cytosolic Ca^{2+} in HeLa cells.
- 30 9. Sala-Newby, GB, Taylor, KT, Badminton, MN, Rembold, CR and Campbell, AK (1998). Imaging bioluminescent indicators shows Ca^{2+} and ATP permeability thresholds in, live cells attacked by complement. Immunology. 93:4:601-609
- 10.Sala-Newby, GB, Kendall, JM, Jones, H, Taylor, KM, Badminton, MN, Llewellyn, DH and Campbell, AK (1999). Targeting bioluminescent proteins to defined
35 compartments fo living cells. Methods in Enzymology Bioluminescence and Chemiluminescence. ed Ziegler, M and Baldwin, T.

EXAMPLE 1: Production of a BOIP in bacteria

c or genomic DNA coding for apopholasin, with or without the cDNA coding for the signal peptide, is amplified by PCR with restriction sites such as BamHI at each end. The cDNA
5 is run on an agarose gel and the full length DNA eluted and purified. The DNA is then cut with BamHI to generate sticky ends and ligated into an expression plasmid such as pET3a, which has been cut with BamHI also. After ligation the sealed plasmid is transformed into a standard *E.coli* K12 strain such as JM109, a colony picked off for a large plasmid preparation. After checking that the plasmid contains the correct sequence for apopholasin
10 and is in the correct orientation the plasmid is then used to transform a standard expression strain of *E.coli* such as BL21(DE3) or other expression strain. A colony is picked off the agar plate and grown up for 2h in standard LB broth. IPTG is added as inducer for a further 2h. Apopholasin can then be extracted by breaking the bacteria by lysozyme digestion or sonication in a standard salt medium such as 50mM HEPES pH 7 +/- 1mM ascorbate. Since
15 the apopholasin is unglycosylated it tends to aggregate and form inclusion bodies. These can be broken using 8M urea or guanidinium chloride and these then dialysed off. If the pH of PAGE gels is alkaline this also tends to allow aggregation of both the unglycosylated and glycosylated apo- and full pholasin. A signal peptide such β -lactamase signal will target the BOIP to the periplasmic space, resulting in the ability to secrete the expressed protein from
20 the external fluid of the cells.

EXAMPLE 2: Production of a BOIP in insect cells

c or genomic DNA coding for apopholasin is inserted into a plasmid suitable for
25 conversion into baculovirus when transfected into insect cells. Since pholasin is secreted by *Pholas* itself there is a signal peptide at the N-terminus. Removal of this by PCR will allow cytosolic expression in insect cells. If the signal peptide is left on or changed for honey bee mellitin signal peptide, the apopholasin is secreted into the external medium. The virus containing the DNA for apopholasin is then purified and stored until required.
30 An aliquot is then added to fresh insect cells and these incubated for 3-7 days. The apopholasin is then isolated from the supernatant if a signal peptide is used, or from the cells if not. The apopholasin can then be purified by ammonium sulphate precipitation, gel filtration and DEAE chromatography. The state of glycosylation can be assessed by

running the protein on PAGE when the molecular weight is 34Kda. Removal of the glycosylation by enzymes returns the protein to the size of apopholasin 23.5Kda. It can be stored frozen or freeze dried, and activated to form pholasin by addition of luciferin as described in Example 3.

5

Since the apopholasin tends to aggregate in the insect supernatant it is important to get the protein into non-aggregating buffer, e.g. 50mM HEPES pH 6, 1-10mM ascorbate, as soon as possible.

10 Formation of pholasin can then be achieved as described in Example 3.

EXAMPLE 3: Generating pholasin and light emission

To generate light the apopholasin must first be converted into pholasin with the luciferin.

15 The luciferin can be extracted from native pholasin by mild acid, or by methanol, mild acid or alkaline treatment of light organs isolated from *Pholas dactylus* or the whole organism. After homogenisation the extract is centrifuged or filtered to remove particulate material. Further purification can be achieved by tlc of hplc. The luciferin is best stored dry, but can be stored at -70°C. The intactness and concentration can be
20 estimated by measuring the absorbance or fluorescence. The details are as follows:

(a) Isolation of the luciferin

Four protocols (1-4) have been developed to extract and isolate the luciferin responsible for light emission in pholasin. The luciferin is a small organic moiety
25 tightly bound to apopholasin when pholasin is isolated from *Pholas dactylus*, but also can be found not bound to apopholasin. Thus the extraction procedure isolates either form of luciferin.

1. The organism *Pholas dactylus* or its light organs are homogenised in 50mM sodium phosphate pH 6.0 on ice. The pholasin is precipitated with
30 saturated ammonium sulphate (4°C stirred), and then removed by centrifugation at ca 15,000g for 30min in the cold. The supernatant is then passed down a SEP-PAK silica column, which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The

active fractions containing the luciferin are assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl. The luciferin is concentrated and can be purified further on tlc or hplc with a standard solvent. It is dried and stored at -70°C.

- 5 2. The organism *Pholas dactylus* or its light organs are homogenised in cold acetone on ice, filtered through a Buchner funnel, and extracted with methanol:acetone (1:1), the residual powder being extracted 3 times with methanol and extracts combined. These are then concentrated in a Rotavaporator and left to stand for 1h on ice to allow further precipitation.
10 The suspension is then refiltered and concentrated. The solution containing the luciferin is then passed down a SEP-PAK silica column which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The active fractions containing the luciferin are assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO,
15 DMF, or NaOCl. The luciferin is concentrated and can be purified further on tlc or hplc with a standard solvent. It can be dried and stored at -70°C.
3. The organism *Pholas dactylus* or its light organs are homogenised in cold acetone on ice, and filtered through a Buchner funnel to give an acetone powder. This is then extracted with methanol:acetone (1:1), twice for
20 10min and then 3 times with methanol. The extracts are combined and concentrated in a Rotavaporator. They are left to stand for 1h on ice to allow further precipitation, refiltered and concentrated. The residual powder is resuspended in 50mM sodium phosphate pH 6.0, 10mM ascorbate, and ultrafiltered with a 10kD Amicon membrane at 4 C for
25 pholasin. The solution containing the luciferin is then passed down a SEP-PAK silica column which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The active fractions containing the luciferin assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl. The luciferin is
30 concentrated and can be purified further on tlc or hplc with a standard solvent. It is dried and stored at -70°C.
4. The organism *Pholas dactylus* or its light organs are homogenised in 50mM HEPES buffer, with methanol and 100mM HCl on ice, and

incubated for 2h on ice. After centrifugation at *ca* 15,000g for 30min in the cold, the supernatant is then passed down a SEP-PAK silica column which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The active fractions containing the luciferin are assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl. The luciferin is concentrated and can be purified further on tlc with a standard solvent. It is dried and stored at -70°C.

Method 4 normally generates most luciferin. The luciferin is characterised by its absorbance and fluorescence spectrum, and by its chemiluminescence with DMSO, NaOCl and apopholasin.

(b) *Generation of pholasin from apopholasin and the luciferin*

A small sample of the luciferin (1-10µl) is added to apopholasin in an appropriate buffer (50mM HEPES pH 6-7.5, +/- 0.1% gelatine, +/- 1-10mM ascorbate, or 500mM NaCl, 10mM TES, 1mM EDTA, 1mM mercaptoethanol pH 6-7.5). The mixture is incubated at room temperature for up to 24h, and the pholasin assayed by adding an oxygen metabolite, e.g. NaOCl, or luciferase to a sample. When apopholasin has been expressed in cells, the luciferin is added externally, microinjected into individual cells or added via liposomes to get the luciferin into the cell.

Light is detected and quantified in a standard luminometer, imaging camera (intensified or CCD), or by a silicon chip.

EXAMPLE 4: Production of a BOIP in vitro

c or genomic DNA coding for apopholasin, with or without the signal peptide, is amplified by PCR with the 5' primer containing the DNA coding for T7 RNA polymerase. The DNA product is purified and precipitated. After dissolving in 10mM tris/1mMEDTA pH7, the DNA is added to a standard *in vitro* transcription/translation system such as rabbit reticulocyte lysate or wheat germ agglutinin and incubated at 30°C for 30-60min. The apopholasin can then be purified and activated to form pholasin as described in Example 3.

EXAMPLE 5: Targeting a BOIP in vitro

The BOIP can also be incorporated into a defined part of a live cell by chemical means or by genetically engineering the BOIP to contain a signal peptide which locates the BOIP to the inner or outer surface of the plasma membrane or within a particular organelle such as peroxisome, mitochondrion, chloroplast, tonoplast, endoplasmic reticulum, Golgi, endosome, lysosome, secretory vesicle, nucleus, nucleolus, proteosome, or gap junction, or structure such as microtubule, cytoskeleton, nuclear skeleton, nuclear receptor, or mitotic spindle. The signal peptide, added either chemically or genetically, will normally target the normal or altered BOIP to a particular intra- or extra-cellular site for example, the sequence MLSRLSLRLLSRYLL or part of cytochrome oxidase on the N-terminus will target the BOIP to the mitochondrion; KKSALLALMYVCPGKADKE or MLLPVPLLLGLLGLAA or the ER protein calreticulin at the N-terminus will target the BOIP to the endoplasmic reticulum, a KDEL or HDEL sequence at the C-terminus retaining it there. SKL at C-terminus targets BOIP to the peroxisome, PKKKRKV or an extension of this SV40 large T-antigen signal will target it to the nucleus, and a palmitoylation and/or a myristoylation signal (MGCVCSSNPD = the LCK N-terminal acylation motif from tyrosine kinase) will target it to the plasma membrane. By coupling the BOIP to another protein which targets itself to a particular site then the BOIP is also targeted here. For example, coupling the nuclear proteins nucleoplasmin or lamin B receptor to BOIP targets it to the nucleus; cytochrome oxidase at the N-terminus targets BOIP to the mitochondria; chlorophyll at the N-terminus targets BOIP to the chloroplast; and a connexin at the N-terminus targets BOIP to the gap junction or plasma membrane, SNAP 25 to the plasma membrane.

25

In order to target pholasin to defined sites in living cells, the DNA coding for these targeting sequences are added by using PCR. For cytosolic apopholasin the native signal peptide is removed and also the BOIP can be linked to larger proteins at the N- or C-terminus such as firefly luciferase or aequorin to prevent it getting into the nucleus. This also enables ATP and oxygen metabolites, or Ca^{2+} and oxygen metabolites to be measured simultaneously in the same cells by intensity, colour or polarisation of the different bioluminescent indicators. A multiple bioluminescent indicator can also be engineered by PCR, or by using restriction enzyme sites, from the DNA coding for 3 or more

30

bioluminescent proteins. A simple screen of the transformed bacteria enables the multiple rainbow protein to be isolated with 2-3 colours or more.

The DNA is then added to an *in vitro* transcription/translation system as described in
5 Example 4 in the presence of the organelle to be targeted (e.g. microsomes for the endoplasmic reticulum, which glycosylate apopholasin).

The new DNA can also be inserted into a plasmid by standard techniques, and transformed into bacteria or transfected or injected into eukaryotic cells such as HeLa or
10 COS.

Addition of the luciferin as described in Example 3 allows formation of pholasin which can then be detected by light emission. Changes in oxygen metabolite production are then be detected by a luminometer or imaging camera when the cells are exposed to external
15 oxygen metabolites, a change in oxygen concentration, addition of stimuli e.g. TNF, EGF, hormones or drugs, or attack by pathogens such as bacteria, viruses, complement, antibodies, toxins, and cells of the immune system.

EXAMPLE 6: Engineering a covalent modification site into a BOIP

20 (a) The site coding a protein kinase A (RRAS or kemptide), protein kinase C (MARCKS), MAP kinase, ERK, the ER - nuclear signalling kinase IRE1P or a phosphatase is added to the N- or C-terminus or inserted at various sites within the apopholasin by PCR and expressed as described in Examples 1-5. Pholasin is
25 then generated by addition of the luciferin as described in Example 3.

Addition of the catalytic subunit for protein kinase A, or activation via cyclic AMP inside cells, leads to phosphorylation or dephosphorylation of the modified pholasin and change in light emission (intensity, colour or polarisation).

30

A preliminary screen is necessary to select the appropriate proteins and to discard any which have lost all activity.

- (b) The site coding a protease (thrombin, enterokinase, HIV protease, caspase) is added to the N- or C-terminus of the apopholasin by PCR or inserted at various sites within the protein, and expressed as described in Examples 1-5. Pholasin is then generated by addition of the luciferin as described in Example 3.

5

EXAMPLE 7: Engineering a BOIP into a "Rainbow Protein"

- cDNA coding for apopholasin is linked to another protein by using the cDNA coding for that protein. For example, wild type GFP, the S65T mutant of the green fluorescent protein, YGFP, or EGFP are linked to apopholasin by PCR at the N- or C-terminus, or by splitting one or both proteins using multi-step PCR. In between there is a 'reactive' peptide with a protease site (α thrombin or enterokinase) and a binding site for IP_3 , or the 15 amino acid sequence form IP_3 kinase (an IP_4 binding site). At the C-terminus of the GFP, a peptide containing 6 lysine residues may also be added via PCR. The protein is expressed and fluorescein covalently linked to these lysines by addition of fluorescein isothiocyanate. Addition of the luciferin forms pholasin as described in Example 3. The change in colour occurs by chemiluminescence resonance energy transfer. Without fluorescein the rainbow protein emits blue-green light (508nm), which changes to blue (490nm) when the reactive substance binds to the reactive peptide, or when either thrombin or enterokinase is added. When the 6 amino acid linker is used the colour starts as green (530nm), and will then change from green, to blue-green and then blue as the particular reactive sequence binds their respective analytes. Use of rhodamine instead of fluorescein generates a rainbow protein which changes from red to green to blue.
- A preliminary screen is necessary to select the appropriate rainbow proteins and to discard any which have lost all activity.

The other protein linked to apopholasin may be, for example, any one of the following linked chemically or genetically:

30

1. Firefly or any benzothiazole luciferase to the N or C terminus gives two colours for ATP and oxygen metabolites.

2. Any imidazolopyrazine luciferase, including coelenterazine systems - decapod shrimp, fish, squid, *Renilla*, anthozoan, Chaetognate, radiolarian, or copepod and *Vargula* systems - ostracod, *Porichthys* and similar fish, cyprinids and *Vargula*.
3. Any tetrapyrrole luciferase such as dinoflagellate, euphausiid or stomiatoid fish.
- 5 4. Bacterial luciferase and other aldehyde or flavin luciferases, including polychaete worm.
5. Any GFP, including wild type, S65T, enhanced GFP, blue GFP, yellow GFP, *Renilla* GFP, *Ptilocarpus* GFP, and *Pennatula* GFP, any anthozoan GFP, or any coelenterate GFP.
- 10 6. The red fluorescent proteins from stomiatoid fish - *Malactosteus*, *Aristostomias*, *Photostomias*.
7. The phycobiliproteins - phycoerythrin and phycocyanobilin.
8. The blue fluorescent lumazine protein in the bacterium *Photobacterium*.
9. The yellow flavin fluorescent protein in *Vibrio*.
- 15 10. Any lysine or arginine or other amino acid side chain where a fluor can be added covalently. In which the case the rainbow protein may emit more than two colours. For example, rhodamine on a pholasin-linker-GFP chimera will turn from red to green to blue.
- 20 A preliminary screen may be necessary to select chimeras which have not lost all bioluminescent activity.

The 'reactive' peptide may be a binding site for any analyte, protein or DNA, metabolite, substrate vitamin, an enzyme such as protein kinase C or phosphatase, ion channel, ion pump, antigen, antibody, nucleotide or nucleoside such as ATP, GTP, ADP, AMP, adenosine, cAMP, cCMP, cCCP or their deoxy equivalents, and inositol phosphates such as IP₃ or IP₄, a lipid such as diacyl glycerol, phosphatidyl inositol bisphosphate, phosphate, a cation such as Ca²⁺, K⁺ or Na⁺, Cu²⁺ or Zn²⁺, or anion such as Cl⁻, sulphate, or gas such as NO, O₂ or H₂, or a protein binding site such as calmodulin, kinesin, dynein, 25 tubulin, or myosin.

When pholasin is triggered by oxygen metabolites, the *Pholas* luciferase or peroxidase, energy transfer occurs from pholasin oxyluciferin through GFP to fluorescein resulting in

a yellow emission. Addition of thrombin for 3h cleaves the GFP-fluorescein from the pholasin and the light emission returns to the blue of native pholasin. Addition of IP₃ to the full chimera alters the efficiency of energy transfer. As a result there is a change in the ratio of light emitted in the yellow to blue. This ratio is directly related and can be plotted against the concentration or amount of analyte. The light is detected in a dual wavelength luminometer or ratiometric imaging camera and the ratio of blue to green light measured.

Alternatively any fluors can be used, and any binding sites with the right characteristics as shown in these examples will work provided a simple screen is used to select the right chimeras.

EXAMPLE 8: Engineering a BOIP into a "Rainbow Protein" for two analytes together

Apopholasin is linked to firefly luciferase by using cDNAs and PCR, followed by expression in insect cells as described in Example 2. Addition of the luciferin as described in Example 3 generates the pholasin. In the presence of firefly luciferin (1mM), ATP and oxygen metabolites, this chimera emits blue and yellow simultaneously which can be independently measured by using a dual wavelength luminometer or imaging camera.

EXAMPLE 9: Expression of BOIPs in mammalian cells

Apopholasin, c or genomic, in an expression plasmid with the CMV promoter, is transfected into HeLa cells. After incubation for 3 days to allow expression of the apopholasin, the luciferin is added to form pholasin. Expression is checked using a polyclonal antibody to pholasin raised in rabbits. Addition of oxygen metabolites outside the cell allows the permeability of the plasma membrane to oxygen metabolites to be assessed. As the oxygen metabolites permeate into the cytosol, the light emission increases.

EXAMPLE 10: Expression of BOIPs in plants

c or genomic DNA coding for apopholasin is inserted into a plasmid with the cauliflower mosaic virus promoter and transformed into *Agrobacterium tumefaciens*. These are then
5 added to a tobacco leaf, seedlings generated, and those expressing apopholasin selected. The plants are grown to seed, and seedlings grown from this seed. Addition of luciferin forms the pholasin as described in Example 3. Stressing the plant, e.g. with wind, touch, cold, or peroxide, or during growth and development or by a hormone, generates light, showing the formation of oxygen metabolites within the live plant. A cell-specific
10 promoter engineered on to the apopholasin cDNA before making the transgenic plant enables oxygen metabolites to be detected in specific cells within the whole, living plant.

EXAMPLE 11: Detection of oxidative damage in vitro

15 Addition of pholasin to serum or plasma from a rat, mouse or human enables oxygen metabolites to be detected and measured on addition of a drug or other substance of interest.

EXAMPLE 12: Detection of ROMs in a heart cells

20 Reperfusion has been proposed to lead to oxygen metabolite damage in cardiac myocytes. Pholasin allows this to be tested for the first time. Plasmid containing apopholasin cDNA and the CMV promoter is transfected into isolated cardiac myocytes in culture. Expression occurs within 1-3 days, and pholasin is formed by addition of the luciferin as
25 described in Example 3. Subjecting the cells to hypoxia followed by readmission of normal oxygen leads to light emission, showing that oxygen metabolites have been generated inside the cells. By using an imaging camera, the digital or analogue nature of this can be assessed as the number of cells emitting light can be visualised and counted.

EXAMPLE 13: Detection of ROMs in the nucleus and endoplasmic reticulum (ER)

Plasmid-containing apopholasin cDNA with either nucleoplasmin DNA or calreticulin DNA (with or without KDEL on the C-terminus) linked to the pholasin DNA, to target
5 the apopholasin to the nucleus or ER respectively, and the CMV promoter for expression, is transfected into HeLa cells in culture. Expression occurs within 1-3 days, and pholasin is formed by addition of the luciferin as described in Example 3. Addition of oxygen metabolites outside the cells, or hypoxic/oxygen shock generates light measured in a luminometer, showing how fast oxygen metabolites penetrate into these organelles. By
10 imaging with a photon counting imaging camera, the number of cells permeable to oxygen metabolites can be counted. Location of the pholasin can be assessed by imaging live cells, or by using immunofluorescence with the pholasin antibody on partially-fixed cells or GFP-pholasin in live cells. Using a rainbow protein, two or more analytes can be detected together.

15

EXAMPLE 14: Use of pholasin as a protein label

Pholasin can be used as a label in homogeneous or heterogeneous immunoassay. Apopholasin is first covalently linked to an antibody to HIV, and pholasin formed by
20 addition of luciferin as described in Example 3. The antibody is then used in a standard chemiluminometric immunoassay format. Addition of HIV antigen leads to an increase in antibody binding and an increase in light emission dependent on the amount of HIV added. The amount of HIV in a blood sample can be assessed by relating the pholasin light emission in the sample to the standard curve.

25

EXAMPLE 15: Pholasin as a DNA label

Apopholasin is covalently linked to an oligonucleotide probe for detecting the presence of the cystic fibrosis gene. Addition of the probe to DNA in a standard Southern blot allows
30 the probe to bind when the gene is present. Addition of luciferin as described in Example 3 allows the pholasin to form. Addition of hypochlorite (10mM) in barbitone buffer pH 9 causes the pholasin to flash and the gene can be visualised by the photon counting imaging camera.

CLAIMS

1. An isolated, purified or recombinant nucleic acid sequence comprising:
 - (a) a sequence that encodes the apophotoprotein of pholasin (alternatively,
5 'apopholasin');
 - (b) a sequence substantially homologous to or that hybridises to sequence (a) under stringent conditions; or
 - (c) a sequence substantially homologous to or that hybridises under stringent conditions to the sequence (a) or (b) but for the degeneracy of the genetic code; or
 - 10 (d) an oligonucleotide specific for any of the sequences (a), (b) or (c).
2. A sequence according to claim 1, wherein the sequence that encodes for apopholasin is as shown in Figure 4B.
3. A sequence according to claim 1, wherein the sequence that encodes for apopholasin is as shown in any one of Figures 1, 2, 3, 4A, 6 or 9.
- 15 4. A sequence according to any preceding claim, wherein the apopholasin is non-glycosylated.
5. A sequence according to any preceding claim, wherein the apopholasin is glycosylated.
6. An isolated, purified or recombinant construct incorporating a sequence encoding
20 apopholasin protein according to any preceding claim.
7. An isolated, purified or recombinant construct incorporating a sequence encoding an apophotoprotein whose expression in a substrate, in association with a luciferin therefor, signals the presence of oxygen or an oxygen metabolite in the substrate.
8. An isolated, purified or recombinant construct incorporating a sequence encoding
25 an apophotoprotein whose expression in a substrate, in association with a luciferin therefor, signals the presence of oxygen or an oxygen metabolite in the absence of a corresponding luciferase in the substrate.
9. A recombinant construct according to any one of claims 1 to 8, wherein the nucleic acid sequence is linked operably with nucleotides enabling expression and
30 secretion of the apopholasin in a cellular host.
10. DNA or RNA according to any of claims 1 to 9.
11. An isolated, purified or recombinant polypeptide comprising apophotoprotein of pholasin (apopholasin) or a mutant or variant thereof having substantially the

EXAMPLE 16: Pholasin in a two hybrid system

Protein-protein interaction can be detected by engineering apopholasin to one half of a
5 two hybrid system and GFP to the other. Binding will allow the yeast to grow.

EXAMPLE 17: Pholasin in genetic entertainment

Pholasin is able to chemiluminesce at a wide range of pH (3-10), including acid pH such
10 as 3-4. Thus it can be added to drinks such as beer, cola, soft drinks, and spirits to make
them glow. It can also make food glow by adding to them to the ingredients of cakes,
icing, popcorn; by painting the pholasin or apopholasin on to the food, or by making it
genetically in the source of the food. It can be used in a wide range of toys and other
entertaining devices including squirt guns, greeting cards, pens.

15

The rainbow proteins can also be used as an alternative to pholasin alone, resulting in a
rainbow of colours and colour changes.

EXAMPLE 18: Pholasin in transgenic animals

20

Transgenic animals such as nematodes, mice or plants can be generated from apopholasin
cDNA by standard techniques. Injecting the luciferin or incubating whole plant in it forms
the active pholasin. Oxygen or its metabolites can then be detected, measured and imaged,
in an intact organ, or from the whole organism. It can also be used in humans, in DNA
25 therapy or diagnosis.

EXAMPLE 19: Apoprotein from the luminous squid *Ommastrophes*

The use of apoprotein from the luminous squid *Ommastrophes* is substituted for
30 apopholasin, and the methods of Examples 1 to 18, above, are carried out.

EXAMPLE 20: Apoprotein from the mollusc *Rocellaria*

The use of the apoprotein from the mollusc *Rocellaria* is substituted for apopholasin, and the methods of Examples 1 to 18, above, are carried out.

EXAMPLE 21: Earthworm luciferase

5

The use of earthworm luciferase as a BOIP is substituted for apopholasin, and the methods of Examples 1 to 18, above, are carried out.

10 **EXAMPLE 22**

Genomic DNA from *Pholas*, *Rocellaria*, *Ommastrophes*, or earthworm is substituted for the recombinant protein in Examples 1 to 18, above, the methods of which are carried out in an analogous manner.

same activity as apopholasin.

12. An isolated, purified or recombinant polypeptide according to claim 11 comprising the amino acid sequence of Figure 4 or Figure 5.
13. The apopholasin according to claim 11 or claim 12 when expressed by recombinant DNA or RNA according to claim 10.
14. The apopholasin according to claim 13, which is non-glycosylated.
15. A cell, plasmid, virus or live organism that has been genetically engineered to produce an apoprotein, said cell, plasmid, virus or live organism having incorporated expressibly therein a sequence according to any one of claims 1 to 10.
16. A vector comprising a sequence according to any one of claims 1 to 10.
17. A host cell transformed or transfected with a vector according to claim 16.
18. A BOIP, as defined herein, comprising an apophotoprotein according to any one of claims 11 to 14 in association with a luciferin.
19. A BOIP according to claim 18, wherein the luciferin is derived from *Pholas dactylus*.
20. A method for the preparation of a BOIP, as defined herein, which method comprises bringing an apophotoprotein, such as recombinant apopholasin, into association with a luciferin therefor, such as a luciferin derived from *Pholas dactylus*.
21. A BOIP, apophotoprotein thereof, or a nucleic acid sequence encoding either of these, which comprises a sequence according to any one of Figures 2 to 6 or 9 that has been chemically or genetically modified.
22. A method for the detection and/or measurement of oxygen or one of its metabolites extracellularly, which method comprises providing a BOIP, such as native or chemically- or genetically- modified BOIP or a 'rainbow protein' based on such a BOIP, extracellularly and thereafter detecting and/or quantifying light emission therefrom and/or changes in colour, intensity and/or polarisation of emission(s), wherein the apophotoprotein comprises recombinant apopholasin.
23. A method for the detection and/or measurement of oxygen or one of its metabolites in live cells (intracellularly), which method comprises providing a BOIP, such as native or chemically- or genetically- modified BOIP or a 'rainbow

protein' based on such a BOIP, intracellularly and thereafter detecting and/or quantifying light emission therefrom and/or changes in colour, intensity and/or polarisation of emission(s) therefrom.

24. A method according to claim 22 or 23, wherein said BOIP includes a signal peptide, targetting it to a pre-determined extra- or intra- cellular site.
25. A method according to claim 22 or claim 23, comprising incubating a test sample with a cell according to claim 15 or with a membrane preparation derived therefrom.
26. A method according to any one of claims 22 to 24, wherein light emission takes place in the absence of a luciferase.
27. The use of a sequence or a protein according to any one of claims 1 to 21 in the detection, diagnosis or measurement of oxygen or a metabolite thereof.
28. A diagnostic kit incorporating a sequence or protein according to any one of claims 1 to 21.
29. A process for obtaining a substantially homologous source of apopholasin, which comprises culturing cells having incorporated expressibly therein a polynucleotide encoding apopholasin as defined in any one of claims 1 to 10, and thereafter recovering the cultured cells.
30. A method, use or kit according to any one of claims 20 to 27, substantially as hereinbefore described with particular reference to the Examples.

Clone 40:

GAATTCGGCACGAGTCGGAAAAGAACAAAATGGCTTGTATCGTTTTCGTT
GCTCTTGTGCTCTATGCTTAATGCAACCGGGTCCGGTGAGGAAGTACA
ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT
GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAA
GATCGGGCTTTGGGGCTGTGTCGGATTGAACGGGCGGGCCAGGTACCAC
AAAAGCCGCTCGGATTAACCTGGAGTAACGACACGCAGTCATGTGTAACAA
GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC
TACAGACCACAGGAAGACGGAACTGAGAAAACCTTTACAAGAAAATTCTC
TAGCAAAATGCCAGGCACCTACATGCTTATGGACGTGTGCGCTACAAGGG
ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG
TCCCTATATGACGAAGATAACAATGGTGTAAATGGATGAAGGTAAGGTGAT
TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC
AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA
GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT
CTGGTAGATCTATCAGACTACTTTTATCAGCAGGACAACCTGGTCGTTACC
AGACACCTATAACGTGTCCTCATCAATAATGTGTAACACAGAAATAATCG
ATAGAATATTGAAAATAAAATGTTAATAAACACTGGTTGAAATATGAAAA
AAAAAAAAAAAAAAAACTCGAG

Clone 3:

GAATTCGGCACGAGGGAAAAGAACAAAATGGCTTGTATCGTTTTCGTT
GCTCTTGTGCTCTATGCTTAATGCAACCGGGTCCGGTGAGGAAGTACA
ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT
GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAG
GATCGGGCTTTGGGGCTGTGTCGGATTGAACGGGCGGGCCAGGTACCAC
AAAAGCCGCTCGGATTAACCTGGAGTAACGACACGCAGTCATGTGTAACAA
GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC
TACAGACCACAGGAAGACGGAACTGAGAAAACCTTTACAAGAAAATTCTC
TAGCAAAATGCCAGGCACCTACATGCTTATGGACGTGTGCGCTACAAGGG
ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG
TCCCTATATGACGAAGATAACAATGGTGTAAATGGATGAAGGTAAGGTTAT
TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC
AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA
GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT
CTGGTAGATCTATCAGACCACCTTTATCAGCAGGACAACCTGGTCGTTACC
AGACACCTATAACGTGTCCTCATCAATAATGTGTAACACAGAAATAATCG
ATAGAATATTGAAAATAA

Clone 5:

GTCGAAAAGAACAAAATGGCTTGTATCGTTTTCGTTGCTCTTGTGCTCTATGCTTAATGCAACCGGG
TCCGGTGAGGAAGTACAATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACTG
GATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAGGATCGGGCTTTGGGGCTGTG
TCGGATTGAACGGGCGGGCCAGGTACCACAAAAGCCGCTCGGATTAACCTGGAGTAACGACACGCAGTC
ATGTGTAACAAGAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGACTACAGACC
ACAGGAAGACGGAACTGAGAAAACCTTTACAAGAAAATTCTCTAGCAAAATGCCAGGCACCTACATGCT
TATGGACGTGTGCGCTACAAGGGACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAG
GGTGTCCCTATATGACGAAGATAACAATGGTGTAAATGGATGAAGGTAAGGTTATTCCATCTGAGACAAT
CGAGGATGATATCAAGGACTGTGGGCTCTTAGACCAAGATGTTGAACTCGATTATACGTGGACTCAAAA
CGAGTGTGATCTACCAGACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTTCTG
GTAGATCTATCAGACCACCTTTATCAGCAGGACAACCTGGTCGTTACCAGACACCTATAACGTGTCCTCA
TCAATAATGTGTAACACAGAAATAATCGATAGAATATTGAAAATAAAATGTTAATAGACACTGGTTGAA
AAAAAAAAAAAAAAAACTCGAG

Fig. 1

clone 40 GAATTCGGCACGAGTCGGAAAAGAACAAAATGGCTTGTATCGTTTTCGTT
clone 3 GAATTCGGCACGAG--GGAAAAGAACAAAATGGCTTGTATCGTTTTCGTT
clone 5 -----GTCGAAAAGAACAAAATGGCTTGTATCGTTTTCGTT
* *****

clone 40 GCTCTTGTGCTCTATGCTTAATGCAACCGGGTTCCGGTGAGGAAGTACA
clone 3 GCTCTTGTGCTCTATGCTTAATGCAACCGGGTTCCGGTGAGGAAGTACA
clone 5 GCTCTTGTGCTCTATGCTTAATGCAACCGGGTTCCGGTGAGGAAGTACA

clone 40 ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT
clone 3 ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT
clone 5 ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT

clone 40 GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAA
clone 3 GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAG
clone 5 GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAG

clone 40 GATCGGGCTTTGGGGCTGTGTGCGATTGAACGGGCGGGCCAGGTACCAC
clone 3 GATCGGGCTTTGGGGCTGTGTGCGATTGAACGGGCGGGCCAGGTACCAC
clone 5 GATCGGGCTTTGGGGCTGTGTGCGATTGAACGGGCGGGCCAGGTACCAC

clone 40 AAAAGCCGTCTGGATTAACCTGGAGTAACGACACGCAGTCATGTGTAACAA
clone 3 AAAAGCCGTCTGGATTAACCTGGAGTAACGACACGCAGTCATGTGTAACAA
clone 5 AAAAGCCGTCTGGATTAACCTGGAGTAACGACACGCAGTCATGTGTAACAA

clone 40 GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC
clone 3 GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC
clone 5 GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC

clone 40 TACAGACCACAGGAAGACGGAACCTGAGAAAACCTTTTACAAGAAAATTCTC
clone 3 TACAGACCACAGGAAGACGGAACCTGAGAAAACCTTTTACAAGAAAATTCTC
clone 5 TACAGACCACAGGAAGACGGAACCTGAGAAAACCTTTTACAAGAAAATTCTC

clone 40 TAGCAAAATGCCAGGCACCTTACATGCTTATGGACGTGTGCGCTACAAGGG
clone 3 TAGCAAAATGCCAGGCACCTTACATGCTTATGGACGTGTGCGCTACAAGGG
clone 5 TAGCAAAATGCCAGGCACCTTACATGCTTATGGACGTGTGCGCTACAAGGG

clone 40 ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG
clone 3 ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG
clone 5 ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG

clone 40 TCCCTATATGACGAAGATAACAATGGTGTAATGGATGAAGGTAAGGTGAT
clone 3 TCCCTATATGACGAAGATAACAATGGTGTAATGGATGAAGGTAAGGTTAT
clone 5 TCCCTATATGACGAAGATAACAATGGTGTAATGGATGAAGGTAAGGTTAT

clone 40 TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC
clone 3 TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC
clone 5 TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC

Fig. 2 (Part 1 of 2)

clone 40 AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA
clone 3 AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA
clone 5 AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA

clone 40 GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT
clone 3 GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT
clone 5 GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT

clone 40 CTGGTAGATCTATCAGACTACTTTTATCAGCAGGACAACCTGGTCGTTACC
clone 3 CTGGTAGATCTATCAGACCACTTTTATCAGCAGGACAACCTGGTCGTTACC
clone 5 CTGGTAGATCTATCAGACCACTTTTATCAGCAGGACAACCTGGTCGTTACC

clone 40 AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCG
clone 3 AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCG
clone 5 AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCG

clone 40 ATAGAATATTGAAAATAAAATGTTAATAAACACTGGTTGAAATATGAAAA
clone 3 ATAGAATATTGAAAATAA-----
clone 5 ATAGAATATTGAAAATAAAATGTTAATAGACACTGGTTGAAA-----AAA

clone 40 AAAAAAAAAAAAAAACTCGAG
clone 3 -----
clone 5 AAAAAAAAAAAAAAACTCGAG

Fig. 2 (Part 2 of 2)

GAATTTCGGCACGAGTCGGAAAAGAACAAAATGGCTTGTATCGTTTTTCGTTGCTCTTG
8S
TCGCTCTATGCTTAATGCAACCGGGTCCGGTGAGGAAGTACAATGCGCGATGAATT
GGACACAAGCTAATGAATATGTGTTCAACGTGGACTGGATGACCATTTTCATCTACG
ACTATGGCGCTCAAGAGCAACTGTACGAAGATCGGGCTTTGGGGCTGTGTGCGATTG
3A
AACGGGCCGGCCAGGTACCACAAAAGCCGTCTGGATTAAGTGGAGTAACGACACGC
AGTCATGTGTAACAAGAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCCGGC
4S
TAGTTGACTACAGACCACAGGAAGACGGAAGTGAAGAACTTTTACAAGAAAATTCT
CTAGCAAAATGCCAGGCACTTACATGCTTATGGACGTGTGCGCTACAAGGGACGCTG
ATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTGTCCCTATATGACG
6A
AAGATAACAATGGTGTAAATGGATGAAGGTAAGGTGTTCCATCTGAGACAATCGAGGA
TGATATCAAGGACTGTGGGCTCTTAGACCAAGATGTTGAACTCGATTATACGTGGAC
7S
TCAAAACGAGTGTGATCTACCAGACACAGTAGACGAGGCTGAAGACACACCGTCAGA
AACTGGAGAATTCTTCTGGTAGATCTATCAGACTACTTTTATCAGCAGGACAACTGG
TCGTTACCAGACACCTATAACGTGTCCTCATCAATAATGTGTAAACAGAAATAATC
GATAGAATATTGAAAATAAAATGTTAATAAACACTGGTTGAAATATGAAAAAAAAAA
5A
AAAAAAAAACTCGAG

Fig. 3

Untranslated region

GAATTTCGGCACGAGTCGGAAAAGAACAAA

Translated region

ATG GCT TGT ATC GTT TTC GTT GCT CTT GTC GCT CTA TGC TTA ATG	45
M A C I V F V A L V A L C L M	
CAA CCG GGT TCC GGT GAG GAA GTA CAA TGC GCG ATG AAT TGG ACA	90
Q P G S G E E V Q C A M N W T	
CAA GCT AAT GAA TAT GTG TTC AAC GTG GAC TGG ATG ACC ATT TTC	135
Q A N E Y V F N V D W M T I F	
ATC TAC GAC TAT GGC GCT CAA GAG CAA CTG TAC GAA GAT CGG GCT	180
I Y D Y G A Q E Q L Y E D R A	
TTG GGG CTG TGT CGG ATT GAA CGG GCC GGC CCA GGT ACC ACA AAA	225
L G L C R I E R A G P G T T K	
GCC GTC TGG ATT AAC TGG AGT AAC GAC ACG CAG TCA TGT GTA ACA	270
A V W I N W S N D T Q S C V T	
AGA AAA ACA ATC TTC TTC GAG GTT GGT GGA GAA ATT GCC CGG CTA	315
R K T I F F E V G G E I A R L	
GTT GAC TAC AGA CCA CAG GAA GAC GGA ACT GAG AAA ACT TTT ACA	360
V D Y R P Q E D G T E K T F T	
AGA AAA TTC TCT AGC AAA ATG CCA GGC ACT TAC ATG CTT ATG GAC	405
R K F S S K M P G T Y M L M D	
GTG TGC GCT ACA AGG GAC GCT GAT GAT AAA TGC ATC GAA GGC ACA	450
V C A T R D A D D K C I E G T	
ATT GTG GTG ACA GTC AGG GTG TCC CTA TAT GAC GAA GAT AAC AAT	495
I V V T V R V S L Y D E D N N	
GGT GTA ATG GAT GAA GGT AAG GTG ATT CCA TCT GAG ACA ATC GAG	540
G V M D E G K V I P S E T I E	
GAT GAT ATC AAG GAC TGT GGG CTC TTA GAC CAA GAT GTT GAA CTC	585
D D I K D C G L L D Q D V E L	
GAT TAT ACG TGG ACT CAA AAC GAG TGT GAT CTA CCA GAC ACA GTA	630
D Y T W T Q N E C D L P D T V	
GAC GAG GCT GAA GAC ACA CCG TCA GAA ACT GGA GAA TTC TTC TGG	675
D E A E D T P S E T G E F F W	
TAG ATC TAT CAG ACT ACT TTT ATC AGC AGG ACA ACT GGT CGT TAC	720
*	
CAG ACA CCT ATA ACG TGT CCT CAT CAA TAA	750

* = stop for translation

Fig. 4A

EcoR I

GAATTCGGCACGAGTCGGAAAAGAACAAA

ATG GCT TGT ATC GTT TTC GTT GCT CTT GTC GCT CTA
TGC TTA ATG CAA CCG GGT TCC GGT GAG GAA GTA CAA
TGC GCG ATG AAT TGG ACA CAA GCT AAT GAA TAT GTG
TTC AAC GTG GAC TGG ATG ACC ATT TTC ATC TAC GAC
TAT GGC GCT CAA GAG CAA CTG TAC GAA GAT CGG GCT
TTG GGG CTG TGT CGG ATT GAA CGG GCC GGC CCA GGT
ACC ACA AAA GCC GTC TGG ATT AAC TGG AGT AAC GAC
ACG CAG TCA TGT GTA ACA AGA AAA ACA ATC TTC TTC
GAG GTT GGT GGA GAA ATT GCC CGG CTA GTT GAC TAC
AGA CCA CAG GAA GAC GGA ACT GAG AAA ACT TTT ACA
AGA AAA TTC TCT AGC AAA ATG CCA GGC ACT TAC ATG
CTT ATG GAC GTG TGC GCT ACA AGG GAC GCT GAT GAT
AAA TGC ATC GAA GGC ACA ATT GTG GTG ACA GTC AGG
GTG TCC CTA TAT GAC GAA GAT AAC AAT GGT GTA ATG
GAT GAA GGT AAG GTG ATT CCA TCT GAG ACA ATC GAG
GAT GAT ATC AAG GAC TGT GGG CTC TTA GAC CAA GAT
GTT GAA CTC GAT TAT ACG TGG ACT CAA AAC GAG TGT
GAT CTA CCA GAC ACA GTA GAC GAG GCT GAA GAC ACA
CCG TCA GAA ACT GGA GAA TTC TTC TGG **TAG**

ATCTATCAGACTACTTTTATCAGCAGGACAACCTGGTCGTTACCAGAC
ACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCGA
TAGAATATTGAAAATAAAATGTTAATAAACACTGGTTGAAATATGAA
AAAAAAAAAAAAAAAAAACTCGAG

Xho I

Fig. 4B

EEVQCAMNWTQANEYVFNVDMWTIFIYDYGAQEQLYEDRALGLCRIERAGPGTTKAV
WINWSNDTQSCVTRKTIFFEVGGEIARLVDIRPQEDGTEKTFTRKFSSKMPGTMYLM
DVCATRDADDDKCIEGTIVVTVRVSLYDEDNNGVMDEGKVIPSETIEDDIKDCGLLDQ
DVELDYTWTQNECDLPDTVDEAEDTPSETGEFFW

Fig. 5A

MACIVFVALVALCLMQPGSGEEVQCAMNWTQANEYVFNVDMWTIFIYDYGAQEQLYE
DRALGLCRIERAGPGTTKAVWINWSNDTQSCVTRKTIFFEVGGEIARLVDIRPQEDG
TEKTFTRKFSSKMPGTMYLMDVCATRDADDDKCIEGTIVVTVRVSLYDEDNNGVMDEG
KVIPSETIEDDIKDCGLLDQDVELDYTWTQNECDLPDTVDEAEDTPSETGEFFW

Fig. 5B

clone 40 BioXAct rTth	GAATTCGGCACGAGTCGGAAAAGAACAAAATGGCTTGTATCGTTTTCGTT TGGCTTGTATCGTTTTCGTT
clone 40 BioXAct rTth	GCTCTTGTGCGCTCTATGCTTAATGCAACCGGGTCCGGTGAGGAAGTACA GCTCTTGTGCGCTCTATGCTTAATGCAACCGGGTCCGGTGAGGAAGTACA TATGCTTAATGCAACCGGGTCCGGTGAGGAAGTACA *****
clone 40 BioXAct rTth	ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT ATGCGCGATGAATTGGACACAAGCTAATGAATATGTGTTCAACGTGGACT *****
clone 40 BioXAct rTth	GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAA GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAA GGATGACCATTTTCATCTACGACTATGGCGCTCAAGAGCAACTGTACGAA *****
clone 40 BioXAct rTth	GATCGGGCTTTGGGGCTGTGTCGGATTGAACGGGCGGCCAGGTACCAC GATCGGGCTTTGGGGCTGTGTCGGATTGAACGGGCGGCCAGGTACCAC GATCGGGCTTTGGGGCTGTGTCGGATTGAACGGGCGGCCAGGTACCAC *****
clone 40 BioXAct rTth	AAAAGCCGTCTGGATTAAGTGGAGTAACGACACGCAGTCATGTGTAACAA AAAAGCCGTCTGGATTAAGTGGAGTAACGACACGCAGTCATGTGTAACAA AAAAGCCGTCTGGATTAAGTGGAGTAACGACACGCAGTCATGTGTAACAA *****
clone 40 BioXAct rTth	GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC GAAAAACAATCTTCTTCGAGGTTGGTGGAGAAATTGCCCGGCTAGTTGAC *****
clone 40 BioXAct rTth	TACAGACCACAGGAAGACGGAAGTGGAGAACTTTTACAAGAAATTCTC TACAGACCACAGGAAGACGGAAGTGGAGAACTTTTACAAGAAATTCTC TACAGACCACAGGAAGACGGAAGTGGAGAACTTTTACAAGAAATTCTC *****
clone 40 BioXAct rTth	TAGCAAAATGCCAGGCACCTTACATGCTTATGGACGTGTGCGCTACAAGGG TAGCAAAATGCCAGGCACCTTACATGCTTATGGACGTGTGCGCTACAAGGG TAGCAAAATGCCAGGCACCTTACATGCTTATGGACGTGTGCGCTACAAGGG *****
clone 40 BioXAct rTth	ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG ACGCTGATGATAAATGCATCGAAGGCACAATTGTGGTGACAGTCAGGGTG *****
clone 40 BioXAct rTth	TCCCTATATGACGAAGATAACAATGGTGTAAATGGATGAAGGTAAGGTGAT TCCCTATATGACGAAGATAACAATGGTGTAAATGGATGAAGGTAAGGTGAT TCCCTATATGACGAAGATAACAATGGTGTAAATGGATGAAGGTAAGGTGAT *****
clone 40 BioXAct	TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC

Fig. 6 (Part 1 of 2)

rTth	TCCATCTGAGACAATCGAGGATGATATCAAGGACTGTGGGCTCTTAGACC *****
clone 40 BioXAct rTth	AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA AAGATGTTGAACTCGATTATACGTGGACTCAAAACGAGTGTGATCTACCA *****
clone 40 BioXAct rTth	GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT GACACAGTAGACGAGGCTGAAGACACACCGTCAGAACTGGAGAATTCTT *****
clone 40 BioXAct rTth	CTGGTAGATCTATCAGACTACTTTTATCAGCAGGACAACCTGGTCGTTACC CTGGTAGATCTATCAGACTACTTTTATCAGCAGGACAACCTGGTCGTTACC CTGGTANATCTATCAGACTACTTTTATCAGCAGGACAACCTGGTCGTTACC *****
clone 40 BioXAct rTth	AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCG AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAACAGAAATAATCG AGACACCTATAACGTGTCCTCATCAATAATGTGTAAAAC *****
clone 40 BioXAct rTth	ATAGAATATTGAAAATAAAATGTTAATAAACACTGGTTGAAATATGAAAA ATAGAATATTGAAAATAAAATGTTAATAAACACTGGTTGAAATATGAA
clone 40 BioXAct rTth	AAAAAAAAAAAAAACTCGAG

Fig. 6 (Part 2 of 2)

Oligo 1

ACI ATH TTY TTY CAR GT

Oligo 2

CAR GAR GAR GGN ACI GA

Oligo 2A

TCI GTN CCY TCY TCY TG

Oligo N

TTY AAY GTI GAY TGG ATG

M=A/C

R=A/G

W=A/T

S=G/C

Y=C/T

K=G/T

V=A/C/G

H=A/C/T

D=A/G/T

B=C/G/T

N=A/C/G/T

I=inosine

Fig. 7A

Oligo 3A

ACA CAG CCC CAA AGC CCG AT

Oligo 4S

TTG CCC GGC TAG TTG ACT AC

Oligo 5A

CAT ATT TCA ACC AGT GTT TAT TAA

Oligo 6A

CAA TTG TGC CTT CGA TGC A

Oligo 7S

GGA CTG TGG GCT CTT AG

Oligo 8S

ATG GCT TGT ATC GTT TTC GT

Oligo T7

Fig. 7B

Oligo ExS

CCA CAC GGA TCC TGA GGA AGT ACA ATG

Oligo ExA

CCA CAC GGA TCC TTA TTG ATG AGG ACA

Oligo BacI

CTT GTT TTT ATG GTC GTC TAC ATT TCT TAC ATC TAT GCG GAG
GAA GTA CAA TG

Oligo C9 12

CCA CAC AGA TCT AGA ATG AAA TTC TTA GTC AAC GTT GCC CTT
GTT TTT ATG GTC

Oligo BV5

TTT ACT GTT TTC GTA ACA GTT TTG

Oligo BV3

CAA CAA CGC ACA GAA TCT AG

Fig. 7C

AccI		630				
AflIII		405		734		
AluI 95						
AlwNI	659					
Asp 718		215				
AsuI		204	209			
BanI		215				
BanII		564				
BcnI		51	310			
BglII		678				
BspI 286		564				
BstNI		213		384		
BstUI	77					
Cfr10I	206					
Cfr13I	204		209			
DdeI		345		528		565
DpnI		174		615		680
EcoRI	665					
EcoRII	211		382			
EcoRV	547					
FokI		136		518		554
HaeII		153				
HaeIII	206		210			
HgaI		431				
HhaI		77		152		413
HincII		319				
HinfI		520		598		
HinPII	75		150		411	
HpaII	50		57		207	310
HphI	71		469		529	
KpnI		219				
MaeI		314		372		
MaeII		114		405		593
MaeIII	245		265		457	716
MboII	182		274		277	347
	497	653	661			
MnlI		54	282		531	627
	750					
MseI	41		237			
NaeI	208					
NciI		51		310		
NlaIII	264	397				
NlaIV	55		217			
NsiI		440				
NspHI	397					
PleI	592					
RsaI	69		167		217	
Sau3AI	172	613	678			
Sau96I	204	209				
ScrFI	51	213	310	384		
SfaNI	428					
TaqI 288		441	537	585		
XhoII		678				

Fig. 8





Fig. 9 (Part 1 of 2)

[illegible]

Fig. 9 (Part 2 of 2)

FIGURE 10



PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference WN/NV/WCM.69	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/GB 99/ 03654	International filing date (day/month/year) 05/11/1999	(Earliest) Priority Date (day/month/year) 07/11/1998
Applicant UNIVERSITY OF WALES COLLEGE OF MEDICINE et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the language, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international search was carried out on the basis of the sequence listing:

☐ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☒ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ Certain claims were found unsearchable (See Box I).

3. ☐ Unity of invention is lacking (see Box II).

4. With regard to the title,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

PHOLASIN

5. With regard to the abstract,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the drawings to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☐ None of the figures.

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C12N15/62 C07K14/435 G01N33/542 G01N33/533
G01N33/84

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ROBERTS, P. ET AL.: "Pholasin - A Bioluminiscent Indicator for Detecting Activation of Single Neutrophils." ANAL. BIOCHEM., vol. 160, no. 1, 1987, pages 139-148, XP000891565 figure 3 page 142, column 1, paragraph 6 ---	1-6, 9-19,22, 26-30
X	COTTON, B. ET AL.: "Pholasin: a novel bioluminiscent probe for monitoring oxidative stress in single cardiomyocytes." BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 17, no. 4, 1989, pages 705-706, XP000891824 page 706, column 2, paragraph 2 --- -/--	1-6, 9-19,22, 23,26-30



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 April 2000

Date of mailing of the international search report

04/05/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Mata Vicente, T.

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>MÜLLER, T. ET AL.: "Pholasin Chemiluminescence Detects Mostly Superoxide Anion Released from Activated Human Neutrophils." J. BIOLUMIN. CHEMILUMIN., vol. 3, 1989, pages 105-113, XP000901798 page 109, column 1, paragraph 2 page 113, column 1, paragraph 2 -----</p>	<p>1-6, 9-19, 22, 26-30</p>
P, X	<p>DATABASE GENBANK 'Online! 10 February 1999 (1999-02-10) DUNSTAN, S. L. ET AL.: "Cloning and expression of the photoprotein pholasin from the bivalve Pholas dactylus; a bioluminescent indicator of reactive oxygen species." XP002135876 Acc. No. AJ131051 & JBC, 2000, 275:9403-9409. -----</p>	<p>1-6, 10-17</p>

CLAIMS

1. An isolated, purified or recombinant nucleic acid sequence comprising:
 - (a) a sequence that encodes the apophotoprotein of pholasin (alternatively, 'apopholasin');
 - (b) a sequence substantially homologous to or that hybridises to sequence (a) under stringent conditions; or
 - (c) a sequence substantially homologous to or that hybridises under stringent conditions to the sequence (a) or (b) but for the degeneracy of the genetic code; or
 - (d) an oligonucleotide specific for any of the sequences (a), (b) or (c).
2. A sequence according to claim 1, wherein the sequence that encodes for apopholasin is as shown in Figure 4B.
3. A sequence according to claim 1, wherein the sequence that encodes for apopholasin is as shown in any one of Figures 1, 2, 3, 4A, 6 or 9.
4. A sequence according to any preceding claim, wherein the apopholasin is non-glycosylated.
5. A sequence according to any preceding claim, wherein the apopholasin is glycosylated.
6. An isolated, purified or recombinant construct incorporating a sequence encoding apopholasin protein according to any preceding claim.
7. An isolated, purified or recombinant construct incorporating a sequence encoding an apophotoprotein whose expression in a substrate, in association with a luciferin therefor, signals the presence of oxygen or an oxygen metabolite in the substrate.
8. An isolated, purified or recombinant construct incorporating a sequence encoding an apophotoprotein whose expression in a substrate, in association with a luciferin therefor, signals the presence of oxygen or an oxygen metabolite in the absence of a corresponding luciferase in the substrate.
9. A recombinant construct according to any one of claims 1 to 8, wherein the nucleic acid sequence is linked operably with nucleotides enabling expression and secretion of the apopholasin in a cellular host.
10. DNA or RNA according to any of claims 1 to 9.
11. An isolated, purified or recombinant polypeptide comprising apophotoprotein of pholasin (apopholasin) or a mutant or variant thereof having substantially the

same activity as apopholasin.

12. An isolated, purified or recombinant polypeptide according to claim 11 comprising the amino acid sequence of Figure 4 or Figure 5.
13. The apopholasin according to claim 11 or claim 12 when expressed by recombinant DNA or RNA according to claim 10.
14. The apopholasin according to claim 13, which is non-glycosylated.
15. A cell, plasmid, virus or live organism that has been genetically engineered to produce an apoprotein, said cell, plasmid, virus or live organism having incorporated expressibly therein a sequence according to any one of claims 1 to 10.
16. A vector comprising a sequence according to any one of claims 1 to 10.
17. A host cell transformed or transfected with a vector according to claim 16.
18. A BOIP, as defined herein, comprising an apophotoprotein according to any one of claims 11 to 14 in association with a luciferin.
19. A BOIP according to claim 18, wherein the luciferin is derived from *Pholas dactylus*.
20. A method for the preparation of a BOIP, as defined herein, which method comprises bringing an apophotoprotein, such as recombinant apopholasin, into association with a luciferin therefor, such as a luciferin derived from *Pholas dactylus*.
21. A BOIP, apophotoprotein thereof, or a nucleic acid sequence encoding either of these, which comprises a sequence according to any one of Figures 2 to 6 or 9 that has been chemically or genetically modified.
22. A method for the detection and/or measurement of oxygen or one of its metabolites extracellularly, which method comprises providing a BOIP, such as native or chemically- or genetically- modified BOIP or a 'rainbow protein' based on such a BOIP, extracellularly and thereafter detecting and/or quantifying light emission therefrom and/or changes in colour, intensity and/or polarisation of emission(s), wherein the apophotoprotein comprises recombinant apopholasin.
23. A method for the detection and/or measurement of oxygen or one of its metabolites in live cells (intracellularly), which method comprises providing a BOIP, such as native or chemically- or genetically- modified BOIP or a 'rainbow

protein' based on such a BOIP, intracellularly and thereafter detecting and/or quantifying light emission therefrom and/or changes in colour, intensity and/or polarisation of emission(s) therefrom.

24. A method according to claim 22 or 23, wherein said BOIP includes a signal peptide, targetting it to a pre-determined extra- or intra- cellular site.
25. A method according to claim 22 or claim 23, comprising incubating a test sample with a cell according to claim 15 or with a membrane preparation derived therefrom.
26. A method according to any one of claims 22 to 24, wherein light emission takes place in the absence of a luciferase.
27. The use of a sequence or a protein according to any one of claims 1 to 21 in the detection, diagnosis or measurement of oxygen or a metabolite thereof.
28. A diagnostic kit incorporating a sequence or protein according to any one of claims 1 to 21.
29. A process for obtaining a substantially homologous source of apopholasin, which comprises culturing cells having incorporated expressibly therein a polynucleotide encoding apopholasin as defined in any one of claims 1 to 10, and thereafter recovering the cultured cells.
30. A method, use or kit according to any one of claims 20 to 27, substantially as hereinbefore described with particular reference to the Examples.

The present invention relates to a protein, capable of bioluminescence, cDNA coding therefor and their uses, *inter alia*, in diagnostics and therapy. In particular, this invention
5 relates to the cloning and sequencing of cDNA coding for pholasin from the bivalve mollusc *Pholas dactylus*.

The term 'bioluminescence' refers to the emission of light resulting from a chemical reaction within, or produced by, a living organism. The essential components to the
10 chemical reaction are: an organic molecule, usually comprising a luciferin; oxygen or one of its metabolites; and an enzyme or luciferase that catalyses the oxidation of the luciferin. The chemiluminescent reaction responsible for bioluminescence may be represented as follows:

15 Luciferin + O₂, or O₂⁻, or H₂O₂, or ·OH or OCl⁻ or OX⁻ or ¹O₂ (+ luciferase) ———→ oxyluciferin + light.

Up to three other substances may also be required to generate light or to generate light of the required colour and intensity. These are as follows:

- 20
- (a) A cation, such as H⁺, Ca²⁺, Mg²⁺ or a transition metal cation (eg Cu⁺/Cu²⁺, Fe²⁺/Fe³⁺, La³⁺ and V³⁺);
 - (b) A co-factor such as NAD(P)H, FMN or ATP; and/or
 - (c) A fluor as an energy transfer acceptor.

25 Five chemical families of luciferin are known:

- (a) Aldehydes (found in the freshwater limpet *Latia*, earthworms, and with FMN in bacteria);
- 30 (b) Imidazolopyrazines, which are the compounds most commonly responsible for bioluminescence in the sea (found in Sarcomastigophora, Cnidaria, Ctenophora, Annelida, Chaetognatha, some Arthropoda, some Mollusca and some Chordata);
- (c) Benzothiazoles (found in beetles such as fireflies and glow-worms);
- (d) Linear tetrapyrroles (found in dinoflagellates, euphausiid shrimp and some fish);

and

- (e) Flavins (found in bacteria, fungi, polychaete worms and some molluscs).

Chemiluminescent reactions involving these luciferins may produce a glow or a flash with
 5 an emission of violet, blue, blue-green, green, yellow, orange or red light, or occasionally
 UV or IR light. The light emission may be linearly or circularly polarised. The luciferin
 or its product may also be detected and quantified by fluorescence or phosphorescence.
 As a chemical reaction is directly responsible for the light emission, it does not require
 exposure to UV, visible or IR light. However, some bioluminescent systems, such as that
 10 in the red organ of the deep sea fish *Malacosteus*, exhibit a photo-chemiluminescence,
 where light can trigger or enhance the chemiluminescent reaction. [Reference is directed
 to Chemiluminescence: Principles and Applications in Biology and Medicine, A K
 Campbell (1988), Horwood/VCH Chichester, Weinheim.]

15 In the case of some bioluminescent proteins, the luciferin is so tightly or covalently bound
 to the protein molecule that it does not diffuse away into the surrounding fluid as a result
 of the chemiluminescent reaction. In this case, the protein-luciferin complex is known as
 a photoprotein; and the protein itself is referred to as an apophotoprotein. Some
 bioluminescent proteins are proteins whose light emission or radiation depends on or may
 20 be altered by oxygen or one of its metabolites; these bioluminescent proteins are
 hereinafter referred to as 'bioluminescent oxidative indicator proteins' (BOIPs). BOIPs
 may thus be photoproteins or luciferin-luciferase systems.

BOIPs, therefore, may be used to detect and quantify oxygen or one of its metabolites in
 25 individual cells, defined compartments of living cells such as the nucleus, whole organs
 and organisms - both animals and plants, including microbes such as viruses and bacteria
 and protozoa - as well as substances of biological interest such as substrates, metabolites,
 vitamins, drugs, intra- and extra-cellular signals, enzymes, antigens, antibodies and
 nucleic acids. Heretofore, it has only been known to employ native BOIPs extracellularly.

30 The present invention therefore relates to a method for the detection and/or measurement
 of oxygen or one of its metabolites in live cells (intracellular), which method comprises
 providing a BOIP, such as native or chemically- (or genetically-) modified BOIP or a
 'rainbow protein' based on such a BOIP, intracellularly and thereafter detecting and/or

quantifying light emission therefrom and/or changes in colour, intensity and/or polarisation of emission(s) therefrom.

Furthermore, it has now been found that, by sequencing the BOIP and identifying the cDNA encoding therefor, the recombinant BOIP can also be used in such a method, or chemically- or genetically-modified recombinant BOIP, or a 'rainbow protein' based on such a BOIP. For example, the bivalve mollusc *Pholas dactylus* has been shown to comprise a native photoprotein, which interacts with a luciferase, when they are secreted together by the mollusc to produce light when O₂ or one of its metabolites is present.

References to the Purification and Properties of *Pholas Dactylus* Luciferin and Luciferase can be found by Michelson in Methods in Enzymology LVII 385-406 (1978). References to detection of activation of neutrophils by detection of superoxide anion can be found by Roberts in Anal Biochem 160 139-148 (1987) and by Müller *et al* in J Biolum Chemilum 3 105-113 (1989). The native photoprotein (known as pholasin) is made up of a glycosylated apoprotein (34kDa) with a small organic molecule, the luciferin, tightly bound to it. This luciferin (whose structure is unknown - Müller and Campbell in J Biolum Chemilum 5 25-30 (1990)) can be extracted from the protein moiety - the apopholasin - or from the organism by a standard treatment, such as mild acid. The pholasin may be collected from live molluscs found in sedimentary rocks at low water along the south coast of England from Plymouth to Folkestone and also along the French channel coast and in the Mediterranean. Further details may be obtained from marine fauna and the references cited herein.

We have surprisingly found that pholasin can generate light even without the presence of the corresponding luciferase by addition of oxygen metabolites such as O₂⁻, H₂O₂, OCl- or other oxyhalide anions, or organic peroxides, and certain organic solvents such as dimethyl sulphide (DMSO) or dimethyl formamide (DMF).

We have now identified the cDNA encoding for the (non-glycosylated) apoprotein of pholasin, which may also be called 'apopholasin'. Accordingly, the present invention therefore further provides an isolated, purified or recombinant nucleic acid sequence comprising:

(a) The apophotoprotein of pholasin (alternatively, 'apopholasin');

- (b) A sequence substantially homologous to or that hybridises to sequence (a) under stringent conditions; or
- (c) A sequence substantially homologous to or that hybridises under stringent conditions to the sequence (a) or (b) but for the degeneracy of the genetic code; or
- 5 (d) An oligonucleotide specific for any of the sequences (a), (b) or (c).

The present invention will now be further described with reference to the accompanying Figures, in which:

- 10 Figure 1 (SEQ ID NOS 1-3) shows three different cDNAs encoding apopholasin, referred to as clones 40, 3 and 5. Nucleotides in bold type show codons used for initiation and termination of translation;

- 15 Figure 2 (SEQ ID NOS 1-3) shows the three sequences of Figure 1 (SEQ ID NOS 1-3) aligned to demonstrate the sequence similarity. This figure was generated by Clustal. Positions which are indicated with a star are identical in all three clones. The codons for the initiation and termination of translation are highlighted in bold;

- 20 Figure 3 (SEQ ID NO: 1) shows the oligonucleotides used for the complete sequencing of the positive clones. These were identified from the cDNA library; their positions in clone 40 are shown. Oligonucleotides are shown in bold type, portions of the flanking sequence of the Bluescript plasmid are shown in italic type;

- 25 Figure 4 (SEQ ID NOS 1 and 4) describes the protein sequence described by the DNA sequence coding for apopholasin and shows, in Figure 4A, the complete sequence (SEQ ID Nos 1 and 4) of the positive clone 40 identified from the *Pholas dactylus* light organ library. The first 20 amino acids at the N-terminus are a signal peptide, and this can either be retained or removed when generating the BIOP as described in this invention and, in Figure 4B (SEQ ID NO: 1), the cDNA coding for apopholasin with untranslated 5' and 3'
- 30 ends. The untranslated regions are also shown;

Figure 5 (SEQ ID NOS 5-6) describes the protein sequence for pholasin with (5B) (SEQ ID NO: 6) and without (5A) (SEQ ID NO: 5) the signal peptide;

Figure 6 (SEQ ID NO: 1, piece of SEQ ID NO: 1 and SEQ ID NO: 23) shows the sequence for apopholasin genomic DNA. Two gDNA clones were indentified but no introns were found; the Figure shows an alignment of the cDNA from cDNA clone 40 (SEQ ID NO: 1) and the gDNA amplified by both *rTth* DNA polymerase XL (SEQ ID NO: 23) and BioXAct polymerase (piece of SEQ ID NO: 1). The sequences of the PCR product and the inserts in pGEM T were aligned with the sequence of the cDNA of clone 40 and were identical to this cDNA;

Figure 7 (SEQ ID NOS 7-22) describes the oligonucleotides used for screening and expression. Degenerate oligonucleotides for library screening are shown in Figure 7A; (SEQ ID NOS 7-10) non-degenerate ones in Figure 7B (SEQ ID NOS 7-16); and oligonucleotides used for protein expression are shown in figure 7C (SEQ ID NOS 17-22).

Figure 8 lists the main restriction sites in the DNA for engineering pholasin;

Figure 9 (piece of SEQ ID NO: 1) is a schematic representation of Figure 8 mapped to the sequence of Figure 4A (translated region), and

Figure 10 is a time course of hypo-chlorite triggered chemiluminescence.

Accordingly, the present invention provides recombinant DNA encoding the apophotoprotein apopholasin and comprising the nucleotide sequence of the sequence disclosed in Figure 4B (SEQ ID NO: 1). Three different cDNAs coding for apopholasin have been isolated, having differing non-coding regions, respectively disclosed in Figure 1 (SEQ ID NOS 1-3). The genomic DNA (gDNA), which contains no introns, has been shown (Figure 6) (SEQ ID NO: 1, piece of SEQ ID NO: 1, SEQ ID NO: 23) to comprise the same basic sequence as the cDNA.

Pholasin is a glycoprotein having 11.1 glusamine, 9.8 fructose, 7.1 mannose and 5.2 galactose residues. The cDNA for apopholasin has a molecular weight of 23,456 compared to 34,600 of the pholasin extracted from *Pholas*. The difference in the molecular weights of native versus recombinant apopholasin is due to the glycosylation of the native protein and luciferin. The isoelectric point of the translated protein calculated by the ISOELECTRIC command of the GCG programme is at 3.84. The native protein has a lower isoelectric point (<3.5), probably due to the presence of bound sulphate.

The three clones (Figure 2) (SEQ ID NOS 1-3) isolated from the library encode a unique protein (Figures 4 and 5) (SEQ ID NOS 1 and 4-6), which does not have the same amino acid sequence as any known protein in the SwissProt database. The present invention

therefore not only provides cDNA and RNA coding for the protein, but also the recombinant protein *per se*, with or without glycosylation units. A comparison of segments of the pholasin protein sequence with the proteins in the SwissProt database identified several proteins with regions having a high sequence similarity to regions of the cloned protein. These included several proteins which interact with nucleotides (Table 1).

Table 1 *A comparison of sections of the sequence of the cloned protein with sections of proteins which interact with nucleotides.*

Protein	Homologous region cloned protein homology (+ denotes a conserved amino acid) selected protein
tRNA-splicing endonuclease β subunit (piece of SEQ ID NO: 4) <i>Saccharomyces cerevisiae</i> EC 3.1.27.9 (SEQ ID NO: 24)	SLYDEDNNGVMDEGKVIPSETIE +L DEDNN + + G ++P E++E NLRDEDNNLLDENGDLLPLESLE LDQDVVELDYTW LD DV DYTW LDHDSKDYTW
ATP-AMP transphosphorylase (piece of SEQ ID NO: 5) <i>Cyprinus carpio</i> EC 2.7.4.3 (SEQ ID NO: 25)	VMDEGKVIPSETIEDDIKDCGLLDQDVVELDY +M +G+++P +T+ D IKD + DV Y IMQKGELVPLDVLDMIKDAMIAKADVSKGY
DNA primase (piece of SEQ ID NO: 6) <i>Synechocystis sp.</i> EC 2.7.7. -(SEQ ID NO: 26)	EEVQCAMNWTQANEYVFNV ++VQ M ++Q+ + +FN D DQVQSLMRFSQSKQIIFNFD
purine permease (piece of SEQ ID NO: 6) <i>Emericella nidulans</i> (SEQ ID NO: 27)	VQCAMNWTQANEYV + C+++WT+ N ++ IMCSVDWTRNRFI
DNA repair protein complementing XP-A cells homologue (piece of SEQ ID NO: 5) <i>Drosophila melanogaster</i> (SEQ ID NO: 28)	PDTVDEAEDTPSET PDT DE EDT + T PDTYDEEEDTYTHT
ATP synthase β chain (piece of SEQ ID NO: 5) <i>Peptococcus niger</i> EC 3.6.1.34 (SEQ ID NO: 29)	DTVDEAEDTPSET D +DEA + PSET DPIDEAGEVPSET
DNA polymerase α (piece of SEQ ID NO: 6) <i>Homo sapiens</i>	DEDNNGVMDEGKVIPSETIEDDIKD D+D G +++G+ I + +EDD D DDDGIGYVEDGREIFDDDLEDDALD

Similarity was found between the *Vargula* luciferase and *Renilla* LBP, but no other bioluminescent protein.

- 5 Sequence homology between the cloned protein (piece of SEQ ID NO: 5) and (a) *Vargula* luciferase (SEQ ID NO: 31) (b) *Renilla* LBP (SEQ ID NO: 32). An area of high homology in all three proteins is in bold print.

10 (a) 148 206
 GTIVVT**VRVSLY**DEDNNGVMDEGKVIPSETIEDDIKDCGLLD-QDVELDYTWTQNECDL
 V+VSL D + + + T+ D I D + .V++ + +
 YWNTWD**VKVSLRD**VESYTEVEKVTIRKQSTVVDLIVDGKQVKVGGVDVSIPIYSSENTSI
 353 412

15 (b) 105 166
 STMPGTYMLMDVCATRDADDKCIEGTIVVT**VRVSLY**DEDNNGVMDEGKVIPSETIEDDIKDC
 + TR + **VR+S+** + N+ K I
 AIKIAKLSAEKAEETRGLRVADQLGLAPG**VRISVEE**AAVNATDSLLKMKAEEKAMAVIQSL
 20 41 104

- Three potential glycosylation sites on the protein have the consensus triplet sequence Asn-Xaa-Ser/Thr (where Xaa can be any residue except proline). Thr 216 was identified as a potential site of O-linked glycosylation by a neural network which has been trained to
 25 identify this type of glycosylation. The amino acid sequence was also entered into a neural network which had been trained to identify eukaryotic signal peptides. This confirmed that the most likely cleavage site is between positions 20 and 21 (GSG-EE).

- Many families of proteins contain a "signature" sequence of amino acids. The sequence of
 30 the clones did not contain any of these signatures present in the PROSITE database. The amino acids from 170 to 185 correspond to the calcium binding consensus sequence [DENQST]X[DENQST]X[DENQST]X[DENQST]X[DENQST]XX[DENQST]. Thirteen potential phosphorylation sites were discovered that matched the consensus sequences for either the kinase phosphorylation site [RK](2)-x-[ST], the protein kinase C phosphorylation

site [ST]-x[RK] or the casein kinase II phosphorylation site [ST]-x(2)-[E].

- Three N-linked glycosylation sites were identified in the translated sequence of the clones. A neural network has been trained to identify this type of glycosylation which identified Thr 216 as a potential site of O-linked glycosylation. At least one of these sites must be glycosylated in the native protein in order to account for the presence of the sugar residues. A putative signal peptide region preceded the N terminus of the secreted protein (determined by amino acid sequencing and was identified as a signal peptide by a neural network). To confirm this result the protein sequence was searched with PSORT for motifs which would locate the cloned protein in a cellular compartment. The protein sequence did not contain any transmembrane regions or N-myristoylation patterns which would indicate the presence of a lipid anchor. No targeting or retention sequences were found for the nucleus, mitochondria, endoplasmic reticulum or peroxisome.
- The fact that the clones had some sequence similarity with proteins that interact with nucleotides may suggest that pholasin binds a co-factor as part of the chemiluminescent reaction. Beetle luciferases require ATP binding for chemiluminescent activity. There is no P-loop binding motif ((A,G)x4GK(S,T) or (A)x{4}GK(T)) (SEQ ID NO: 33) in the amino acid sequence of these clones. However, not all ATP binding proteins contain this motif.
- Neither does the cloned protein contain the GXGXXG phosphate binding consensus sequence necessary for the binding of other co-factors such as nicotinamide adenine dinucleotide.

- The amino acid and sugar components of pholasin are not able to emit light at the wavelength of the native protein (490nm). This indicates that there must be a chromophore bound to the protein. There are, however, proteins in which the chromophore is composed of modified amino acid residues within the polypeptide. The best characterised of these is the green fluorescent protein (GFP). This has a chromophore which is a ring formed by the autocatalytic cyclisation of the residues Ser-dehydroTyr-Gly. The serine may be mutated to a threonine, which increases the amplitude of the emission at 488nm. Pholasin had no similar amino acid sequence. Putative luciferin binding regions have been identified for two bioluminescent chemistries. Aequorin has a putative coelenterazine binding region, which is also present in two sections of the *Vargula hilgendorfi* luciferase. The sequence of the cloned protein has no homology to the putative luciferin binding site of aequorin, but the

region of the *Vargula* luciferase from residue 353 to 411 has some similarity, as does the LBP of *Renilla reniformis*, which also binds an imidazolopyrazine. This may indicate that the chemistry of pholasin bioluminescence involves an imidazolopyrazine luciferin. However, the region of homology is very small. The beetle luciferases contain an area of low sequence homology which may bind the benzothiazole luciferin. This low homology may account for the different colours of beetle bioluminescence. used a luciferin analogue (2-(4-benzoylphenyl) thiazole-4-carboxylic acid which photoinactivated the luciferase active site of the firefly *Photinus pyralis*. This photoinactivation was directly linked to the degradation of a small peptide sequence HHGF (SEQ ID NO: 34) (residues 244-257). This is therefore postulated as a luciferin-binding site. The cloned protein does not have any sequence homology with these putative binding regions. Two strongly conserved regions of amino acids have also been found in both the luciferase and the luciferin binding protein of the dinoflagellate *Gonyaulax polyedra*. These regions were compared to the cloned protein, but no sequence similarity was found. No sequence identity could be established between the bacterial luciferases and the cloned protein.

Therefore, the present invention provides cloned apophotoprotein apopholasin (and the cDNA coding therefor), which has identical properties to native (but non-glycosylated) apopholasin with respect to molecular weight, amino acid composition, potential for glycosylation, its highly acidic pI and its cellular location. Hence, the present invention can further provide the corresponding BOIP or modified BOIP, according to standard methods.

The corresponding BOIP is preparable by bringing the apophotoprotein pholasin into association with the luciferin, also using standard methods. Although the luciferin is tightly bound in the native pholasin BOIP, it has been found that it may not be the case in the recombinant pholasin BOIP; indeed the luciferin may be weakly bound or merely present with the apoprotein. For example, a methanol, aqueous, acidic or other extract of *Pholas dactylus* (whole organism or light organ dissected from the animal) containing the 'luciferin', or the pure luciferin, may be added to the solution, cell or organism (Figure 10 shows the time course of hypo-chlorite triggered luminescence in these circumstances). A time course of apopholasin reactivation was performed by incubating partially purified recombinant pholasin secreted by insect cells with acid:menthanol extract of *Pholas dactylus* (●) for 0 (solid line), 1 (---), 2 (-- —), 6(- —) or 24 hours (— —), or incubated

without extract (○). Controls of buffers only with no protein or acid:methanol extract (□)

and extract alone (■) were treated in identical conditions. Chemiluminescence was triggered by the addition of 2% sodium hypochlorite at 10 seconds (arrow) and is shown as chemiluminescent counts minus background light. A typical curve obtained by hypochlorite triggering of native pholasin is also shown (X). A representative experiment carried out in duplicate is shown.

The luciferin associates with the apo-BOIP forming the photoprotein or remains loosely bound so that it turns over like a luciferase. The luciferin on the photoprotein then reacts with oxygen or one of its metabolites to produce light, in the presence or absence of the luciferase. The light emission may be detected, quantified, or imaged using a luminometer, photographic film or imaging camera, or by the naked eye. Alternatively, light emission may be generated spontaneously by intra- or extra-cellular metabolites reacting with the apo-BOIP.

15

Although illustrated with respect to pholasin, the following may apply to any BOIP: the BOIP can be produced directly from native DNA, or from DNA engineered or amplified by the polymerase chain reaction. By this means, sites can be inserted within the protein by splitting the DNA into two or more pieces, or by adding DNA sequences to the 5' or 3' ends. For example, the DNA may be expressed in bacteria, yeast, an insect or human cell, or other suitable organism to produce protein which can be extracted and used.

20

In this instance, the protein produced from the cloned DNA reacts with oxygen or a metabolite of oxygen, such as the superoxide anion (O_2^-), hydrogen peroxide (H_2O_2), hydroxy radical (OH^\cdot), an oxyhalide anion (OCl^- , OBr^- , OI^- , $OSCN^-$), nitric oxide (NO), an organic hydroperoxide or a radical ROO^\cdot . The change in light emission enables the oxygen or metabolite(s) to be detected and quantified in live cells, organelles, or on the outer or inner surface of the plasma membrane, or within an organ of a live organism without the need to break them open or the need to separate bound and free fractions. This also enables an enzyme producing oxygen or one of its metabolites, such as chlorophyll, or enzymes such as oxidases and oxygenases which react directly with oxygen or one of its metabolites to attach oxygen to the substrate to be detected and

30

quantified in live cells, organs and whole organisms, or extracts from any one of these.

Also the BOIP can be made *in vitro* by transcription/translation in a cell lysate such as rabbit reticulocyte lysate or wheat germ extract containing RNA polymerase. The DNA
 5 for the BOIP is first engineered to contain an RNA polymerase promoter, such as T7, SP6; bacterial promoter(s), such as lac, ara or trp; or mammalian promoter(s), such as actin, myosin, myelin proteins, TK, MRT-V, SV40, CMV, RSV, metallothionein, antibody, G6P dehydrogenase, and can be amplified *in vitro* using the polymerase chain reaction. A poly-A tail may be added at the 3' end and a tissue specific promoter or
 10 enhancer sequence added to the 5' or 3' end of the DNA coding for the BOIP or modified BOIP, enabling it to be expressed specifically in a target cell, such as a myocardial cell or a cancer cell. The expression of the BOIP in the target cell is detected and quantified by light intensity, colour or polarisation, as previously mentioned.

15 The BOIP, or its DNA or RNA, may be incorporated into a live bacteria or eukaryotic cell using phage, virus, plasmid, calcium phosphate transfection, electroporation, liposome fusion, membrane pore forming proteins, micro-injection or DNA gun. Once inside cells or an appropriate extracellular environment, cell activation or injury will initiate or change the light emission from the BOIP. For example, expression in live organisms by
 20 micro-injection of protein, RNA or DNA, or by transgenic manipulation to produce a cell, such as a bacterial, microbial, animal or plant cell, eg a white blood cell, a heart cell, or a yeast, protozoan, fruit fly (*Drosophila*), nematode worm, polychaete worm, fish, human, mouse, rat, sheep, pig, horse or plant, which can generate its own light.

25 The BOIP can also be incorporated into a defined part of a live cell by chemical means or by genetically engineering the BOIP to contain a signal peptide, which locates the BOIP to the inner or outer surface of the plasma membrane or within a particular organelle, such as peroxisome, mitochondrion, chloroplast, tonoplast, endoplasmic, reticulum, Golgi
 30 apparatus, endosome, lysosome, secretory vesicle, nucleus, nucleolus, nuclear membrane, plasma membrane, proteosome, or gap junction, or structure such as membrane receptor ion channel microtubule, cytoskeleton, nuclear skeleton, nuclear receptor, mitotic spindle or microfilaments. The signal peptide, added either chemically or genetically, will normally target the normal or modified BOIP to a particular intra- or extra-cellular site.

For example, the sequence MLSRLSLRLLSRYLL (SEQ ID NO: 35) or part of cytochrome oxidase on the N-terminus will target the BOIP to the mitochondrion; KKSALLALMYVCPGKADKE (SEQ ID NO: 36) or MLLPVPLLLGLLGLAA (SEQ ID NO: 37) at the N-terminus will target the BOIP to the endoplasmic reticulum, a KDEL (SEQ ID NO: 38) or HDEL (SEQ ID NO: 39) or KEEL sequence (SEQ ID NO: 40) at the C-terminus retaining it there. SKL at C-terminus targets BOIP to the peroxisome; PKKKRKV (SEQ ID NO: 41) or an extension of this SV40 large T-antigen signal will target it to the nucleus; and a palmitoylation and/or a myristoylation signal will target it to the plasma membrane. By coupling the BOIP to another protein that targets itself to a particular site, the BOIP can also be targeted there. For example, coupling the nuclear proteins nucleoplasmin or lamin B receptor to BOIP targets it to the nucleus; cytochrome oxidase at the N-terminus targets BOIP to the mitochondria; chlorophyll at the N-terminus targets BOIP to the chloroplast; a connexin at the N-terminus targets BOIP to the gap junction or plasma membrane; and SNAP 25 to the plasma membrane.

15

Other modifications to the apoprotein, BOIP, or nucleotides coding therefor include, but are not limited to:

The apoprotein, such as apopholasin, may also be glycosylated, and used to detect and quantify secretion or movement of proteins through the secretory pathway.

Nucleic acid coding for the BOIP when expressed inside a live cell may not only be modified but also regulated in this cell by gene expression, such as by promoters, enhancers or oncogenes. For example, the apoprotein, such as apopholasin, may be coupled to a gene regulator protein, such as a transcription factor, by genetic or chemical manipulation, such that the movement through a cell or of the regulator protein or its activity, can be detected or quantified.

The BOIP or apoprotein, or its DNA may be linked to another protein or DNA used in therapy, such that the other protein or DNA can be detected in live cells or in a whole organism, eg a human.

The apoprotein, such as apopholasin, can also engineered genetically or chemically to contain a site or sites which can be covalently modified by enzymes such as

phosphorylation (including ser/thr, his and tyr kinases and phosphatases),
 transglutamination, proteolysis, ADP ribosylation, gly- or glu-cosylation, halogenation,
 oxidation, methylation, palmitoylation, myristylation and farnesylation.

- 5 The apoprotein, such as apopholasin, can be engineered genetically or chemically to
 contain an antigen or intracellular signal binding site, such as Ca^{2+} , cyclic AMP, cyclic
 GMP, cyclic CMP, IP_3 , IP_4 , diacyl glycerol, ATP, ADP, AMP, GTP, or any oxy- or
 deoxy-ribonucleoside or nucleotide, a substrate, a drug, a nucleic acid and/or a gene regulator
 protein.

10

The BOIP may also be converted to a rainbow protein by engineering a particular site
 such as described hereinabove into the BOIP, at the N- or C-terminus, or between a
 chimera of the BOIP and an energy transfer acceptor, such as GFP (wild type or any of the
 mutant GFPs). This is known as chemiluminescence, bioluminescence or fluorescence
 15 resonance transfer (CRET, BRET or FRET, respectively). Conversion of the BOIP to a
 'rainbow protein' may be effected by reaction with a cellular substance, modification
 genetically or chemically, or by linking the BOIP to a fluor, such as the green fluorescent
 protein or the red fluorescent protein in the deep sea fish *Malacosteus*. The result is a
 BOIP which changes its colour and/or intensity and/or polarisation of emission. The
 20 change in colour occurs by energy transfer, eg resonance transfer (CRET or FRET) or
 electron transfer.

The initial (unmodified) BOIP may be the apophotoprotein, its DNA or RNA, from the
 bivalve mollusc *Pholas dactylus*, or it may be another BOIP, such as one from the
 25 mollusc *Rocellaria grandis* or the squid *Ommastrephes*, or earthworm luciferase, which
 produce light with oxygen metabolites in a way very similar to *Pholas dactylus*.

The BOIP, apo-BOIP, or nucleic acid coding for it, whether modified or not, may
 therefore be used in a range of biology and investigations such as:

30

- (a) Detection, location and measurement of signals in substrates, such as live cells,
 organs or organisms, or in extracellular fluids;
- (b) Detection, location and measurement of oxygen and its metabolites in substrates,
 such as live cells, organs or organisms, or in extracellular fluids, water (sea and

fresh), soil or the atmosphere;

- (c) Detection and location of normal cells such as microbes (protozoa, yeast, fungi, moulds, bacteria, viruses);
- (d) Detection and location of abnormal cells, such as cancer cells, hyperactive cells in rheumatoid arthritis and other inflammatory diseases, cells infected with a pathogen, such as a virus or other infectious agents, cells damaged by physical, chemical or biological attack, cells damaged by perfusion or reperfusion injury or cells damaged by oxygen or one of its metabolites;
- (e) Measurement and location of enzymes, particularly those producing oxygen or its metabolites, and other tumour reactions in cells or biological fluids;
- (f) DNA and RNA binding assays;
- (g) Immunoassay and other protein binding assays;
- (h) In genetic engineering, in the development of transgenic animals and plants, and microbes; in horticulture; agriculture; medicine and veterinary medicine; and/or
- (i) in genetic entertainment by incorporation into light sticks, greeting cards or toys to produce light of various colour, intensities, oscillations, flashes and glows; or in comestibles, such as food, drinks, including beers, wines, spirits, colas and other soft drinks.

20

Accordingly, the present invention further provides an apoprotein, such as pholasin apoprotein (or apopholasin) in both unglycosylated and glycosylated forms, and a BOIP thereof, such as pholasin, either alone (but excluding native proteins *per se* that have already been isolated, such as native pholasin *per se*) or in association with one or more of: a targeting or signal peptide; a glycosylate; a site capable of modification by an enzyme; an antigen or intracellular signal binding site; a promoter, an enhancer or an oncogene or a pharmacologically active substance; or the like. The present invention further provides a recombinant construct comprising a nucleic acid sequence encoding for any of these proteins; a vector containing a nucleic acid sequence encoding for any of these proteins; a host transformed by such vector; a live cell, such as bacterial, insect, eukaryotic, prokaryotic, archae or plant cells containing or expressing any of these proteins; and a rainbow protein, as described herein, together with a nucleic acid sequence encoding therefor.

The present invention will now be illustrated with reference to the following non-limiting examples, in which the methodology referred to is known to those skilled in the art and/or may be carried out by analogy with reference to the protocols disclosed in the following references, the contents of which are herein incorporated by reference in their entirety:

5 BOOKS

1. Campbell,AK. (1988). Chemiluminescence: principles and applications in biology and medicine, pp608. Horwood/VCH, Chichester and Weinheim.
2. Campbell,AK. (1994). Rubicon: the fifth dimension of biology. pp 304. Duckworth, London.

10 PAPERS

1. Campbell,AK Patel,A. (1983) Biochem J. 216:185-194. A homogeneous immunoassay for cyclic nucleotides based on chemiluminescence energy transfer.
2. Roberts,PA Knight,J Campbell,AK. (1987) Anal. Biochem. 160:139-148. Pholasin - a bioluminescent indicator for detecting activation of single neutrophils.
- 15 3. Mueller,T Davies,EV Campbell,AK. (1989) J. Biolum. Chemilum. 3:105-113. Pholasin Chemiluminescence Detects Mostly Superoxide Anion Released from Activated Human Neutrophils.
4. Mueller,T Campbell,AK. (1989) J. Biolum. Chemilum. 5:25-30. The Chromophore of Pholasin: A Highly Luinescent Protein.
- 20 5. Sala-Newby,G and Campbell,AK (1991) Biochem.J. 279:727-732. Engineering a bioluminescent indicator for cyclic AMP dependent protein kinase .
6. Campbell, AK, Trewavas, AJ and Knight, MR (1996). Calcium imaging shows differential sensitivity to cooling and communication in luminous transgenic plants. Cell Calcium 19: 211-218.
- 25 7. Kendall, JM, Sala-Newby, G Badminton, M, Campbell AK and Rembold, CR (1996). Free Ca^{2+} in the endoplasmic reticulum of living cells measured using aequorin as a pseudo luciferase. Biochem.J 318:383-387
8. Badminton, MN, Campbell, AK and Rembold, CR (1996). J.Biol. Chem. 271:31210-31214. Differential regulation of nuclear and cytosolic Ca^{2+} in HeLa cells.
- 30 9. Sala-Newby, GB, Taylor, KT, Badminton, MN, Rembold, CR and Campbell, AK (1998). Imaging bioluminescent indicators shows Ca^{2+} and ATP permeability thresholds in, live cells attacked by complement. Immunology. 93:4:601-609
10. SaSala-Newby, GB, Kendall, JM, Jones, H, Taylor, KM, Badminton, MN, Llewellyn, DH and Campbell, AK (1999). Targeting bioluminescent proteins to defined
35 compartments fo living cells. Methods in Enzymology Bioluminescence and Chemiluminescence. ed Ziegler, M and Baldwin, T.

EXAMPLE 1: Production of a BOIP in bacteria

c or genomic DNA coding for apopholasin, with or without the cDNA coding for the signal peptide, is amplified by PCR with restriction sites such as BamHI at each end. The cDNA is run on an agarose gel and the full length DNA eluted and purified. The DNA is then cut with BamHI to generate sticky ends and ligated into an expression plasmid such as pET3a, which has been cut with BamHI also. After ligation the sealed plasmid is transformed into a standard *E.coli* K12 strain such as JM109, a colony picked off for a large plasmid preparation. After checking that the plasmid contains the correct sequence for apopholasin and is in the correct orientation the plasmid is then used to transform a standard expression strain of *E.coli* such as BL21(DE3) or other expression strain. A colony is picked off the agar plate and grown up for 2h in standard LB broth. IPTG is added as inducer for a further 2h. Apopholasin can then be extracted by breaking the bacteria by lysozyme digestion or sonication in a standard salt medium such as 50mM HEPES pH 7 +/- 1mM ascorbate. Since the apopholasin is unglycosylated it tends to aggregate and form inclusion bodies. These can be broken using 8M urea or guanidinium chloride and these then dialysed off. If the pH of PAGE gels is alkaline this also tends to allow aggregation of both the unglycosylated and glycosylated apo- and full pholasin. A signal peptide such β -lactamase signal will target the BOIP to the periplasmic space, resulting in the ability to secrete the expressed protein from the external fluid of the cells.

EXAMPLE 2: Production of a BOIP in insect cells

c or genomic DNA coding for apopholasin is inserted into a plasmid suitable for conversion into baculovirus when transfected into insect cells. Since pholasin is secreted by *Pholas* itself there is a signal peptide at the N-terminus. Removal of this by PCR will allow cytosolic expression in insect cells. If the signal peptide is left on or changed for honey bee mellitin signal peptide, the apopholasin is secreted into the external medium. The virus containing the DNA for apopholasin is then purified and stored until required. An aliquot is then added to fresh insect cells and these incubated for 3-7 days. The apopholasin is then isolated from the supernatant if a signal peptide is used, or from the cells if not. The apopholasin can then be purified by ammonium sulphate precipitation, gel filtration and DEAE chromatography. The state of glycosylation can be assessed by running the protein on PAGE when the molecular weight is 34Kda. Removal of the

glycosylation by enzymes returns the protein to the size of apopholasin 23.5Kda. It can be stored frozen or freeze dried, and activated to form pholasin by addition of luciferin as described in Example 3.

- 5 Since the apopholasin tends to aggregate in the insect supernatant it is important to get the protein into non-aggregating buffer, e.g. 50mM HEPES pH 6, 1-10mM ascorbate, as soon as possible.

Formation of pholasin can then be achieved as described in Example 3.

10

EXAMPLE 3: Generating pholasin and light emission

To generate light the apopholasin must first be converted into pholasin with the luciferin. The luciferin can be extracted from native pholasin by mild acid, or by methanol, mild
15 acid or alkaline treatment of light organs isolated from *Pholas dactylus* or the whole organism. After homogenisation the extract is centrifuged or filtered to remove particulate material. Further purification can be achieved by tlc or hplc. The luciferin is best stored dry, but can be stored at -70°C. The intactness and concentration can be estimated by measuring the absorbance or fluorescence. The details are as follows:

20

(a) Isolation of the luciferin

Four protocols (1-4) have been developed to extract and isolate the luciferin responsible for light emission in pholasin. The luciferin is a small organic moiety tightly bound to apopholasin when pholasin is isolated from *Pholas dactylus*, but
25 also can be found not bound to apopholasin. Thus the extraction procedure isolates either form of luciferin.

1. The organism *Pholas dactylus* or its light organs are homogenised in 50mM sodium phosphate pH 6.0 on ice. The pholasin is precipitated with saturated ammonium sulphate (4°C stirred), and then removed by
30 centrifugation at *ca* 15,000g for 30min in the cold. The supernatant is then passed down a SEP-PAK silica column, which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The active fractions containing the luciferin are assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl.

The luciferin is concentrated and can be purified further on tlc or hplc with a standard solvent. It is dried and stored at -70°C.

2. The organism *Pholas dactylus* or its light organs are homogenised in cold acetone on ice, filtered through a Buchner funnel, and extracted with methanol:acetone (1:1), the residual powder being extracted 3 times with methanol and extracts combined. These are then concentrated in a Rotavaporator and left to stand for 1h on ice to allow further precipitation. The suspension is then refiltered and concentrated. The solution containing the luciferin is then passed down a SEP-PAK silica column which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The active fractions containing the luciferin are assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl. The luciferin is concentrated and can be purified further on tlc or hplc with a standard solvent. It can be dried and stored at -70°C.
3. The organism *Pholas dactylus* or its light organs are homogenised in cold acetone on ice, and filtered through a Buchner funnel to give an acetone powder. This is then extracted with methanol:acetone (1:1), twice for 10min and then 3 times with methanol. The extracts are combined and concentrated in a Rotavaporator. They are left to stand for 1h on ice to allow further precipitation, refiltered and concentrated. The residual powder is resuspended in 50mM sodium phosphate pH 6.0, 10mM ascorbate, and ultrafiltered with a 10kD Amicon membrane at 4 C for pholasin. The solution containing the luciferin is then passed down a SEP-PAK silica column which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The active fractions containing the luciferin assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl. The luciferin is concentrated and can be purified further on tlc or hplc with a standard solvent. It is dried and stored at -70°C.
4. The organism *Pholas dactylus* or its light organs are homogenised in 50mM HEPES buffer, with methanol and 100mM HCl on ice, and incubated for 2h on ice. After centrifugation at *ca* 15,000g for 30min in the cold, the supernatant is then passed down a SEP-PAK silica column which binds the luciferin. The column is washed with 5ml ethyl acetate and then

5ml of methanol. The active fractions containing the luciferin are assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl. The luciferin is concentrated and can be purified further on tlc with a standard solvent. It is dried and stored at -70°C.

5 Method 4 normally generates most luciferin. The luciferin is characterised by its absorbance and fluorescence spectrum, and by its chemiluminescence with DMSO, NaOCl and apopholasin.

(b) *Generation of pholasin from apopholasin and the luciferin*

10 A small sample of the luciferin (1-10µl) is added to apopholasin in an appropriate buffer (50mM HEPES pH 6-7.5, +/- 0.1% gelatine, +/- 1-10mM ascorbate, or 500mM NaCl, 10mM TES, 1mM EDTA, 1mM mercaptoethanol pH 6-7.5). The mixture is incubated at room temperature for up to 24h, and the pholasin assayed by adding an oxygen metabolite, e.g. NaOCl, or luciferase to a sample. When apopholasin has been expressed in cells, the luciferin is added externally, 15 microinjected into individual cells or added via liposomes to get the luciferin into the cell.

Light is detected and quantified in a standard luminometer, imaging camera (intensified or CCD), or by a silicon chip.

20

EXAMPLE 4: Production of a BOIP in vitro

c or genomic DNA coding for apopholasin, with or without the signal peptide, is amplified by PCR with the 5' primer containing the DNA coding for T7 RNA 25 polymerase. The DNA product is purified and precipitated. After dissolving in 10mM tris/1mMEDTA pH7, the DNA is added to a standard *in vitro* transcription/translation system such as rabbit reticulocyte lysate or wheat germ agglutinin and incubated at 30°C for 30-60min. The apopholasin can then be purified and activated to form pholasin as described in Example 3.

30 **EXAMPLE 5: Targeting a BOIP in vitro**

The BOIP can also be incorporated into a defined part of a live cell by chemical means or by genetically engineering the BOIP to contain a signal peptide which locates the BOIP to the inner or outer surface of the plasma membrane or within a particular organelle such as

peroxisome, mitochondrion, chloroplast, tonoplast, endoplasmic reticulum, Golgi, endosome, lysosome, secretory vesicle, nucleus, nucleolus, proteosome, or gap junction, or structure such as microtubule, cytoskeleton, nuclear skeleton, nuclear receptor, or mitotic spindle. The signal peptide, added either chemically or genetically, will normally

5 target the normal or altered BOIP to a particular intra- or extra-cellular site for example, the sequence MLSRLSLRLLSRYLL (SEQ ID NO: 35) or part of cytochrome oxidase on the N-terminus will target the BOIP to the mitochondrion; KKSALLALMYVCPGKADKE (SEQ ID NO: 36) or MLLPVPLLLGLLGLAA (SEQ ID NO: 37) or the ER protein calreticulin at the N-terminus will target the BOIP to the

10 endoplasmic reticulum, a KDEL (SEQ ID NO: 38) or HDEL (SEQ ID NO: 39) sequence at the C-terminus retaining it there. SKL at C-terminus targets BOIP to the peroxisome, PKKKRKV (SEQ ID NO: 11) or an extension of this SV40 large T-antigen signal will target it to the nucleus, and a palmitoylation and/or a myristoylation signal (MGCVCSSNPD (SEQ ID NO: 42) = the LCK N-terminal acylation motif from tyrosine

15 kinase) will target it to the plasma membrane. By coupling the BOIP to another protein which targets itself to a particular site then the BOIP is also targeted here. For example, coupling the nuclear proteins nucleoplasmin or lamin B receptor to BOIP targets it to the nucleus; cytochrome oxidase at the N-terminus targets BOIP to the mitochondria; chlorophyll at the N-terminus targets BOIP to the chloroplast; and a connexin at the N-

20 terminus targets BOIP to the gap junction or plasma membrane, SNAP 25 to the plasma membrane.

In order to target pholasin to defined sites in living cells, the DNA coding for these targeting sequences are added by using PCR. For cytosolic apopholasin the native signal

25 peptide is removed and also the BOIP can be linked to larger proteins at the N- or C-terminus such as firefly luciferase or aequorin to prevent it getting into the nucleus. This also enables ATP and oxygen metabolites, or Ca^{2+} and oxygen metabolites to be measured simultaneously in the same cells by intensity, colour or polarisation of the different bioluminescent indicators. A multiple bioluminescent indicator can also be engineered by

30 PCR, or by using restriction enzyme sites, from the DNA coding for 3 or more bioluminescent proteins. A simple screen of the transformed bacteria enables the multiple rainbow protein to be isolated with 2-3 colours or more.

The DNA is then added to an *in vitro* transcription/translation system as described in Example 4 in the presence of the organelle to be targeted (e.g. microsomes for the endoplasmic reticulum, which glycosylate apopholasin).

- 5 The new DNA can also be inserted into a plasmid by standard techniques, and transformed into bacteria or transfected or injected into eukaryotic cells such as HeLa or COS.

10 Addition of the luciferin as described in Example 3 allows formation of pholasin which can then be detected by light emission. Changes in oxygen metabolite production are then be detected by a luminometer or imaging camera when the cells are exposed to external oxygen metabolites, a change in oxygen concentration, addition of stimuli e.g. TNF, EGF, hormones or drugs, or attack by pathogens such as bacteria, viruses, complement, antibodies, toxins, and cells of the immune system.

15

EXAMPLE 6: Engineering a covalent modification site into a BOIP

- 20 (a) The site coding a protein kinase A (RRAS or kemptide), protein kinase C (MARCKS), MAP kinase, ERK, the ER - nuclear signalling kinase IRE1P or a phosphatase is added to the N- or C-terminus or inserted at various sites within the apopholasin by PCR and expressed as described in Examples 1-5. Pholasin is then generated by addition of the luciferin as described in Example 3.

25 Addition of the catalytic subunit for protein kinase A, or activation via cyclic AMP inside cells, leads to phosphorylation or dephosphorylation of the modified pholasin and change in light emission (intensity, colour or polarisation).

A preliminary screen is necessary to select the appropriate proteins and to discard any which have lost all activity.

30

- (b) The site coding a protease (thrombin, enterokinase, HIV protease, caspase) is added to the N- or C-terminus of the apopholasin by PCR or inserted at various sites within the protein, and expressed as described in Examples 1-5. Pholasin is then generated by addition of the luciferin as described in Example 3.

EXAMPLE 7: Engineering a BOIP into a “Rainbow Protein”

cDNA coding for apopholasin is linked to another protein by using the cDNA coding for that protein. For example, wild type GFP, the S65T mutant of the green fluorescent protein, YGFP, or EGFP are linked to apopholasin by PCR at the N- or C-terminus, or by splitting one or both proteins using multi-step PCR. In between there is a ‘reactive’ peptide with a protease site (α thrombin or enterokinase) and a binding site for IP₃, or the 15 amino acid sequence form IP₃ kinase (an IP₄ binding site). At the C-terminus of the GFP, a peptide containing 6 lysine residues may also be added via PCR. The protein is expressed and fluorescein covalently linked to these lysines by addition of fluorescein isothiocyanate. Addition of the luciferin forms pholasin as described in Example 3. The change in colour occurs by chemiluminescence resonance energy transfer. Without fluorescein the rainbow protein emits blue-green light (508nm), which changes to blue (490nm) when the reactive substance binds to the reactive peptide, or when either thrombin or enterokinase is added. When the 6 amino acid linker is used the colour starts as green (530nm), and will then change from green, to blue-green and then blue as the particular reactive sequence binds their respective analytes. Use of rhodamine instead of fluorescein generates a rainbow protein which changes from red to green to blue.

20

A preliminary screen is necessary to select the appropriate rainbow proteins and to discard any which have lost all activity.

The other protein linked to apopholasin may be, for example, any one of the following linked chemically or genetically:

25

1. Firefly or any benzothiazole luciferase to the N or C terminus gives two colours for ATP and oxygen metabolites.
2. Any imidazolopyrazine luciferase, including coelenterazine systems - decapod shrimp, fish, squid, *Renilla*, anthzoan, Chaetognate, radiolarian, or copepod and *Vargula* systems - ostracod, *Porichthys* and similar fish, cyprinidids and *Vargula*.
3. Any tetrapyrrole luciferase such as dinoflagellate, euphausiid or stomiatoid fish.
4. Bacterial luciferase and other aldehyde or flavin luciferases, including polychate worm.

30

5. Any GFP, including wild type, S65T, enhanced GFP, blue GFP, yellow GFP, *Renilla* GFP, *Ptilocarpus* GFP, and *Pennatula* GFP, any anthozan GFP, or any coelenterate GFP.
6. The red fluorescent proteins from stomiatoid fish - *Malactosteus*, *Aristostomias*, *Photostomias*.
7. The phycobiliproteins - phycoerythrin and phycocyanobilin.
8. The blue fluorescent lumazine protein in the bacterium *Photobacterium*.
9. The yellow flavin fluorescent protein in *Vibrio*.
10. Any lysine or arginine or other amino acid side chain where a fluor can be added covalently. In which the case the rainbow protein may emit more than two colours. For example, rhodamine on a pholasin-linker-GFP chimera will turn from red to green to blue.

A preliminary screen may be necessary to select chimeras which have not lost all bioluminescent activity.

The 'reactive' peptide may be a binding site for any analyte, protein or DNA, metabolite, substrate vitamin, an enzyme such as protein kinase C or phosphatase, ion channel, ion pump, antigen, antibody, nucleotide or nucleoside such as ATP, GTP, ADP, AMP, adenosine, cAMP, cGMP, cCCP or their deoxy equivalents, and inositol phosphates such as IP₃ or IP₄, a lipid such as diacyl glycerol, phosphatidyl inositol bisphosphate, phosphate, a cation such as Ca²⁺, K⁺ or Na⁺, Cu²⁺ or Zn²⁺, or anion such as Cl⁻, sulphate, or gas such as NO, O₂ or H₂, or a protein binding site such as calmodulin, kinesin, dynein, tubulin, or myosin.

When pholasin is triggered by oxygen metabolites, the *Pholas* luciferase or peroxidase, energy transfer occurs from pholasin oxyluciferin through GFP to fluorescein resulting in a yellow emission. Addition of thrombin for 3h cleaves the GFP-fluorescein from the pholasin and the light emission returns to the blue of native pholasin. Addition of IP₃ to the full chimera alters the efficiency of energy transfer. As a result there is a change in the ratio of light emitted in the yellow to blue. This ratio is directly related and can be plotted against the concentration or amount of analyte. The light is detected in a dual wavelength luminometer or ratiometric imaging camera and the ratio of blue to green light measured.

Alternatively any fluors can be used, and any binding sites with the right characteristics as shown in these examples will work provided a simple screen is used to select the right chimeras.

5 **EXAMPLE 8: Engineering a BOIP into a “Rainbow Protein” for two analytes together**

10 Apopholasin is linked to firefly luciferase by using cDNAs and PCR, followed by expression in insect cells as described in Example 2. Addition of the luciferin as described in Example 3 generates the pholasin. In the presence of firefly luciferin (1mM), ATP and oxygen metabolites, this chimera emits blue and yellow simultaneously which can be independently measured by using a dual wavelength luminometer or imaging camera.

15 **EXAMPLE 9: Expression of BOIPs in mammalian cells**

20 Apopholasin, c or genomic, in an expression plasmid with the CMV promoter, is transfected into HeLa cells. After incubation for 3 days to allow expression of the apopholasin, the luciferin is added to form pholasin. Expression is checked using a polyclonal antibody to pholasin raised in rabbits. Addition of oxygen metabolites outside the cell allows the permeability of the plasma membrane to oxygen metabolites to be assessed. As the oxygen metabolites permeate into the cytosol, the light emission increases.

25

EXAMPLE 10: Expression of BOIPs in plants

c or genomic DNA coding for apopholasin is inserted into a plasmid with the cauliflower mosaic virus promoter and transformed into *Agrobacterium tumefaciens*. These are then added to a tobacco leaf, seedlings generated, and those expressing apopholasin selected. The plants are grown to seed, and seedlings grown from this seed. Addition of luciferin forms the pholasin as described in Example 3. Stressing the plant, e.g. with wind, touch, cold, or peroxide, or during growth and development or by a hormone, generates light, showing the formation of oxygen metabolites within the live plant. A cell-specific promoter engineered on to the apopholasin cDNA before making the transgenic plant enables oxygen metabolites to be detected in specific cells within the whole, living plant.

EXAMPLE 11: Detection of oxidative damage in vitro

Addition of pholasin to serum or plasma from a rat, mouse or human enables oxygen metabolites to be detected and measured on addition of a drug or other substance of interest.

EXAMPLE 12: Detection of ROMs in a heart cells

Reperfusion has been proposed to lead to oxygen metabolite damage in cardiac myocytes. Pholasin allows this to be tested for the first time. Plasmid containing apopholasin cDNA and the CMV promoter is transfected into isolated cardiac myocytes in culture. Expression occurs within 1-3 days, and pholasin is formed by addition of the luciferin as described in Example 3. Subjecting the cells to hypoxia followed by readmission of normal oxygen leads to light emission, showing that oxygen metabolites have been generated inside the cells. By using an imaging camera, the digital or analogue nature of this can be assessed as the number of cells emitting light can be visualised and counted.

EXAMPLE 13: Detection of ROMs in the nucleus and endoplasmic reticulum (ER)

Plasmid-containing apopholasin cDNA with either nucleoplasmin DNA or calreticulin DNA (with or without KDEL on the C-terminus) linked to the pholasin DNA, to target
 5 the apopholasin to the nucleus or ER respectively, and the CMV promoter for expression, is transfected into HeLa cells in culture. Expression occurs within 1-3 days, and pholasin is formed by addition of the luciferin as described in Example 3. Addition of oxygen metabolites outside the cells, or hypoxic/oxygen shock generates light measured in a
 10 luminometer, showing how fast oxygen metabolites penetrate into these organelles. By imaging with a photon counting imaging camera, the number of cells permeable to oxygen metabolites can be counted. Location of the pholasin can be assessed by imaging live cells, or by using immunofluorescence with the pholasin antibody on partially-fixed cells or GFP-pholasin in live cells. Using a rainbow protein, two or more analytes can be detected together.

15

EXAMPLE 14: Use of pholasin as a protein label

Pholasin can be used as a label in homogeneous or heterogeneous immunoassay. Apopholasin is first covalently linked to an antibody to HIV, and pholasin formed by
 20 addition of luciferin as described in Example 3. The antibody is then used in a standard chemiluminometric immunoassay format. Addition of HIV antigen leads to an increase in antibody binding and an increase in light emission dependent on the amount of HIV added. The amount of HIV in a blood sample can be assessed by relating the pholasin light emission in the sample to the standard curve.

25

EXAMPLE 15: Pholasin as a DNA label

Apopholasin is covalently linked to an oligonucleotide probe for detecting the presence of the cystic fibrosis gene. Addition of the probe to DNA in a standard Southern blot allows
 30 the probe to bind when the gene is present. Addition of luciferin as described in Example 3 allows the pholasin to form. Addition of hypochlorite (10mM) in barbitone buffer pH 9 causes the pholasin to flash and the gene can be visualised by the photon counting imaging camera.

EXAMPLE 16: Pholasin in a two hybrid system

Protein-protein interaction can be detected by engineering apopholasin to one half of a two hybrid system and GFP to the other. Binding will allow the yeast to grow.

5

EXAMPLE 17: Pholasin in genetic entertainment

Pholasin is able to chemiluminesce at a wide range of pH (3-10), including acid pH such as 3-4. Thus it can be added to drinks such as beer, cola, soft drinks, and spirits to make them glow. It can also make food glow by adding to them to the ingredients of cakes, icing, popcorn; by painting the pholasin or apopholasin on to the food, or by making it genetically in the source of the food. It can be used in a wide range of toys and other entertaining devices including squirt guns, greeting cards, pens.

10

The rainbow proteins can also be used as an alternative to pholasin alone, resulting in a rainbow of colours and colour changes.

15

EXAMPLE 18: Pholasin in transgenic animals

Transgenic animals such as nematodes, mice or plants can be generated from apopholasin cDNA by standard techniques. Injecting the luciferin or incubating whole plant in it forms the active pholasin. Oxygen or its metabolites can then be detected, measured and imaged, in an intact organ, or from the whole organism. It can also be used in humans, in DNA therapy or diagnosis.

20

25

EXAMPLE 19: Apoprotein from the luminous squid *Ommastrophes*

The use of apoprotein from the luminous squid *Ommastrophes* is substituted for apopholasin, and the methods of Examples 1 to 18, above, are carried out.

30

EXAMPLE 20: Apoprotein from the mollusc *Rocellaria*

The use of the apoprotein from the mollusc *Rocellaria* is substituted for apopholasin, and the methods of Examples 1 to 18, above, are carried out.

EXAMPLE 21: Earthworm luciferase


The use of earthworm luciferase as a BOIP is substituted for apopholasin, and the
5 methods of Examples 1 to 18, above, are carried out.

EXAMPLE 22

- 10 Genomic DNA from *Pholas*, *Rocellaria*, *Ommastrophes*, or earthworm is substituted for the recombinant protein in Examples 1 to 18, above, the methods of which are carried out in an analogous manner.

The present invention relates to a protein, capable of bioluminescence, cDNA coding therefor and their uses, *inter alia*, in diagnostics and therapy. In particular, this invention
5 relates to the cloning and sequencing of cDNA coding for pholasin from the bivalve mollusc *Pholas dactylus*.

The term 'bioluminescence' refers to the emission of light resulting from a chemical reaction within, or produced by, a living organism. The essential components to the
10 chemical reaction are: an organic molecule, usually comprising a luciferin; oxygen or one of its metabolites; and an enzyme or luciferase that catalyses the oxidation of the luciferin. The chemiluminescent reaction responsible for bioluminescence may be represented as follows:



Up to three other substances may also be required to generate light or to generate light of the required colour and intensity. These are as follows:

20

- (a) A cation, such as H⁺, Ca²⁺, Mg²⁺ or a transition metal cation (eg Cu⁺/Cu²⁺, Fe²⁺/Fe³⁺, La³⁺ and V³⁺);
- (b) A co-factor such as NAD(P)H, FMN or ATP; and/or
- (c) A fluor as an energy transfer acceptor.

25

Five chemical families of luciferin are known:

- (a) Aldehydes (found in the freshwater limpet *Latia*, earthworms, and with FMN in bacteria);
- 30 (b) Imidazolopyrazines, which are the compounds most commonly responsible for bioluminescence in the sea (found in Sarcomastigophora, Cnidaria, Ctenophora, Annelida, Chaetognatha, some Arthropoda, some Mollusca and some Chordata);
- (c) Benzothiazoles (found in beetles such as fireflies and glow-worms);
- (d) Linear tetrapyrroles (found in dinoflagellates, euphausiid shrimp and some fish);

and

(e) Flavins (found in bacteria, fungi, polychaete worms and some molluscs).

Chemiluminescent reactions involving these luciferins may produce a glow or a flash with
 5 an emission of violet, blue, blue-green, green, yellow, orange or red light, or occasionally
 UV or IR light. The light emission may be linearly or circularly polarised. The luciferin
 or its product may also be detected and quantified by fluorescence or phosphorescence.
 As a chemical reaction is directly responsible for the light emission, it does not require
 exposure to UV, visible or IR light. However, some bioluminescent systems, such as that
 10 in the red organ of the deep sea fish *Malacosteus*, exhibit a photo-chemiluminescence,
 where light can trigger or enhance the chemiluminescent reaction. [Reference is directed
 to Chemiluminescence: Principles and Applications in Biology and Medicine, A K
 Campbell (1988), Horwood/VCH Chichester, Weinheim.]

15 In the case of some bioluminescent proteins, the luciferin is so tightly or covalently bound
 to the protein molecule that it does not diffuse away into the surrounding fluid as a result
 of the chemiluminescent reaction. In this case, the protein-luciferin complex is known as
 a photoprotein; and the protein itself is referred to as an apophotoprotein. Some
 bioluminescent proteins are proteins whose light emission or radiation depends on or may
 20 be altered by oxygen or one of its metabolites; these bioluminescent proteins are
 hereinafter referred to as 'bioluminescent oxidative indicator proteins' (BOIPs). BOIPs
 may thus be photoproteins or luciferin-luciferase systems.

BOIPs, therefore, may be used to detect and quantify oxygen or one of its metabolites in
 25 individual cells, defined compartments of living cells such as the nucleus, whole organs
 and organisms - both animals and plants, including microbes such as viruses and bacteria
 and protozoa - as well as substances of biological interest such as substrates, metabolites,
 vitamins, drugs, intra- and extra-cellular signals, enzymes, antigens, antibodies and
 nucleic acids. Heretofore, it has only been known to employ native BOIPs extracellularly.

30 The present invention therefore relates to a method for the detection and/or measurement
 of oxygen or one of its metabolites in live cells (intracellular), which method comprises
 providing a BOIP, such as native or chemically- (or genetically-) modified BOIP or a
 'rainbow protein' based on such a BOIP, intracellularly and thereafter detecting and/or

quantifying light emission therefrom and/or changes in colour, intensity and/or polarisation of emission(s) therefrom.

Furthermore, it has now been found that, by sequencing the BOIP and identifying the cDNA encoding therefor, the recombinant BOIP can also be used in such a method, or chemically- or genetically-modified recombinant BOIP, or a 'rainbow protein' based on such a BOIP. For example, the bivalve mollusc *Pholas dactylus* has been shown to comprise a native photoprotein, which interacts with a luciferase, when they are secreted together by the mollusc to produce light when O₂ or one of its metabolites is present.

References to the Purification and Properties of *Pholas Dactylus* Luciferin and Luciferase can be found by Michelson in Methods in Enzymology LVII 385-406 (1978). References to detection of activation of neutrophils by detection of superoxide anion can be found by Roberts in Anal Biochem 160 139-148 (1987) and by Müller *et al* in J Biolum Chemilum 3 105-113 (1989). The native photoprotein (known as pholasin) is made up of a glycosylated apoprotein (34kDa) with a small organic molecule, the luciferin, tightly bound to it. This luciferin (whose structure is unknown - Müller and Campbell in J Biolum Chemilum 5 25-30 (1990)) can be extracted from the protein moiety - the apopholasin - or from the organism by a standard treatment, such as mild acid. The pholasin may be collected from live molluscs found in sedimentary rocks at low water along the south coast of England from Plymouth to Folkestone and also along the French channel coast and in the Mediterranean. Further details may be obtained from marine fauna and the references cited herein.

We have surprisingly found that pholasin can generate light even without the presence of the corresponding luciferase by addition of oxygen metabolites such as O₂⁻, H₂O₂, OCl⁻ or other oxyhalide anions, or organic peroxides, and certain organic solvents such as dimethyl sulphide (DMSO) or dimethyl formamide (DMF).

We have now identified the cDNA encoding for the (non-glycosylated) apoprotein of pholasin, which may also be called 'apopholasin'. Accordingly, the present invention therefore further provides an isolated, purified or recombinant nucleic acid sequence comprising:

- (a) The apophotoprotein of pholasin (alternatively, 'apopholasin');

- (b) A sequence substantially homologous to or that hybridises to sequence (a) under stringent conditions; or
- (c) A sequence substantially homologous to or that hybridises under stringent conditions to the sequence (a) or (b) but for the degeneracy of the genetic code; or
- 5 (d) An oligonucleotide specific for any of the sequences (a), (b) or (c).

The present invention will now be further described with reference to the accompanying Figures, in which:

10 Figure 1 (SEQ ID NOS 1-3) shows three different cDNAs encoding apopholasin, referred to as clones 40, 3 and 5. Nucleotides in bold type show codons used for initiation and termination of translation;

Figure 2 (SEQ ID NOS 1-3) shows the three sequences of Figure 1 (SEQ ID NOS 1-3) aligned to demonstrate the sequence similarity. This figure was generated by Clustal.
15 Positions which are indicated with a star are identical in all three clones. The codons for the initiation and termination of translation are highlighted in bold;

Figure 3 (SEQ ID NO: 1) shows the oligonucleotides used for the complete sequencing of
20 the positive clones. These were identified from the cDNA library; their positions in clone 40 are shown. Oligonucleotides are shown in bold type, portions of the flanking sequence of the Bluescript plasmid are shown in italic type;

Figure 4 (SEQ ID NOS 1 and 4) describes the protein sequence described by the DNA
25 sequence coding for apopholasin and shows, in Figure 4A, the complete sequence (SEQ ID Nos 1 and 4) of the positive clone 40 identified from the *Pholas dactylus* light organ library. The first 20 amino acids at the N-terminus are a signal peptide, and this can either be retained or removed when generating the BIOP as described in this invention and, in Figure 4B (SEQ ID NO: 1), the cDNA coding for apopholasin with untranslated 5' and 3'
30 ends. The untranslated regions are also shown;

Figure 5 (SEQ ID NOS 5-6) describes the protein sequence for pholasin with (5B) (SEQ ID NO: 6) and without (5A) (SEQ ID NO: 5) the signal peptide;

Figure 6 (SEQ ID NO: 1, piece of SEQ ID NO: 1 and SEQ ID NO: 23) shows the sequence for apopholasin genomic DNA. Two gDNA clones were indentified but no introns were found; the Figure shows an alignment of the cDNA from cDNA clone 40 (SEQ ID NO: 1) and the gDNA amplified by both *rTth* DNA polymerase XL (SEQ ID NO: 23) and BioXAct polymerase (piece of SEQ ID NO: 1). The sequences of the PCR product and the inserts in pGEM T were aligned with the sequence of the cDNA of clone 40 and were identical to this cDNA;

Figure 7 (SEQ ID NOS 7-22) describes the oligonucleotides used for screening and expression. Degenerate oligonucleotides for library screening are shown in Figure 7A; (SEQ ID NOS 7-10) non-degenerate ones in Figure 7B (SEQ ID NOS 7-16); and oligonucleotides used for protein expression are shown in figure 7C (SEQ ID NOS 17-22).

Figure 8 lists the main restriction sites in the DNA for engineering pholasin;

Figure 9 (piece of SEQ ID NO: 1) is a schematic representation of Figure 8 mapped to the sequence of Figure 4A (translated region), and

Figure 10 is a time course of hypo-chlorite triggered chemiluminescence.

Accordingly, the present invention provides recombinant DNA encoding the apophotoprotein apopholasin and comprising the nucleotide sequence of the sequence disclosed in Figure 4B (SEQ ID NO: 1). Three different cDNAs coding for apopholasin have been isolated, having differing non-coding regions, respectively disclosed in Figure 1 (SEQ ID NOS 1-3). The genomic DNA (gDNA), which contains no introns, has been shown (Figure 6) (SEQ ID NO: 1, piece of SEQ ID NO: 1, SEQ ID NO: 23) to comprise the same basic sequence as the cDNA.

Pholasin is a glycoprotein having 11.1 glucosamine, 9.8 fructose, 7.1 mannose and 5.2 galactose residues. The cDNA for apopholasin has a molecular weight of 23,456 compared to 34,600 of the pholasin extracted from *Pholas*. The difference in the molecular weights of native versus recombinant apopholasin is due to the glycosylation of the native protein and luciferin. The isoelectric point of the translated protein calculated by the ISOELECTRIC command of the GCG programme is at 3.84. The native protein has a lower isoelectric point (<3.5), probably due to the presence of bound sulphate.

The three clones (Figure 2) (SEQ ID NOS 1-3) isolated from the library encode a unique protein (Figures 4 and 5) (SEQ ID NOS 1 and 4-6), which does not have the same amino acid sequence as any known protein in the SwissProt database. The present invention

therefore not only provides cDNA and RNA coding for the protein, but also the recombinant protein *per se*, with or without glycosylation units. A comparison of segments of the pholasin protein sequence with the proteins in the SwissProt database identified several proteins with regions having a high sequence similarity to regions of the cloned protein. These included several proteins which interact with nucleotides (Table 1).

Table 1 *A comparison of sections of the sequence of the cloned protein with sections of proteins which interact with nucleotides.*

Protein	Homologous region cloned protein homology (+ denotes a conserved amino acid) selected protein
tRNA-splicing endonuclease β subunit (piece of SEQ ID NO: 4) <i>Saccharomyces cerevisiae</i> EC 3.1.27.9 (SEQ ID NO: 24)	SLYDEDNNGVMDEGKVIPSETIE +L DEDNN + + G ++P E++E NLRDEDNNLLDENGDLLPLESLE LDQDVVELDYTW LD DV DYTW LDHDSKDYTW
ATP-AMP transphosphorylase (piece of SEQ ID NO: 5) <i>Cyprinus carpio</i> EC 2.7.4.3 (SEQ ID NO: 25)	VMDEGKVIPSETIEDDIKDCGLLDQDVLDY +M +G+++P +T+ D IKD + DV Y IMQKGELVPLDTVLDMIKDAMIAKADVSKGY
DNA primase (piece of SEQ ID NO: 6) <i>Synechocystis sp.</i> EC 2.7.7. -(SEQ ID NO: 26)	EEVQCAMNWTQANEYVFNV ++VQ M ++Q+ + +FN D DQVQSLMRFSQSKQIIFNFD
purine permease (piece of SEQ ID NO: 6) <i>Emmericella nidulans</i> (SEQ ID NO: 27)	VQCAMNWTQANEYV + C+++WT+ N ++ IMCSVDWTRRNRFI
DNA repair protein complementing XP-A cells homologue (piece of SEQ ID NO: 5) <i>Drosophila melanogaster</i> (SEQ ID NO: 28)	PDTVDEAEDTPSET PDT DE EDT + T PDTYDEEEDTYTHT
ATP synthase β chain (piece of SEQ ID NO: 5) <i>Peptococcus niger</i> EC 3.6.1.34 (SEQ ID NO: 29)	DTVDEAEDTPSET D +DEA + PSET DPIDEAGEVPSET
DNA polymerase α (piece of SEQ ID NO: 6) <i>Homo sapiens</i>	DEDNNGVMDEGKVIPSETIEDDIK D+D G +++G+ I + +EDD D DDDGIGYVEDGREIFDDDLEDDALD

Similarity was found between the *Vargula* luciferase and *Renilla* LBP, but no other bioluminescent protein.

- 5 Sequence homology between the cloned protein (piece of SEQ ID NO: 5) and (a) *Vargula* luciferase (SEQ ID NO: 31) (b) *Renilla* LBP (SEQ ID NO: 32). An area of high homology in all three proteins is in bold print.

10 (a) 148 206
 GTIVVT**VRVSLY**DEDNNGVMDEGKVIPSETIEDDIKDCGLLD-QDVELDYTWQTNECDL
 V+VSL D + + + T+ D I D + V++ + +
 YWNTWD**VKVSLRD**VESYTEVEKVTIRKQSTVVDLIVDGKQVKVGGVDVSIPIYSSENTSI
 353 412

15 (b)
 105 166
 STMPGTYMLMDVCATRDADDKCIEGTIVVT**VRVSLY**DEDNNGVMDEGKVIPSETIEDDIKDC
 + TR + **VR+S+** + N+ K I
 AIKIAKLSAEKAEETRGFLRVADQLGLAPG**VRISVEE**AAVNATDSLKMKAEKAMAVIQSL
 20 41 104

- Three potential glycosylation sites on the protein have the consensus triplet sequence Asn-Xaa-Ser/Thr (where Xaa can be any residue except proline). Thr 216 was identified as a potential site of O-linked glycosylation by a neural network which has been trained to identify this type of glycosylation. The amino acid sequence was also entered into a neural network which had been trained to identify eukaryotic signal peptides. This confirmed that the most likely cleavage site is between positions 20 and 21 (GSG-EE).
- 25

- Many families of proteins contain a "signature" sequence of amino acids. The sequence of the clones did not contain any of these signatures present in the PROSITE database. The amino acids from 170 to 185 correspond to the calcium binding consensus sequence [DENQST]X[DENQST]X[DENQST]X[DENQST]X[DENQST]XX[DENQST]. Thirteen potential phosphorylation sites were discovered that matched the consensus sequences for either the kinase phosphorylation site [RK](2)-x-[ST], the protein kinase C phosphorylation
- 30

site [ST]-x[RK] or the casein kinase II phosphorylation site [ST]-x(2)-[DE].

Three N-linked glycosylation sites were identified in the translated sequence of the clones A
 neural network has been trained to identify this type of glycosylation which identified Thr
 5 216 as a potential site of O-linked glycosylation. At least one of these sites must be
 glycosylated in the native protein in order to account for the presence of the sugar residues.
 A putative signal peptide region preceded the N terminus of the secreted protein (determined
 by amino acid sequencing and was identified as a signal peptide by a neural network). To
 confirm this result the protein sequence was searched with PSORT for motifs which would
 10 locate the cloned protein in a cellular compartment. The protein sequence did not contain
 any transmembrane regions or N-myristoylation patterns which would indicate the presence
 of a lipid anchor. No targeting or retention sequences were found for the nucleus,
 mitochondria, endoplasmic reticulum or peroxisome.

15 The fact that the clones had some sequence similarity with proteins that interact with
 nucleotides may suggest that pholasin binds a co-factor as part of the chemiluminescent
 reaction. Beetle luciferases require ATP binding for chemiluminescent activity. There is no
 P-loop binding motif ((A,G)x4GK(S,T) or (A)x{4}GK(T)) (SEQ ID NO: 33) in the amino
 acid sequence of these clones. However, not all ATP binding proteins contain this motif.

20 Neither does the cloned protein contain the GXGXXG phosphate binding consensus
 sequence necessary for the binding of other co-factors such as nicotinamide adenine
 dinucleotide.

The amino acid and sugar components of pholasin are not able to emit light at the
 25 wavelength of the native protein (490nm). This indicates that there must be a chromophore
 bound to the protein. There are, however, proteins in which the chromophore is composed
 of modified amino acid residues within the polypeptide. The best characterised of these is
 the green fluorescent protein (GFP). This has a chromophore which is a ring formed by the
 autocatalytic cyclisation of the residues Ser-dehydroTyr-Gly. The serine may be mutated to
 30 a threonine, which increases the amplitude of the emission at 488nm. Pholasin had no
 similar amino acid sequence. Putative luciferin binding regions have been identified for two
 bioluminescent chemistries. Aequorin has a putative coelenterazine binding region, which
 is also present in two sections of the *Vargula hilgendorfii* luciferase. The sequence of the
 cloned protein has no homology to the putative luciferin binding site of aequorin, but the

region of the *Vargula* luciferase from residue 353 to 411 has some similarity, as does the LBP of *Renilla reniformis*, which also binds an imidazolopyrazine. This may indicate that the chemistry of pholasin bioluminescence involves an imidazolopyrazine luciferin. However, the region of homology is very small. The beetle luciferases contain an area of low sequence homology which may bind the benzothiazole luciferin. This low homology may account for the different colours of beetle bioluminescence. used a luciferin analogue (2-(4-benzoylphenyl) thiazole-4-carboxylic acid which photoinactivated the luciferase active site of the firefly *Photinus pyralis*. This photoinactivation was directly linked to the degradation of a small peptide sequence HHGF (SEQ ID NO: 34) (residues 244-257). This is therefore postulated as a luciferin-binding site. The cloned protein does not have any sequence homology with these putative binding regions. Two strongly conserved regions of amino acids have also been found in both the luciferase and the luciferin binding protein of the dinoflagellate *Gonyaulax polyedra*. These regions were compared to the cloned protein, but no sequence similarity was found. No sequence identity could be established between the bacterial luciferases and the cloned protein.

Therefore, the present invention provides cloned apophotoprotein apopholasin (and the cDNA coding therefor), which has identical properties to native (but non-glycosylated) apopholasin with respect to molecular weight, amino acid composition, potential for glycosylation, its highly acidic pI and its cellular location. Hence, the present invention can further provide the corresponding BOIP or modified BOIP, according to standard methods.

The corresponding BOIP is preparable by bringing the apophotoprotein pholasin into association with the luciferin, also using standard methods. Although the luciferin is tightly bound in the native pholasin BOIP, it has been found that it may not be the case in the recombinant pholasin BOIP; indeed the luciferin may be weakly bound or merely present with the apoprotein. For example, a methanol, aqueous, acidic or other extract of *Pholas dactylus* (whole organism or light organ dissected from the animal) containing the 'luciferin', or the pure luciferin, may be added to the solution, cell or organism (Figure 10 shows the time course of hypo-chlorite triggered luminescence in these circumstances). A time course of apopholasin reactivation was performed by incubating partially purified recombinant pholasin secreted by insect cells with acid:menthanol extract of *Pholas dactylus* (●) for 0 (solid line), 1 (---), 2 (- - -), 6(- —) or 24 hours (— —), or incubated

without extract (○). Controls of buffers only with no protein or acid:methanol extract (□)

and extract alone (■) were treated in identical conditions. Chemiluminescence was triggered by the addition of 2% sodium hypochlorite at 10 seconds (arrow) and is shown as chemiluminescent counts minus background light. A typical curve obtained by hypochlorite triggering of native pholasin is also shown (X). A representative experiment carried out in duplicate is shown.

The luciferin associates with the apo-BOIP forming the photoprotein or remains loosely bound so that it turns over like a luciferase.. The luciferin on the photoprotein then reacts with oxygen or one of its metabolites to produce light, in the presence or absence of the luciferase. The light emission may be detected, quantified, or imaged using a luminometer, photographic film or imaging camera, or by the naked eye. Alternatively, light emission may be generated spontaneously by intra- or extra-cellular metabolites reacting with the apo-BOIP.

Although illustrated with respect to pholasin, the following may apply to any BOIP: the BOIP can be produced directly from native DNA, or from DNA engineered or amplified by the polymerase chain reaction. By this means, sites can be inserted within the protein by splitting the DNA into two or more pieces, or by adding DNA sequences to the 5' or 3' ends. For example, the DNA may be expressed in bacteria, yeast, an insect or human cell, or other suitable organism to produce protein which can be extracted and used.

In this instance, the protein produced from the cloned DNA reacts with oxygen or a metabolite of oxygen, such as the superoxide anion (O_2^-), hydrogen peroxide (H_2O_2), hydroxy radical (OH^\cdot), an oxyhalide anion (OCI^- , OBr^- , OI^- , $OSCN^-$), nitric oxide (NO), an organic hydroperoxide or a radical ROO^\cdot . The change in light emission enables the oxygen or metabolite(s) to be detected and quantified in live cells, organelles, or on the outer or inner surface of the plasma membrane, or within an organ of a live organism without the need to break them open or the need to separate bound and free fractions. This also enables an enzyme producing oxygen or one of its metabolites, such as chlorophyll, or enzymes such as oxidases and oxygenases which react directly with oxygen or one of its metabolites to attach oxygen to the substrate to be detected and

quantified in live cells, organs and whole organisms, or extracts from any one of these.

Also the BOIP can be made *in vitro* by transcription/translation in a cell lysate such as rabbit reticulocyte lysate or wheat germ extract containing RNA polymerase. The DNA
 5 for the BOIP is first engineered to contain an RNA polymerase promoter, such as T7, SP6; bacterial promoter(s), such as lac, ara or trp; or mammalian promoter(s), such as actin, myosin, myelin proteins, TK, MRT-V, SV40, CMV, RSV, metallothionine, antibody, G6P dehydrogenase, and can be amplified *in vitro* using the polymerase chain reaction. A poly-A tail may be added at the 3' end and a tissue specific promoter or
 10 enhancer sequence added to the 5' or 3' end of the DNA coding for the BOIP or modified BOIP, enabling it to be expressed specifically in a target cell, such as a myocardial cell or a cancer cell. The expression of the BOIP in the target cell is detected and quantified by light intensity, colour or polarisation, as previously mentioned.

15 The BOIP, or its DNA or RNA, may be incorporated into a live bacteria or eukaryotic cell using phage, virus, plasmid, calcium phosphate transfection, electroporation, liposome fusion, membrane pore forming proteins, micro-injection or DNA gun. Once inside cells or an appropriate extracellular environment, cell activation or injury will initiate or change the light emission from the BOIP. For example, expression in live organisms by
 20 micro-injection of protein, RNA or DNA, or by transgenic manipulation to produce a cell, such as a bacterial, microbial, animal or plant cell, eg a white blood cell, a heart cell, or a yeast, protozoan, fruit fly (*Drosophila*), nematode worm, polychaete worm, fish, human, mouse, rat, sheep, pig, horse or plant, which can generate its own light.

25

The BOIP can also be incorporated into a defined part of a live cell by chemical means or by genetically engineering the BOIP to contain a signal peptide, which locates the BOIP to the inner or outer surface of the plasma membrane or within a particular organelle, such as peroxisome, mitochondrion, chloroplast, tonoplast, endoplasmic, reticulum, Golgi
 30 apparatus, endosome, lysosome, secretory vesicle, nucleus, nucleolus, nuclear membrane, plasma membrane, proteosome, or gap junction, or structure such as membrane receptor ion channel microtubule, cytoskeleton, nuclear skeleton, nuclear receptor, mitotic spindle or microfilaments. The signal peptide, added either chemically or genetically, will normally target the normal or modified BOIP to a particular intra- or extra-cellular site.

For example, the sequence MLSRLSLRLLSRYLL (SEQ ID NO: 35) or part of cytochrome oxidase on the N-terminus will target the BOIP to the mitochondrion; KKSALLALMYVCPGKADKE (SEQ ID NO: 36) or MLLPVPLLLGLLGLAA (SEQ ID NO: 37) at the N-terminus will target the BOIP to the endoplasmic reticulum, a KDEL (SEQ ID NO: 38) or HDEL (SEQ ID NO: 39) or KEEL sequence (SEQ ID NO: 40) at the C-terminus retaining it there. SKL at C-terminus targets BOIP to the peroxisome; PKKKRKV (SEQ ID NO: 41) or an extension of this SV40 large T-antigen signal will target it to the nucleus; and a palmitoylation and/or a myristoylation signal will target it to the plasma membrane. By coupling the BOIP to another protein that targets itself to a particular site, the BOIP can also be targeted there. For example, coupling the nuclear proteins nucleoplasmin or lamin B receptor to BOIP targets it to the nucleus; cytochrome oxidase at the N-terminus targets BOIP to the mitochondria; chlorophyll at the N-terminus targets BOIP to the chloroplast; a connexin at the N-terminus targets BOIP to the gap junction or plasma membrane; and SNAP 25 to the plasma membrane.

15

Other modifications to the apoprotein, BOIP, or nucleotides coding therefor include, but are not limited to:

The apoprotein, such as apopholasin, may also be glycosylated, and used to detect and quantify secretion or movement of proteins through the secretory pathway.

Nucleic acid coding for the BOIP when expressed inside a live cell may not only be modified but also regulated in this cell by gene expression, such as by promoters, enhancers or oncogenes. For example, the apoprotein, such as apopholasin, may be coupled to a gene regulator protein, such as a transcription factor, by genetic or chemical manipulation, such that the movement through a cell or of the regulator protein or its activity, can be detected or quantified.

The BOIP or apoprotein, or its DNA may be linked to another protein or DNA used in therapy, such that the other protein or DNA can be detected in live cells or in a whole organism, eg a human.

The apoprotein, such as apopholasin, can also engineered genetically or chemically to contain a site or sites which can be covalently modified by enzymes such as

phosphorylation (including ser/thr, his and tyr kinases and phosphatases),
 transglutamination, proteolysis, ADP ribosylation, gly- or glu-cosylation, halogenation,
 oxidation, methylation, palmitoylation, myristylation and farnesylation.

- 5 The apoprotein, such as apopholasin, can be engineered genetically or chemically to
 contain an antigen or intracellular signal binding site, such as Ca^{2+} , cyclic AMP, cyclic
 GMP, cyclic CMP, IP_3 , IP_4 , diacyl glycerol, ATP, ADP, AMP, GTP, or any oxy- or
 deoxy-ribonucleoside or nucleotide, a substrate, a drug, a nucleic acid and/or a gene regulator
 protein.

10

- The BOIP may also be converted to a rainbow protein by engineering a particular site
 such as described hereinabove into the BOIP, at the N- or C-terminus, or between a
 chimera of the BOIP and an energy transfer acceptor, such as GFP (wild type or any of the
 mutant GFPs). This is known as chemiluminescence, bioluminescence or fluorescence
 15 resonance transfer (CRET, BRET or FRET, respectively). Conversion of the BOIP to a
 'rainbow protein' may be effected by reaction with a cellular substance, modification
 genetically or chemically, or by linking the BOIP to a fluor, such as the green fluorescent
 protein or the red fluorescent protein in the deep sea fish *Malacosteus*. The result is a
 BOIP which changes its colour and/or intensity and/or polarisation of emission. The
 20 change in colour occurs by energy transfer, eg resonance transfer (CRET or FRET) or
 electron transfer.

- The initial (unmodified) BOIP may be the apophotoprotein, its DNA or RNA, from the
 bivalve mollusc *Pholas dactylus*, or it may be another BOIP, such as one from the
 25 mollusc *Rocellaria grandis* or the squid *Ommastraphes*, or earthworm luciferase, which
 produce light with oxygen metabolites in a way very similar to *Pholas dactylus*.

The BOIP, apo-BOIP, or nucleic acid coding for it, whether modified or not, may
 therefore be used in a range of biology and investigations such as:

30

- (a) Detection, location and measurement of signals in substrates, such as live cells,
 organs or organisms, or in extracellular fluids;
- (b) Detection, location and measurement of oxygen and its metabolites in substrates,
 such as live cells, organs or organisms, or in extracellular fluids, water (sea and

fresh), soil or the atmosphere;

- (c) Detection and location of normal cells such as microbes (protozoa, yeast, fungi, moulds, bacteria, viruses);
- (d) Detection and location of abnormal cells, such as cancer cells, hyperactive cells in rheumatoid arthritis and other inflammatory diseases, cells infected with a pathogen, such as a virus or other infectious agents, cells damaged by physical, chemical or biological attack, cells damaged by perfusion or reperfusion injury or cells damaged by oxygen or one of its metabolites;
- (e) Measurement and location of enzymes, particularly those producing oxygen or its metabolites, and other tumour reactions in cells or biological fluids;
- (f) DNA and RNA binding assays;
- (g) Immunoassay and other protein binding assays;
- (h) In genetic engineering, in the development of transgenic animals and plants, and microbes; in horticulture; agriculture; medicine and veterinary medicine; and/or
- (i) in genetic entertainment by incorporation into light sticks, greeting cards or toys to produce light of various colour, intensities, oscillations, flashes and glows; or in comestibles, such as food, drinks, including beers, wines, spirits, colas and other soft drinks.

20

Accordingly, the present invention further provides an apoprotein, such as pholasin apoprotein (or apopholasin) in both unglycosylated and glycosylated forms, and a BOIP thereof, such as pholasin, either alone (but excluding native proteins *per se* that have already been isolated, such as native pholasin *per se*) or in association with one or more of: a targeting or signal peptide; a glycosylate; a site capable of modification by an enzyme; an antigen or intracellular signal binding site; a promoter, an enhancer or an oncogene or a pharmacologically active substance; or the like. The present invention further provides a recombinant construct comprising a nucleic acid sequence encoding for any of these proteins; a vector containing a nucleic acid sequence encoding for any of these proteins; a host transformed by such vector; a live cell, such as bacterial, insect, eukaryotic, prokaryotic, archae or plant cells containing or expressing any of these proteins; and a rainbow protein, as described herein, together with a nucleic acid sequence encoding therefor.

30

The present invention will now be illustrated with reference to the following non-limiting examples, in which the methodology referred to is known to those skilled in the art and/or may be carried out by analogy with reference to the protocols disclosed in the following references, the contents of which are herein incorporated by reference in their entirety:

5 BOOKS

1. Campbell,AK. (1988). Chemiluminescence: principles and applications in biology and medicine, pp608. Horwood/VCH, Chichester and Weinheim.
2. Campbell,AK. (1994). Rubicon: the fifth dimension of biology. pp 304. Duckworth, London.

10 PAPERS

1. Campbell,AK Patel,A. (1983) Biochem J. 216:185-194. A homogeneous immunoassay for cyclic nucleotides based on chemiluminescence energy transfer.
2. Roberts,PA Knight,J Campbell,AK. (1987) Anal. Biochem. 160:139-148. Pholasin - a bioluminescent indicator for detecting activation of single neutrophils.
- 15 3. Mueller,T Davies,EV Campbell,AK. (1989) J. Biolum. Chemilum. 3:105-113. Pholasin Chemiluminescence Detects Mostly Superoxide Anion Released from Activated Human Neutrophils.
4. Mueller,T Campbell,AK. (1989) J. Biolum. Chemilum. 5:25-30. The Chromophore of Pholasin: A Highly Luinescent Protein.
- 20 5. Sala-Newby,G and Campbell,AK (1991) Biochem.J. 279:727-732. Engineering a bioluminescent indicator for cyclic AMP dependent protein kinase .
6. Campbell, AK, Trewavas, AJ and Knight, MR (1996). Calcium imaging shows differential sensitivity to cooling and communication in luminous transgenic plants. Cell Calcium 19: 211-218.
- 25 7. Kendall, JM, Sala-Newby, G Badminton, M, Campbell AK and Rembold, CR (1996). Free Ca^{2+} in the endoplasmic reticulum of living cells measured using aequorin as a pseudo luciferase. Biochem.J 318:383-387
8. Badminton, MN, Campbell, AK and Rembold, CR (1996). J.Biol. Chem. 271:31210-31214. Differential regulation of nuclear and cytosolic Ca^{2+} in HeLa cells.
- 30 9. Sala-Newby, GB, Taylor, KT, Badminton, MN, Rembold, CR and Campbell, AK (1998). Imaging bioluminescent indicators shows Ca^{2+} and ATP permeability thresholds in, live cells attacked by complement. Immunology. 93:4:601-609
- 10.Sala-Newby, GB, Kendall, JM, Jones, H, Taylor, KM, Badminton, MN, Llewellyn, DH and Campbell, AK (1999). Targeting bioluminescent proteins to defined
- 35 compartments fo living cells. Methods in Enzymology Bioluminescence and Chemiluminescence. ed Ziegler, M and Baldwin, T.

EXAMPLE 1: Production of a BOIP in bacteria

c or genomic DNA coding for apopholasin, with or without the cDNA coding for the signal peptide, is amplified by PCR with restriction sites such as BamHI at each end. The cDNA is run on an agarose gel and the full length DNA eluted and purified. The DNA is then cut with BamHI to generate sticky ends and ligated into an expression plasmid such as pET3a, which has been cut with BamHI also. After ligation the sealed plasmid is transformed into a standard *E.coli* K12 strain such as JM109, a colony picked off for a large plasmid preparation. After checking that the plasmid contains the correct sequence for apopholasin and is in the correct orientation the plasmid is then used to transform a standard expression strain of *E.coli* such as BL21(DE3) or other expression strain. A colony is picked off the agar plate and grown up for 2h in standard LB broth. IPTG is added as inducer for a further 2h. Apopholasin can then be extracted by breaking the bacteria by lysozyme digestion or sonication in a standard salt medium such as 50mM HEPES pH 7 +/- 1mM ascorbate. Since the apopholasin is unglycosylated it tends to aggregate and form inclusion bodies. These can be broken using 8M urea or guanidinium chloride and these then dialysed off. If the pH of PAGE gels is alkaline this also tends to allow aggregation of both the unglycosylated and glycosylated apo- and full pholasin. A signal peptide such β -lactamase signal will target the BOIP to the periplasmic space, resulting in the ability to secrete the expressed protein from the external fluid of the cells.

EXAMPLE 2: Production of a BOIP in insect cells

c or genomic DNA coding for apopholasin is inserted into a plasmid suitable for conversion into baculovirus when transfected into insect cells. Since pholasin is secreted by *Pholas* itself there is a signal peptide at the N-terminus. Removal of this by PCR will allow cytosolic expression in insect cells. If the signal peptide is left on or changed for honey bee mellitin signal peptide, the apopholasin is secreted into the external medium. The virus containing the DNA for apopholasin is then purified and stored until required. An aliquot is then added to fresh insect cells and these incubated for 3-7 days. The apopholasin is then isolated from the supernatant if a signal peptide is used, or from the cells if not. The apopholasin can then be purified by ammonium sulphate precipitation, gel filtration and DEAE chromatography. The state of glycosylation can be assessed by running the protein on PAGE when the molecular weight is 34Kda. Removal of the

glycosylation by enzymes returns the protein to the size of apopholasin 23.5Kda. It can be stored frozen or freeze dried, and activated to form pholasin by addition of luciferin as described in Example 3.

- 5 Since the apopholasin tends to aggregate in the insect supernatant it is important to get the protein into non-aggregating buffer, e.g. 50mM HEPES pH 6, 1-10mM ascorbate, as soon as possible.

Formation of pholasin can then be achieved as described in Example 3.

10

EXAMPLE 3: Generating pholasin and light emission

To generate light the apopholasin must first be converted into pholasin with the luciferin. The luciferin can be extracted from native pholasin by mild acid, or by methanol, mild
15 acid or alkaline treatment of light organs isolated from *Pholas dactylus* or the whole organism. After homogenisation the extract is centrifuged or filtered to remove particulate material. Further purification can be achieved by tlc or hplc. The luciferin is best stored dry, but can be stored at -70°C. The intactness and concentration can be estimated by measuring the absorbance or fluorescence. The details are as follows:

20

(a) *Isolation of the luciferin*

Four protocols (1-4) have been developed to extract and isolate the luciferin responsible for light emission in pholasin. The luciferin is a small organic moiety tightly bound to apopholasin when pholasin is isolated from *Pholas dactylus*, but
25 also can be found not bound to apopholasin. Thus the extraction procedure isolates either form of luciferin.

1. The organism *Pholas dactylus* or its light organs are homogenised in 50mM sodium phosphate pH 6.0 on ice. The pholasin is precipitated with saturated ammonium sulphate (4°C stirred), and then removed by
30 centrifugation at *ca* 15,000g for 30min in the cold. The supernatant is then passed down a SEP-PAK silica column, which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The active fractions containing the luciferin are assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl.

The luciferin is concentrated and can be purified further on tlc or hplc with a standard solvent. It is dried and stored at -70°C.

2. The organism *Pholas dactylus* or its light organs are homogenised in cold acetone on ice, filtered through a Buchner funnel, and extracted with methanol:acetone (1:1), the residual powder being extracted 3 times with methanol and extracts combined. These are then concentrated in a Rotavaporator and left to stand for 1h on ice to allow further precipitation. The suspension is then refiltered and concentrated. The solution containing the luciferin is then passed down a SEP-PAK silica column which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The active fractions containing the luciferin are assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl. The luciferin is concentrated and can be purified further on tlc or hplc with a standard solvent. It can be dried and stored at -70°C.
3. The organism *Pholas dactylus* or its light organs are homogenised in cold acetone on ice, and filtered through a Buchner funnel to give an acetone powder. This is then extracted with methanol:acetone (1:1), twice for 10min and then 3 times with methanol. The extracts are combined and concentrated in a Rotavaporator. They are left to stand for 1h on ice to allow further precipitation, refiltered and concentrated. The residual powder is resuspended in 50mM sodium phosphate pH 6.0, 10mM ascorbate, and ultrafiltered with a 10kD Amicon membrane at 4 C for pholasin. The solution containing the luciferin is then passed down a SEP-PAK silica column which binds the luciferin. The column is washed with 5ml ethyl acetate and then 5ml of methanol. The active fractions containing the luciferin assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl. The luciferin is concentrated and can be purified further on tlc or hplc with a standard solvent. It is dried and stored at -70°C.
4. The organism *Pholas dactylus* or its light organs are homogenised in 50mM HEPES buffer, with methanol and 100mM HCl on ice, and incubated for 2h on ice. After centrifugation at *ca* 15,000g for 30min in the cold, the supernatant is then passed down a SEP-PAK silica column which binds the luciferin. The column is washed with 5ml ethyl acetate and then

5ml of methanol. The active fractions containing the luciferin are assayed either by reactivation of the apopholasin or by chemiluminescence in DMSO, DMF, or NaOCl. The luciferin is concentrated and can be purified further on tlc with a standard solvent. It is dried and stored at -70°C.

5 Method 4 normally generates most luciferin. The luciferin is characterised by its absorbance and fluorescence spectrum, and by its chemiluminescence with DMSO, NaOCl and apopholasin.

(b) *Generation of pholasin from apopholasin and the luciferin*

A small sample of the luciferin (1-10µl) is added to apopholasin in an appropriate buffer (50mM HEPES pH 6-7.5, +/- 0.1% gelatine, +/- 1-10mM ascorbate, or 10 500mM NaCl, 10mM TES, 1mM EDTA, 1mM mercaptoethanol pH 6-7.5). The mixture is incubated at room temperature for up to 24h, and the pholasin assayed by adding an oxygen metabolite, e.g. NaOCl, or luciferase to a sample. When apopholasin has been expressed in cells, the luciferin is added externally, 15 microinjected into individual cells or added via liposomes to get the luciferin into the cell.

Light is detected and quantified in a standard luminometer, imaging camera (intensified or CCD), or by a silicon chip.

20

EXAMPLE 4: Production of a BOIP in vitro

c or genomic DNA coding for apopholasin, with or without the signal peptide, is amplified by PCR with the 5' primer containing the DNA coding for T7 RNA 25 polymerase. The DNA product is purified and precipitated. After dissolving in 10mM tris/1mMEDTA pH7, the DNA is added to a standard *in vitro* transcription/translation system such as rabbit reticulocyte lysate or wheat germ agglutinin and incubated at 30°C for 30-60min. The apopholasin can then be purified and activated to form pholasin as described in Example 3.

30 **EXAMPLE 5: Targeting a BOIP in vitro**

The BOIP can also be incorporated into a defined part of a live cell by chemical means or by genetically engineering the BOIP to contain a signal peptide which locates the BOIP to the inner or outer surface of the plasma membrane or within a particular organelle such as

peroxisome, mitochondrion, chloroplast, tonoplast, endoplasmic reticulum, Golgi, endosome, lysosome, secretory vesicle, nucleus, nucleolus, proteosome, or gap junction, or structure such as microtubule, cytoskeleton, nuclear skeleton, nuclear receptor, or mitotic spindle. The signal peptide, added either chemically or genetically, will normally

5 target the normal or altered BOIP to a particular intra- or extra-cellular site for example, the sequence MLSRLSLRLLSRYLL (SEQ ID NO: 35) or part of cytochrome oxidase on the N-terminus will target the BOIP to the mitochondrion; KKSALLALMYVCPGKADKE (SEQ ID NO: 36) or MLLPVPLLLGLLGLAA (SEQ ID NO: 37) or the ER protein calreticulin at the N-terminus will target the BOIP to the

10 endoplasmic reticulum, a KDEL (SEQ ID NO: 38) or HDEL (SEQ ID NO: 39) sequence at the C-terminus retaining it there. SKL at C-terminus targets BOIP to the peroxisome, PKKKRKV (SEQ ID NO: 11) or an extension of this SV40 large T-antigen signal will target it to the nucleus, and a palmitoylation and/or a myristoylation signal (MGCVCSSNPD (SEQ ID NO: 42) = the LCK N-terminal acylation motif from tyrosine

15 kinase) will target it to the plasma membrane. By coupling the BOIP to another protein which targets itself to a particular site then the BOIP is also targeted here. For example, coupling the nuclear proteins nucleoplasmin or lamin B receptor to BOIP targets it to the nucleus; cytochrome oxidase at the N-terminus targets BOIP to the mitochondria; chlorophyll at the N-terminus targets BOIP to the chloroplast; and a connexin at the N-

20 terminus targets BOIP to the gap junction or plasma membrane, SNAP 25 to the plasma membrane.

In order to target pholasin to defined sites in living cells, the DNA coding for these targeting sequences are added by using PCR. For cytosolic apopholasin the native signal

25 peptide is removed and also the BOIP can be linked to larger proteins at the N- or C-terminus such as firefly luciferase or aequorin to prevent it getting into the nucleus. This also enables ATP and oxygen metabolites, or Ca^{2+} and oxygen metabolites to be measured simultaneously in the same cells by intensity, colour or polarisation of the different bioluminescent indicators. A multiple bioluminescent indicator can also be engineered by

30 PCR, or by using restriction enzyme sites, from the DNA coding for 3 or more bioluminescent proteins. A simple screen of the transformed bacteria enables the multiple rainbow protein to be isolated with 2-3 colours or more.

The DNA is then added to an *in vitro* transcription/translation system as described in Example 4 in the presence of the organelle to be targeted (e.g. microsomes for the endoplasmic reticulum, which glycosylate apopholasin).

- 5 The new DNA can also be inserted into a plasmid by standard techniques, and transformed into bacteria or transfected or injected into eukaryotic cells such as HeLa or COS.

10 Addition of the luciferin as described in Example 3 allows formation of pholasin which can then be detected by light emission. Changes in oxygen metabolite production are then be detected by a luminometer or imaging camera when the cells are exposed to external oxygen metabolites, a change in oxygen concentration, addition of stimuli e.g. TNF, EGF, hormones or drugs, or attack by pathogens such as bacteria, viruses, complement, antibodies, toxins, and cells of the immune system.

15

EXAMPLE 6: Engineering a covalent modification site into a BOIP

- (a) 20 The site coding a protein kinase A (RRAS or kemptide), protein kinase C (MARCKS), MAP kinase, ERK, the ER - nuclear signalling kinase IRE1P or a phosphatase is added to the N- or C-terminus or inserted at various sites within the apopholasin by PCR and expressed as described in Examples 1-5. Pholasin is then generated by addition of the luciferin as described in Example 3.

25 Addition of the catalytic subunit for protein kinase A, or activation via cyclic AMP inside cells, leads to phosphorylation or dephosphorylation of the modified pholasin and change in light emission (intensity, colour or polarisation).

A preliminary screen is necessary to select the appropriate proteins and to discard any which have lost all activity.

30

- (b) The site coding a protease (thrombin, enterokinase, HIV protease, caspase) is added to the N- or C-terminus of the apopholasin by PCR or inserted at various sites within the protein, and expressed as described in Examples 1-5. Pholasin is then generated by addition of the luciferin as described in Example 3.

EXAMPLE 7: Engineering a BOIP into a “Rainbow Protein”

cDNA coding for apopholasin is linked to another protein by using the cDNA coding for that protein. For example, wild type GFP, the S65T mutant of the green fluorescent protein, YGFP, or EGFP are linked to apopholasin by PCR at the N- or C-terminus, or by splitting one or both proteins using multi-step PCR. In between there is a ‘reactive’ peptide with a protease site (α thrombin or enterokinase) and a binding site for IP₃, or the 15 amino acid sequence form IP₃ kinase (an IP₄ binding site). At the C-terminus of the GFP, a peptide containing 6 lysine residues may also be added via PCR. The protein is expressed and fluorescein covalently linked to these lysines by addition of fluorescein isothiocyanate. Addition of the luciferin forms pholasin as described in Example 3. The change in colour occurs by chemiluminescence resonance energy transfer. Without fluorescein the rainbow protein emits blue-green light (508nm), which changes to blue (490nm) when the reactive substance binds to the reactive peptide, or when either thrombin or enterokinase is added. When the 6 amino acid linker is used the colour starts as green (530nm), and will then change from green, to blue-green and then blue as the particular reactive sequence binds their respective analytes. Use of rhodamine instead of fluorescein generates a rainbow protein which changes from red to green to blue.

20

A preliminary screen is necessary to select the appropriate rainbow proteins and to discard any which have lost all activity.

The other protein linked to apopholasin may be, for example, any one of the following linked chemically or genetically:

25

1. Firefly or any benzothiazole luciferase to the N or C terminus gives two colours for ATP and oxygen metabolites.
2. Any imidazolopyrazine luciferase, including coelenterazine systems - decapod shrimp, fish, squid, *Renilla*, anthzoan, Chaetognate, radiolarian, or copepod and *Vargula* systems - ostracod, *Porichthys* and similar fish, cyprinidids and *Vargula*.
3. Any tetrapyrrole luciferase such as dinoflagellate, euphausiid or stomiatoid fish.
4. Bacterial luciferase and other aldehyde or flavin luciferases, including polychate worm.

30

5. Any GFP, including wild type, S65T, enhanced GFP, blue GFP, yellow GFP, *Renilla* GFP, *Ptilocarpus* GFP, and *Pennatula* GFP, any anthozan GFP, or any coelenterate GFP.
6. The red fluorescent proteins from stomiatoid fish - *Malactosteus*, *Aristostomias*, *Photostomias*.
7. The phycobiliproteins - phycoerythrin and phycocyanobilin.
8. The blue fluorescent lumazine protein in the bacterium *Photobacterium*.
9. The yellow flavin fluorescent protein in *Vibrio*.
10. Any lysine or arginine or other amino acid side chain where a fluor can be added covalently. In which the case the rainbow protein may emit more than two colours. For example, rhodamine on a pholasin-linker-GFP chimera will turn from red to green to blue.

A preliminary screen may be necessary to select chimeras which have not lost all bioluminescent activity.

The 'reactive' peptide may be a binding site for any analyte, protein or DNA, metabolite, substrate vitamin, an enzyme such as a protein kinase C or phosphatase, ion channel, ion pump, antigen, antibody, nucleotide or nucleoside such as ATP, GTP, ADP, AMP, adenosine, cAMP, cCMP, cCCP or their deoxy equivalents, and inositol phosphates such as IP₃ or IP₄, a lipid such as diacyl glycerol, phosphatidyl inositol biphosphate, phosphate, a cation such as Ca²⁺, K⁺ or Na⁺, Cu²⁺ or Zn²⁺, or anion such as Cl⁻, sulphate, or gas such as NO, O₂ or H₂, or a protein binding site such as calmodulin, kinesin, dynein, tubulin, or myosin.

When pholasin is triggered by oxygen metabolites, the *Pholas* luciferase or peroxidase, energy transfer occurs from pholasin oxyluciferin through GFP to fluorescein resulting in a yellow emission. Addition of thrombin for 3h cleaves the GFP-fluorescein from the pholasin and the light emission returns to the blue of native pholasin. Addition of IP₃ to the full chimera alters the efficiency of energy transfer. As a result there is a change in the ratio of light emitted in the yellow to blue. This ratio is directly related and can be plotted against the concentration or amount of analyte. The light is detected in a dual wavelength luminometer or ratiometric imaging camera and the ratio of blue to green light measured.

Alternatively any fluors can be used, and any binding sites with the right characteristics as shown in these examples will work provided a simple screen is used to select the right chimeras.

5 **EXAMPLE 8: Engineering a BOIP into a “Rainbow Protein” for two analytes together**

10 Apopholasin is linked to firefly luciferase by using cDNAs and PCR, followed by expression in insect cells as described in Example 2. Addition of the luciferin as described in Example 3 generates the pholasin. In the presence of firefly luciferin (1mM), ATP and oxygen metabolites, this chimera emits blue and yellow simultaneously which can be independently measured by using a dual wavelength luminometer or imaging camera.

15 **EXAMPLE 9: Expression of BOIPs in mammalian cells**

20 Apopholasin, c or genomic, in an expression plasmid with the CMV promoter, is transfected into HeLa cells. After incubation for 3 days to allow expression of the apopholasin, the luciferin is added to form pholasin. Expression is checked using a polyclonal antibody to pholasin raised in rabbits. Addition of oxygen metabolites outside the cell allows the permeability of the plasma membrane to oxygen metabolites to be assessed. As the oxygen metabolites permeate into the cytosol, the light emission increases.

EXAMPLE 10: Expression of BOIPs in plants

c or genomic DNA coding for apopholasin is inserted into a plasmid with the cauliflower mosaic virus promoter and transformed into *Agrobacterium tumefaciens*. These are then added to a tobacco leaf, seedlings generated, and those expressing apopholasin selected. The plants are grown to seed, and seedlings grown from this seed. Addition of luciferin forms the pholasin as described in Example 3. Stressing the plant, e.g. with wind, touch, cold, or peroxide, or during growth and development or by a hormone, generates light, showing the formation of oxygen metabolites within the live plant. A cell-specific promoter engineered on to the apopholasin cDNA before making the transgenic plant enables oxygen metabolites to be detected in specific cells within the whole, living plant.

EXAMPLE 11: Detection of oxidative damage in vitro

Addition of pholasin to serum or plasma from a rat, mouse or human enables oxygen metabolites to be detected and measured on addition of a drug or other substance of interest.

EXAMPLE 12: Detection of ROMs in a heart cells

Reperfusion has been proposed to lead to oxygen metabolite damage in cardiac myocytes. Pholasin allows this to be tested for the first time. Plasmid containing apopholasin cDNA and the CMV promoter is transfected into isolated cardiac myocytes in culture. Expression occurs within 1-3 days, and pholasin is formed by addition of the luciferin as described in Example 3. Subjecting the cells to hypoxia followed by readmission of normal oxygen leads to light emission, showing that oxygen metabolites have been generated inside the cells. By using an imaging camera, the digital or analogue nature of this can be assessed as the number of cells emitting light can be visualised and counted.

EXAMPLE 13: Detection of ROMs in the nucleus and endoplasmic reticulum (ER)

Plasmid-containing apopholasin cDNA with either nucleoplasmin DNA or calreticulin DNA (with or without KDEL on the C-terminus) linked to the pholasin DNA, to target
5 the apopholasin to the nucleus or ER respectively, and the CMV promoter for expression, is transfected into HeLa cells in culture. Expression occurs within 1-3 days, and pholasin is formed by addition of the luciferin as described in Example 3. Addition of oxygen metabolites outside the cells, or hypoxic/oxygen shock generates light measured in a
10 luminometer, showing how fast oxygen metabolites penetrate into these organelles. By imaging with a photon counting imaging camera, the number of cells permeable to oxygen metabolites can be counted. Location of the pholasin can be assessed by imaging live cells, or by using immunofluorescence with the pholasin antibody on partially-fixed cells or GFP-pholasin in live cells. Using a rainbow protein, two or more analytes can be detected together.

15

EXAMPLE 14: Use of pholasin as a protein label

Pholasin can be used as a label in homogeneous or heterogeneous immunoassay. Apopholasin is first covalently linked to an antibody to HIV, and pholasin formed by
20 addition of luciferin as described in Example 3. The antibody is then used in a standard chemiluminometric immunoassay format. Addition of HIV antigen leads to an increase in antibody binding and an increase in light emission dependent on the amount of HIV added. The amount of HIV in a blood sample can be assessed by relating the pholasin light emission in the sample to the standard curve.

25

EXAMPLE 15: Pholasin as a DNA label

Apopholasin is covalently linked to an oligonucleotide probe for detecting the presence of the cystic fibrosis gene. Addition of the probe to DNA in a standard Southern blot allows
30 the probe to bind when the gene is present. Addition of luciferin as described in Example 3 allows the pholasin to form. Addition of hypochlorite (10mM) in barbitone buffer pH 9 causes the pholasin to flash and the gene can be visualised by the photon counting imaging camera.

EXAMPLE 16: Pholasin in a two hybrid system

Protein-protein interaction can be detected by engineering apopholasin to one half of a two hybrid system and GFP to the other. Binding will allow the yeast to grow.

5

EXAMPLE 17: Pholasin in genetic entertainment

Pholasin is able to chemiluminesce at a wide range of pH (3-10), including acid pH such as 3-4. Thus it can be added to drinks such as beer, cola, soft drinks, and spirits to make them glow. It can also make food glow by adding to them to the ingredients of cakes, icing, popcorn; by painting the pholasin or apopholasin on to the food, or by making it genetically in the source of the food. It can be used in a wide range of toys and other entertaining devices including squirt guns, greeting cards, pens.

10

15

The rainbow proteins can also be used as an alternative to pholasin alone, resulting in a rainbow of colours and colour changes.

EXAMPLE 18: Pholasin in transgenic animals

Transgenic animals such as nematodes, mice or plants can be generated from apopholasin cDNA by standard techniques. Injecting the luciferin or incubating whole plant in it forms the active pholasin. Oxygen or its metabolites can then be detected, measured and imaged, in an intact organ, or from the whole organism. It can also be used in humans, in DNA therapy or diagnosis.

20

25

EXAMPLE 19: Apoprotein from the luminous squid *Ommastrophes*

The use of apoprotein from the luminous squid *Ommastrophes* is substituted for apopholasin, and the methods of Examples 1 to 18, above, are carried out.

30

EXAMPLE 20: Apoprotein from the mollusc *Rocellaria*


The use of the apoprotein from the mollusc *Rocellaria* is substituted for apopholasin, and the methods of Examples 1 to 18, above, are carried out.

EXAMPLE 21: Earthworm luciferase

The use of earthworm luciferase as a BOIP is substituted for apopholasin, and the
5 methods of Examples 1 to 18, above, are carried out.

EXAMPLE 22

- 10 Genomic DNA from *Pholas*, *Rocellaria*, *Ommastrophes*, or earthworm is substituted for the recombinant protein in Examples 1 to 18, above, the methods of which are carried out in an analogous manner.



INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference WN/NV/WCM.69		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/GB99/03654	International filing date (day/month/year) 05/11/1999	Priority date (day/month/year) 07/11/1998
International Patent Classification (IPC) or national classification and IPC C12N15/12		
Applicant UNIVERSITY OF WALES COLLEGE OF MEDICINE et al.		



1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.
2. This REPORT consists of a total of 8 sheets, including this cover sheet.

☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 3 sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 01/06/2000	Date of completion of this report 06.02.01
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Giebeler, K Telephone No. +49 89 2399 8546 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/GB99/03654

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):*

Description, pages:

1-28 as originally filed

Claims, No.:

1-30 as received on 07/12/2000 with letter of 07/12/2000

Drawings, sheets:

1/14-14/14 as originally filed

Sequence listing part of the description, pages:

1-9, filed with the letter of 16.02.2000

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☒ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB99/03654

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.
- ☒ claims Nos. 1,4,5,9-11,13-19,27-29 (all partially); 30 (completely).

because:

- ☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):
- ☒ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. 1,4,5,9-11,13-19,27-30 are so unclear that no meaningful opinion could be formed (*specify*):
see separate sheet
- ☒ the claims, or said claims Nos. 1,4,5,9-11,13-19,27-30 are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
- ☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/GB99/03654

1. Statement

Novelty (N)	Yes:	Claims	1-10,14,16,17
	No:	Claims	11-13,15,18-29
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-10,14,16,17
Industrial applicability (IA)	Yes:	Claims	1-20,28,29
	No:	Claims	21-27

2. Citations and explanations **see separate sheet**

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

No meaningful opinion could be formed on claim 1(b)(c)(d) and on claims 4, 5, 9, 10, 15-17 and 27-29 referring thereto since the scope of these claims is completely unclear.

In claim 1(b), the term "substantially homologous" is unclear and no clear definition is given in the description. It should also be noted that an unclear term cannot be used to distinguish the claimed nucleic acid from known nucleic acids encoding luciferin-binding proteins.

Claim 1(c) is even more unclear than (b) since it defines a sequence by its homology or hybridization to the sequence (b) which is also not clearly defined. Claim 1(c) relates to sequences which are homologous or hybridize to sequences which are homologous or hybridize to sequences (a). It is thus completely impossible for the skilled reader to know whether a given nucleic acid sequence is encompassed by the claim. The same applies to claim 1(d) which completely lacks technical features.

Furthermore, no meaningful opinion could be formed on the "mutant or variant ... capable of binding to luciferin" of claim 11, since these terms are unclear and would appear to encompass at least any known luciferin-binding protein.

Claim 30 is completely unclear due to the lack of technical features.

Consequently, the present opinion has only been established for claim 1(a), 2, 3, 6-8, 12, claims 4, 5, 9, 10, 15-17, 27-29 only as far as they refer (directly or indirectly) back to claim 1(a), claim 11 only as far as it relates to apopholasin itself, claims 13, 14, 18, 19, 27 and 28 as far as they refer to this part of claim 11, and claims 20-26.

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. The following documents are cited:

- D1: ROBERTS, P. ET AL., ANAL. BIOCHEM., vol. 160, no. 1, 1987, pages 139-148
- D2: COTTON, B. ET AL., BIOCHEMICAL SOCIETY TRANSACTIONS, vol. 17, no. 4, 1989, pages 705-706
- D3: MÜLLER, T. ET AL., J. BIOLUMIN. CHEMILUMIN., vol. 3, 1989, pages 105-113
- D4: DATABASE GENBANK [Online] 10 February 1999 (1999-02-10) DUNSTAN, S. L. ET AL.: 'Cloning and expression of the photoprotein pholasin from the bivalve *Pholas dactylus*; a bioluminescent indicator of reactive oxygen species.'

- 2. The current assessment is based on the assumption that all claims enjoy priority rights from the filing date of the priority document. If it later turns out that this is not correct, the document D4 cited in the international search report could become relevant.
- 3. The present application does not satisfy the criterion set forth in Article 33(1)(2) PCT because the subject-matter of claims 11-13, 15 and 18-29 is not new.

The present application relates to the cloning and sequencing of cDNA coding for the bioluminescent indicator protein pholasin from the bivalve mollusc Pholas dactylus. The native pholasin is made up of a glycosylated protein of 34 kD and a small organic molecule, the luciferin. The present application refers to this 34 kD glycoprotein as the apoprotein, whereas certain prior art documents use a less precise terminology refer to it as pholasin (see for instance D2, page 705, column 2, lines 7-9: "Pholasin (...) is a 35 kD acidic glycoprotein" or D3, page 112, column 1, paragraph 2: "Pholasin is a chemiluminescent 34 kD glycoprotein").

Irrespective of the terminology used, the glycoprotein of pholasin and its purification from Pholas dactylus are well-known from the prior art, see each of the

documents D1 to D3. Moreover, the use of pholasin in the intra- and extracellular detection/measurement of reactive oxygen metabolites is also known from these prior art documents. Therefore, claims 11-13, 15 and 18-29 lack novelty. It should be noted that the reference to a known protein being produced recombinantly does not establish its novelty.

It should furthermore be noted that the cells and organisms according to claim 15 are not clearly distinguished from naturally occurring Pholas dactylus and cells thereof.

4. The present application does not satisfy the criterion set forth in Article 33(3) PCT because the subject-matter of claims 1-10, 14, 16 and 17 does not involve an inventive step.

Claims 1-10, 16 and 17 relate to nucleic acids encoding the known pholasin protein. However, at the present priority date, the cloning and sequencing of a known protein were routine tasks. A person skilled would therefore have reasonably expected that he would be able to clone and sequence the gene encoding the pholasin protein. Moreover, it appears from the description that this task did not pose such problems as to prove that the expectation of success was ill-founded. Therefore, the claimed subject-matter cannot be considered to involve an inventive step.

Claims 4 and 14 do not involve an inventive step since the expression of recombinant proteins in prokaryotes such as E. coli, resulting in non-glycosylated proteins, is standard in the field.

5. For the assessment of the present claims 21-27, as far as they relate to in vivo methods, on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

Re Item VIII

Certain observations on the international application

6. The subject-matter of claims 6, 7 and 20-26 extends to photoproteins other than pholasin, and is therefore neither enabled (Article 5 PCT) nor supported (Article 6 PCT) by the description.
7. It is not entirely clear in claims 6 and 7 what the claimed "constructs" should be (Article 6 PCT). It would appear that they should be nucleic acids, and although claims 1, 6 and 7 have been drafted as separate independent claims, they appear to relate effectively to the same subject-matter and to differ from each other only with regard to the definition of the subject-matter for which protection is sought and in respect of the terminology used for the features of that subject-matter. The aforementioned claims therefore lack conciseness. Moreover, lack of clarity of the claims as a whole arises, since the plurality of independent claims makes it difficult, if not impossible, to determine the matter for which protection is sought, and places an undue burden on others seeking to establish the extent of the protection. Hence, these claims do not meet the requirements of Article 6 PCT.

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year)

27 July 2000 (27.07.00)

International application No.

PCT/GB99/03654

Applicant's or agent's file reference

WN/NV/WCM.69

International filing date (day/month/year)

05 November 1999 (05.11.99)

Priority date (day/month/year)

07 November 1998 (07.11.98)

Applicant

CAMPBELL, Anthony, Keith

1. The designated Office is hereby notified of its election made:



in the demand filed with the International Preliminary Examining Authority on:

01 June 2000 (01.06.00)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was



was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

R. Chrem

Telephone No.: (41-22) 338.83.38